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Abstract 
Synthesis, characterization, and application of polyethylene glycol modified insulin for 
oral delivery using complexation hydrogels 
Anthony D. Tuesca 
Anthony M. Lowman, Ph.D. 
 
 
 
Therapeutic proteins and peptides represent a major area of research in current 
pharmaceutical and biotechnology companies. Due to their inherent instability, the vast 
majority of these drugs require parenteral administration. Such is the case for as many as 
6 million patients in the United States who use insulin in the treatment of diabetes 
mellitus. Oral insulin delivery would is a highly desirable alternative method of 
administration, though it continues to be an elusive target due the enzymatic digestion of 
insulin and low levels of absorption from the gastrointestinal tract. Hydrogel polymers 
have shown promise as potential carriers for oral insulin delivery. In particular, a pH 
responsive hydrogel composed of poly(methacrylic acid-g-polyethylene glycol), P(MAA-
g-EG), has shown the ability to protect insulin from enzymes in the gastric environment 
and release in small intestines. It was also able to induce a hypoglycemic effect in vivo 
when delivered to isolated ileal segments in rats. However, this material has not shown 
similar potential for oral protein delivery of other model drugs. To date, the unique 
interaction between P(MAA-g-EG) and insulin, which give it such potential for oral 
delivery, are not completely understood.  
The focus of this research is to investigate how P(MAA-g-EG) hydrogels 
interact with insulin and to improve upon current designs for oral insulin delivery. An 
attempt is made to correlate the structure and chemistry of the hydrogel to its interaction 
with insulin over the pH range exhibited by the gastrointestinal tract in vitro. Further 
 
xvii
insight is gained by observing the interaction of the hydrogel with insulin-like proteins 
including insulin glargine, an insulin analog, and polyethylene glycol (PEG) modified 
insulin. The PEG-insulin conjugate is synthesized and characterized to maintain the 
bioactivity of the protein, which is confirmed in vivo using intravenous and subcutaneous 
administration in rats. Finally, the proposed system is tested using an in vivo model in 
Sprague Dawley rats and related to the potential application of P(MAA-g-EG) to deliver 
insulin and PEG modified insulin for the treatment of diabetes. 
 
 
 
 1
CHAPTER 1: INTRODUCTION 
 
Therapeutic proteins and peptides represent a major area of research in current 
pharmaceutical and biotechnology companies. In an editorial by Dr. E. Prosser of Trinity 
College in Dublin it was noted that 38 of the top 100 drugs are proteins or peptides, 
however only one of those drugs are available as an oral medication [1]. Generally 
therapeutic proteins and peptides require parenteral administration. Significant research 
efforts have been made investigating oral protein delivery because of the ease of 
administration, ability to avoid the pain of injections, leading to higher patient 
compliance, and elimination of infection as a potential side effect. However, little success 
has been achieved for oral protein delivery primarily due to the enzymatic degradation of 
proteins and low levels of transport across the epithelial layer of the gastrointestinal tract 
[2-4].  
One promising approach to oral protein delivery is through the use of hydrogels. 
These materials have unique biomimetic properties which allow them to be applied to a 
number of drug delivery applications [5]. Of particular interest are dynamic hydrogels 
which can respond to changes in their environment. One class of environmentally 
responsive hydrogels reacts to the pH of their surroundings. They offer promise for oral 
protein delivery due to the pH shift which occurs in the gastrointestinal tract [6]. One 
particular pH responsive hydrogel for this application is poly(methacrylic acid-g-ethylene 
glycol), P(MAA-g-EG), which has been investigated primarily with insulin. Previous 
research with this material has shown that it has the ability to protect insulin from 
enzymatic degradation in the gastric environment and release it in the intestinal 
environment [7-10]. In doing so, this material has the potential to deliver insulin orally 
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and become a new method to treat diabetes. It induced a hypoglycemic effect in rats 
when delivered to ileal segments in vivo [9, 11]. Additional work has shown that 
P(MAA-g-EG) has other beneficial characteristics for oral insulin delivery including 
mucoadhesion [12, 13], enzyme inhibition [14], and permeation enhancement of the 
intestinal epithelium [15]. Most of this work, however, has strictly investigated the 
macromolecular behavior of the material and its potential as an insulin oral delivery 
device.  
The focus of this research is to investigate how P(MAA-g-EG) hydrogels 
interact with insulin. An attempt is made to correlate the structure and chemistry of the 
hydrogel to its interaction with insulin over the pH range exhibited by the gastrointestinal 
tract in vitro. In doing so, the unique potential for oral insulin delivery using this material 
may be more accurately defined. Further insight can be gained by comparing the 
interaction of P(MAA-g-EG) with insulin to that of similar proteins with small but 
distinct changes in structure or chemistry. In this work, insulin glargine, an insulin 
analog, and polyethylene glycol (PEG) modified insulin are also investigated with the 
hydrogel. The PEG-insulin conjugate is synthesized in a controlled manner such that the 
bioactivity of the protein is maintained. Finally, the proposed system is tested using an in 
vivo model in Sprague Dawley rats and related to the potential application of P(MAA-g-
EG) to deliver insulin and PEG modified insulin for the treatment of diabetes. 
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CHAPTER 2: BACKGROUND 
 
2.1. Diabetes 
Diabetes mellitus is a disease in which the body does not produce or properly 
use insulin [1-3]. Insulin is a protein which is required for the cellular uptake of 
circulating glucose into most tissues in the body. The central identifying feature of 
diabetes mellitus is a chronic and substantial elevation of the circulating blood glucose 
concentration. In addition to blood glucose concentration, glycosylated hemoglobin 
(HbA1c) is used to measure blood glucose levels over a long period of time. Healthy levels 
are considered to be 70-150 mg/dl for blood glucose and < 7 % for HbA1c. The chronic 
effects of diabetes contribute to medical problems such as eye disease, neuropathy, 
cardiovascular disease, gastrointestinal disorders, kidney disease, impaired sexual 
function, bone and rheumatic disorders, endocrine diseases, central nervous system 
problems, and psychological and psychiatric conditions [1]. The population of Americans 
diagnosed with diabetes represented 4.9% of the total population in 1990. Currently, 
diabetes currently affects approximately 20.8 million people in the United States, 7 % of 
the total population [4]. Much of this increase over the last 18 years was due in large part 
to increased frequency of diagnosis, however, the growth of the diabetic population has 
reached epidemic levels. It is currently the fifth leading cause of death in the U.S., and 
the estimated total cost of diabetes in the U.S. increased from $98 billion in 1997 to $132 
billion in 2002 [5]. Diabetes is generally separated into two major categories: insulin 
dependent diabetes mellitus (IDDM), or Type 1 diabetes, and non-insulin dependent 
diabetes mellitus (NIDDM), or Type 2 diabetes. Another significant type of diabetes is 
gestational diabetes, which affects about 4 % of pregnant women in the U.S. [6]. 
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Gestational diabetes represents only a small population of people diagnosed with 
diabetes, and the effects generally subside after childbirth, so it will not be discussed in 
this work. 
 
2.1.1. Type 1 Diabetes 
 
Type 1 diabetes, previously referred to as juvenile onset diabetes, is an 
autoimmune disease in which the body attacks the pancreatic β-cells which produce 
insulin [1]. Those suffering from Type 1 diabetes are unable to produce insulin. Without 
treatment with insulin, Type 1 diabetics experience acute effects of the disease such as 
ketoacidosis, a condition wherein the body begins to burn fat and muscle tissues for 
energy causing the release of ketone bodies into the bloodstream. Ketoacidosis is 
extremely taxing on the kidneys and endothelial cells in the capillaries and eyes, causing 
extreme damage to those tissues and leading to kidney failure, blindness, and amputation 
of tissues of the extremities [1]. Type 1 diabetes affects about 5-10 % of diabetic patients.  
Almost exclusively, the treatment for Type 1 diabetes is insulin therapy. This 
treatment requires self-monitoring of blood glucose levels and intermittent insulin 
administration. Generally insulin is taken subcutaneously in the form of an injection or an 
infusion. Insulin therapy will be discussed in more detail later in this chapter. The only 
other treatment for Type 1 diabetes is transplantation of pancreatic tissue, more 
specifically cells known as the islets of Langerhans, harvested from deceased donors. The 
first attempt for transplantation of pancreatic tissue was performed by Ballinger and Lacy 
in 1972 [7]. In this study, the transplant successfully reversed the effects streptozotocin 
induced diabetes in rats. Significant progress in this approach has occurred in the last 35 
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years [8-11], and islet transplant has the theoretical potential to completely reverse the 
effects of Type 1 diabetes. Insulin independence rates of transplant recipients after 1 year 
have been reported as high as 80% [12]. Islet transplantation has not yet achieved 
widespread practice, however, due to the very high immune response and tissue rejection 
caused by the transplanted tissue. This effect occurs with all islet recipients mandating 
administration of immunosuppressant drugs for the lifetime of the individual. The side 
effects of these drugs greatly increase the risk of infection, sickness, and death of the 
individual. Due to the high risk, this treatment is generally only considered for 
individuals also suffering from renal failure who receive concomitant kidney transplants. 
 
2.1.2. Type 2 diabetes 
Type 2 diabetes, previously referred to as adult onset diabetes, is generally 
caused by a combination of low production of insulin from the pancreas and insulin 
resistance in the tissues that require insulin. It is by far the most common type of diabetes 
affecting approximately 90 % of diabetic patients [13]. The effects of Type 2 diabetes are 
not as acute as Type 1 and there are even many people who are unaware that they have 
the disease. Type 2 diabetics still produce some insulin which significantly reduces the 
possibility of ketoacidosis, although the risk is still much higher than a non-diabetic 
person. The population of diabetics is increasing to epidemic proportions due primarily to 
the rapid increase in Type 2 diabetes. By a large margin, the leading cause of Type 2 
diabetes is obesity [14, 15] In fact, of the patients with Type 2 diabetes, as many as 80-90 
% are overweight or obese [16]. Other factors which have significant impact on the 
likelihood of developing Type 2 diabetes are age, race, and genetic disposition. The 
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prevalence of Type 2 diabetes increases dramatically for all races with advancing age. 
Americans between the ages of 45-55 are four times more likely to have Type 2 diabetes 
than those between 20-44 [17].  Of the major racial populations in the U.S., non-Hispanic 
whites have the lowest incidence of diabetes, while Hispanics have the highest. The racial 
group with the highest frequency of diabetes is the Pima Indian, with roughly 50 % of the 
population between 30-64 years old being diagnosed with one form of diabetes [18]. 
Because one cannot change their age, race, or genetics, the most important factor for the 
prevention of Type 2 diabetes is obesity. 
The most important epidemiological approach to Type 2 diabetes is prevention. 
In most cases, Type 2 diabetes can be controlled by diet and exercise. Because the 
leading cause of the disease is obesity, controlling one’s weight is critical. The key 
feature of diet for those diagnosed or at risk of developing Type 2 diabetes is controlling 
the caloric and carbohydrate intake [19]. Smoking also increases the likelihood in the 
development of the disease. Interestingly, some behaviors or habits which are often 
considered bad for health have caused a reduction in the risk of developing diabetes. 
Studies have shown that increased coffee consumption decreases the risk for Type 2 
diabetes [20]. Also, moderate alcohol consumption (1-3 drinks per day) has been linked 
in improved insulin sensitivity and reduced circulating insulin levels, a sign of insulin 
resistance [20]. For many people, however, changing these environmental factors is not 
enough. For those patients who require additional treatment a variety of pharmacological 
options for Type 2 diabetes are available.  
According to data from the CDC in 2003, 11.6 million adults with diabetes were 
taking some type of medication for their diabetes with 9.5 million taking some form of 
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oral medication [21]. There are a wide variety of drugs for the treatment of Type 2 
diabetes which are distinguished as: sulphonylureas, meglitinides, α-glucosidase 
inhibitors, biguanidines, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, 
and glucagon-like peptide 1 (GLP1) antagonists [22, 23]. Sulphonylureas and 
meglitinides induce increased insulin production by closing ATP-sensitive (KATP) 
potassium channels in the pancreatic β-cells [24, 25]. The secretion of insulin occurs in 
response in the β-cells’ attempt to re-equilibrate osmotic pressure and transmembrane 
potential within the cells. Drugs which are α-glucosidase inhibitors reduce the enzymatic 
cleavage of complex carbohydrates into lower molecular weight absorbable sugars at the 
brush border of the intestines, thus slowing the absorption of carbohydrates and reducing 
postprandial hyperglycemia [26]. The pharmacodynamic mode of action of biguanidines 
is not exactly understood, however they have been shown to reduce gluconeogenesis in 
the liver, reducing the level of endogenous glucose in the blood [27]. Thiazolidinediones 
induce a hypoglycemic effect by binding peroxisome proliferators-activated receptors, or 
PPARs, which stimulates carbohydrate metabolism [28]. This reduces the insulin 
resistance of the affected tissues, although the side effects of bone mass loss and 
increased heart problems may cause this type of drug to be discontinued in regular use 
[29, 30]. Both DPP-4 inhibitor and GLP1 antagonist drugs have similar modes of action: 
to increase the biological effect of GLP1, which increases the release of insulin as well as 
inhibits glucagon release [31, 32].  
While these drugs are currently in clinical use, they all rely on some level of 
endogenous insulin production and sensitivity to be effective. Recently, there has been a 
swelling of support for increased administration of insulin to treat Type 2 diabetes and 
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currently as many as 30 % of Type 2 diabetics take insulin [33]. The American Diabetes 
Association has stated that intensive insulin therapy in addition to comprehensive self-
management training should become the standard therapy in all diabetic patients [34]. 
There have also been several reviews which suggest implementing insulin therapy for 
Type 2 diabetics much earlier than is currently practiced [35-37], especially because 
those with Type 2 diabetes generally have difficulty maintaining healthy HbA1c levels 
with only diet, exercise, oral hypoglycemic agents, or combinations of the three.  
 
2.2. Insulin 
The discovery of insulin is one of the greatest discoveries of modern medical 
history. Its effect on the livelihood of individuals with diabetes was profound even in its 
earliest stages. It is by far the most studied protein in history and it was the first ever 
naturally produced protein to have its amino acid sequence determined, a feat for which 
Frederick Sanger won the Nobel Prize in Chemistry in 1958 [38-44]. Currently insulin 
and insulin analogs are available as several different polypeptide sequences with varying 
biological effects. Details of the history, physiology, use and delivery of insulin are given 
in the following sections.  
 
2.2.1. History of Insulin 
In 1869, a German medical student name Paul Langerhans discovered islet cells 
in the pancreas which are now know as the islet of Langerhans [45]. Unfortunately he 
died before their significance was discovered. Two fellow German researchers, Joseph 
von Mering and Oscar Minkowski, discovered that the removal of the islet of Langerhans 
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from dogs induced a diabetic state [46]. It was this discovery that led researchers to 
believe that these cells were involved in more that just digestion and damage to them 
induced diabetes. This work preceded that of  Frederick Banting and his assistant Charles 
Best from the University of Toronto, however the pair is generally credited for the 
discovery of insulin [45, 47, 48]. Their work was performed in the lab of John Macleod 
and it was Macleod and Banting who received the Nobel Prize in 1923 for the discovery 
of insulin. Originally called “isletin”, it was first harvested from the pancreas of dogs and 
when given to de-pancreatized dogs caused a glucose lowering effect [3]. The group had 
significant difficulty purifying the pancreatic extract and enlisted the help of biochemist 
James Collip. With his help, the purification improved vastly and human trials produced 
immediate improvement in diabetic patients. The first patient to receive the extracts was 
Leonard Thompson at the age of 14 [45, 47]. He went on to live a relatively healthy life 
until dying of pneumonia at age 27. The demand for insulin quickly surpassed the ability 
of the group to produce it and Eli Lilly Pharmaceutical Company was contracted to 
produce insulin [49]. Another researcher from the University of Copenhagen, August 
Krogh, met with the research group at the University of Toronto in 1922. Upon his return 
to Denmark he founded the Nordisk Insulin Company [49]. The two companies are still 
the leading producers of insulin world wide. 
The production of insulin has progressed greatly since its discovery. It 
originally depended largely on purification from extract produced in animals. In 1936, the 
first extended action version of insulin was produced as protamine insulin by Nordisk 
[49]. Ten years later, Nordisk produced Neutral Protamine Hagedorn (NPH) insulin 
which had a more extended effect and higher stability than protamine insulin [48]. In 
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1953, another type of long-acting insulin, Lente® insulin, was produced [49]. This 
formulation stabilized the hexameric form of insulin with the addition of zinc, reducing 
its rate of absorption into the bloodstream [49]. The variety of insulin products 
formulated for longer modes of action allowed diabetics greater flexibility in the self-
administration of the medicines. The major breakthrough occurred in 1982 when Eli Lilly 
& Company produced the first synthetic insulin, made by recombinant DNA modification 
of E. coli, under the brand name Humilin® [50]. Because it did not require the use of 
animal extracts, vastly more quantities of the protein could be produced. Once the ability 
to produce insulin by synthetic means became common practice, it opened up a world of 
opportunity for new types of insulin to be produced with small variations in the amino 
acid sequence. These insulin variations are known as insulin analogs.  
 
2.2.2. Insulin Analogs 
Insulin analogs are synthetically produced variations of insulin which have a 
different in amino acid sequence then that of native human insulin. A diagram of the 
amino acid sequence of native human insulin is given in Figure 2.1. In all cases, insulin 
analogs vary from this structure. When delivered subcutaneously, normal insulin has an 
onset of action of 30-60 minutes, a peak at 2.5-5 hours, and a duration of effect of 5-8 
hours [51]. This profile of action poorly matches that of endogenous insulin secretion. 
Similar to formulator insulin variations, insulin analogs change the timing and duration 
for the effect of insulin and they are separated accordingly.  
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2.2.2.1 Fast-Acting Insulin Analogs 
Fast-acting insulin analogs were designed to give more freedom to the diabetic 
patient such that they could administer insulin near mealtime. The first insulin analog to 
become available to clinicians was insulin lispro [52]. In insulin lispro the two residues in 
the B-chain of insulin are substituted for one another, the lysine at position 29 and the 
proline at position 28. The change causes a reduced tendency of the analog to self-
associate into dimmers by 200-300 times [53]. Because insulin is only biologically active 
as a monomer, the hypoglycemic effect of insulin lispro is more rapid than that of native 
insulin which exhibits some self-associative behavior. Another fast-acting insulin analog 
is insulin aspart in which the B-chain of insulin is again modified. In insulin aspart the 
proline at position 28 is replaced with an aspartic acid residue [52, 54]. The effect is 
similar to that of insulin lispro in terms of reducing self-association of the protein. Both 
analogs induce hypoglycemic behavior more rapidly than normal human insulin when 
administered subcutaneously and are often used in clinical practice [52-54]. Insulin 
glulisine is a third fast-acting insulin analog and has only been available as a 
pharmaceutical drug since 2004 [55]. Insulin glulisine has substitutions in the B-chain 
where glutamate replaces lysine at the 29th position and lysine replaces asparagine at the 
3rd position. This analog exhibits improved monomer stability, reduced self-association, 
and an increased rate of absorption while maintaining an unaltered affinity for the insulin 
receptor [56]. In improving both monomer stability and absorption rate, insulin glilusine 
appears to have the most rapid rate of onset and clearance with similar biological activity 
of these three fast-acting insulin analogs [57]. 
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Another early insulin analog, and on that did not succeed, is insulin Asp(B10). 
This insulin analog replaced a histidine with an aspartic acid at the B10 residue of insulin. 
It exhibited twice the absorption rate of regular insulin making it valuable as a potential 
drug. However, the clinical failure was due to the modified tertiary structure of the 
protein, which affected its pharmacodynamic behavior [52]. It exhibited an increased 
affinity for the insulin receptor in cells, inducing increased mitogenic activity and a dose-
dependent increase in the incidence of adenocarcinomas in laboratory animals [58]. 
 
2.2.2.2. Long-Acting Insulin Analogs 
Long-acting insulin analogs were originally designed due to the need of 
diabetics to maintain a healthy blood glucose levels throughout the night. Regular human 
insulin has a duration of roughly four hours, so a diabetic patient using it had to interrupt 
their sleep in order to maintain normal glucose levels [49]. While the extended action of 
insulin formulations such as NPH and Lente® insulin improved the treatment of diabetes, 
their action did not mimic the natural secretion of basal insulin levels, and these 
formulations are now considered to be intermediate-acting insulin formulations. Only 
within the last 5 years have long-acting insulin analogs become available in the U.S. 
Aventis began selling insulin glargine in the United States in 2003 under the brand name 
Lantus® [48]. Insulin glargine varies from native human insulin by the replacement of an 
asparagine at position A21 with glycine and the addition of two arginine residues at the 
C-terminus of the B-chain [51].  These changes cause the isoelectric point to shift from 
5.4 for native insulin to 6.7 for insulin glargine. The effect of this shift is that the 
solubility of insulin glargine is greatly reduced at neutral pH levels. The formulation of 
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Lantus® is mixed in a solution with a pH of approximately 4.0, under which conditions 
the insulin glargine is completely solubilized. Upon injection and a return to neutral pH 
levels, insulin glargine precipitates causing a subcutaneous insulin depot. The analog is 
then slowly released from this depot, giving insulin glargine its long-acting effect [51, 
54]. Another long-acting insulin analog is insulin detemir, which was approved by the 
FDA for use in the United States in 2006 under the brand name Levemir® [59, 60]. 
Insulin detemir is altered from native insulin by the removal of the threonine B30 residue 
and attachment of a C14 fatty acid chain (myristic acid) onto the lysine B29 [59]. Insulin 
detemir has a protracted effect because it forms hexamers and reversibly binds to 
albumin, causing it to be slowly absorbed into the bloodstream from the sight of injection 
[48, 60].  In a head-to-head comparison of these two long-acting insulin analogs, insulin 
glargine had a longer hypoglycemic effect than insulin detemir and the median time for 
the end of action was 24 hours for insulin glargine versus 17.5 hours for insulin detemir 
[61]. Nonetheless, both analogs have significantly better pharmacokinetic and 
pharmacodynamic effects than traditional long-acting insulin formulations such as NPH 
[51, 59]. 
 
2.2.2.3. Immunogenicity and Mitogenicity 
When changing the molecular structure of insulin from its natural state, it is 
vital to consider the potential for alterations in the immune response to those changes. As 
described previously, one early insulin analog with modification at the aspartic acid at the 
B10 residue was intended to provide a fast-acting insulin effect, however the change also 
caused a significant increase in the mitogenicity of that analog [58]. In a study performed 
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by Kurtzhals et. al. [62] the binding of several insulin analogs to the insulin growth factor 
1 (IGF-1) receptor and the insulin receptor was measured and correlated to the metabolic 
and mitogenic potential. When compared to regular insulin, insulin lispro, insulin aspart, 
and insulin glargine had minimal change in binding to the insulin receptor, whereas 
insulin detemir was significantly lower. Each of the analogs had similar or increased 
dissociation rates from the insulin receptor, which is correlated to a reduced mitogenic 
behavior [63]. Thus, these results are important to determine primarily the metabolic 
potential of the individual analogs. Another important consideration for insulin analogs is 
that increased binding to the IGF-1 receptor has been attributed to increased mitogenicity 
and growth of human mammary epithelial cells [64]. The binding to IGF-1 of the insulin 
aspart was similar to that of native human insulin. Insulin lispro and insulin glargine had 
1.5 and 6.5 fold increases in binding affinity to the IGF-1 receptor, respectively, whereas 
insulin detemir was more than 5 times lower than regular insulin. While this result 
implies that insulin glargine would induce a significantly greater mitogenic response, 
when tested in cultured human skeletal muscle cells no additional mitogenic effects were 
seen with insulin glargine [65]. The impacts of these findings are unclear and the long 
term effects of insulin analogs will continue to be an important point for their use in the 
treatment of diabetes.  
 
2.3. Biological Role of Insulin 
Insulin is composed of two polypeptide chains and has a molecular weight of 
5808 Da. The two chains are connected to one another by two disulfide bonds as seen in 
Figure 2.1. It is produced and secreted from the β-cells in the islets of Langerhans in the 
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pancreas. The primary role of insulin is to facilitate the transport of glucose from the 
bloodstream to cells in the body. This is only the simplified explanation of the biological 
role of insulin, though, and a more detailed description follows. 
 
2.3.1. Insulin Production and Secretion 
In a non-diabetic person, insulin is first synthesized in the β-cells of the 
pancreas as a 110 amino acid chain called preproinsulin [1]. This polypeptide includes 
every amino acid of regular insulin. Upon translocation through the endoplasmic 
reticulum, a 24-peptide sequence at the N-terminus of preproinsulin is cleaved and 
protein becomes proinsulin. The tertiary structure of proinsulin folds and forms the three 
disulfide bonds which are present in insulin [1]. Proinsulin is then converted to insulin 
upon secretion at which point four basic amino acids are individually removed and a 21 
peptide sequence known as the connector peptide, or C-peptide, is cleaved and secreted 
along with insulin [1]. A small amount of proinsulin is also released, but primarily 
equimolar quantities of insulin and C-peptide are released into the bloodstream.  
The secretion of insulin is a carefully regulated process which is meant to 
maintain healthy levels of blood glucose in the bloodstream during periods of both 
feeding and fasting. The principal mediator of insulin secretion is the plasma 
concentration of glucose. Insulin release is also promoted by gastrointestinal inhibitory 
peptide (GIP), glucagon-like peptide 1 (GLP-1), gastrin, secretin, cholecystokinin, 
vasoactive intestinal peptide, gastrin-releasing peptide, and enteroglucagon [47]. Glucose 
stimulates insulin secretion by depolarizing the β-cells of the pancreas.  It enters the β-
cells facilitated by the GLUT2 transporter. Because GLUT2 is a passive transporter, the 
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rate of glucose uptake into β-cells is directly dependent on its plasma concentration. The 
same transporter is responsible for glucose release from hepatocytes when glycogen is 
broken down in the liver [66]. The glucose is phosphorylated and the increase in ATP 
inhibits the ATP-sensitive K+ channel. In response, the voltage sensitive Ca2+ ion channel 
is opened to repolarize the cells. The increased intracellular concentration of Ca2+ induces 
insulin secretion [47].  
 
2.3.2. Effect of Insulin 
Plasma insulin concentrations are often measured in biological units. One 
international unit (IU) of insulin is 6 nmol, equivalent to 34.8 μg [67]. For healthy adults, 
insulin concentrations vary between 5-15 μIU/ml (30-90 pmol/l) for basal levels and 60-
90 μIU/ml (360-540 pmol/l) for postprandial levels [34]. Circulating insulin binds to the 
insulin receptor, which is present in many tissues but primarily in liver, muscle, and 
adipose tissues. Signals from the insulin receptor initiate the translocation of intracellular 
vesicles rich with GLUT4 transporters which fuse with the plasma membrane of the cells 
and are exposed to the extracellular surface [47]. Similarly to the GLUT2 transporter, 
GLUT4 increases the diffusion of glucose into the cytosol of cells. Upon translocation, 
glucose can be used by the cells for energy via glycolysis or stored as glycogen or 
triglycerides [3]. In times of fasting, the breakdown of the glycogen and triglyceride 
stores maintains cell energy levels. 
In addition to glucose transport, insulin has several other significant roles in 
metabolic homeostasis. It stimulates the uptake of amino acids and synthesis of proteins 
in muscle tissues, regulates gene transcription, increases glycogen and fatty acid 
 19
synthesis, and inhibits the breakdown of glycogen, fat, and protein for energy [47]. 
Another very important process influenced by insulin is the hepatic production and 
release of glucose. In times of fasting, when plasma insulin concentrations are low, the 
liver synthesizes glucose from its glycogen stores through glycogenolysis and from other 
non-sugar substrates such as pyruvate through gluconeogenesis [3]. When insulin levels 
increase after a meal, these processes are reversed. A diagram of these processes and their 
relation to insulin is shown in Figure 2.2. Increased levels of insulin in the hepatic portal 
vein, which carries blood from the digestive tract to the liver, effectively eliminate 
endogenous glucose production by the liver [68]. Insulin action in the liver has a rapid 
onset and corresponding rapid recovery. Diabetics, however, often exhibit an insulin 
resistance in the liver and do not stop producing glucose, even when circulating levels are 
above normal. This leads to the primary identifying feature of diabetes: a chronic and 
substantial elevation of the circulating blood glucose concentration [1]. 
  
2.3.2. Insulin Regulation 
The half life of insulin in the bloodstream is relatively short with a t1/2 of only 5-
6 minutes [47]. Its degradation occurs primarily in liver, kidney, and muscle tissues [69]. 
Roughly 50 % of insulin which is released into the portal vein, the route of insulin 
secretion, is destroyed by the liver and never reaches general circulation. Insulin is also 
removed from the plasma through renal clearance. Some insulin degradation occurs in 
peripheral tissues following internalization into the cells, but this accounts for only a 
small amount of insulin elimination. The natural process of regulating insulin 
concentration is important because when injected subcutaneously, insulin first enters the 
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general circulation, thus having its initial effect on peripheral tissues. This does not 
mimic the natural process of insulin secretion and the biological effect is different. The 
implications of these changes are discussed below.  
 
2.4. Insulin Therapy 
There are several different treatments for diabetes, depending on the type and 
severity of the disease. Insulin therapy remains as the most rigorous and physiological 
treatment for diabetes and is the only option for patients suffering from Type 1 diabetes. 
Current insulin administration is parenteral, generally performed by subcutaneous 
injection or continuous subcutaneous insulin infusion (CSII). While insulin production 
and insulin analog technology have made parenteral delivery much more effective, this 
method of treatment has remained relatively unchanged since insulin was first used 
clinically in 1923 [70]. Several studies have been performed examining the effectiveness 
of current insulin therapy, the most important of which was the Diabetes Control and 
Complications Trial (DCCT), which is discussed in the following section [71-74]. For 
each study, the majority of patients exhibited improved but still non-physiological 
glycemic control. This is largely due to the subcutaneous pathway that insulin is 
delivered. When injected, insulin enters the circulatory system from the periphery and has 
the largest effect on muscle and adipose tissues. These tissues have a delayed onset to 
insulin and a sustained duration of action [75]. In healthy individuals, insulin produced 
by the β-cells in the pancreas is released into the portal circulation in response to the 
presence of glucose and its effect on peripheral tissues occurs after first pass hepatic 
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clearance [47]. Nonetheless, insulin therapy based on subcutaneous insulin delivery 
remains the primary means of treatment for diabetes. 
Insulin therapy by multiple daily injections (MDI) attempts to mimic the natural 
production of insulin in response to blood glucose levels. Prior to insulin analogs, normal 
insulin or insulin formulations were used, but they poorly matched normal glucose 
control [76]. Since they have become available more recently, MDI now uses a 
combination of long and short acting insulin analogs. Short-acting analogs are taken 
immediately prior to meals and can more closely mimic the postprandial spikes in insulin 
concentration in response to increase blood glucose levels. Long-acting analogs are taken 
each morning to mimic the basal insulin release from the pancreas. As an alternative to 
intermittent dosing CSII can be used and is currently used by as many as 20% of Type 1 
diabetics [76-80]. Similar to the MDI approach, CSII requires constant monitoring of 
blood glucose levels. It uses a pump to deliver insulin subcutaneously from a small 
solution reservoir to a small port, generally into the patient’s abdomen. Because it can 
deliver insulin slowly or in a bolus, it more closely resembles the pharmacokinetics of 
natural insulin production. However, because the insulin is still delivered subcutaneously, 
the mode of action in the body is not physiological.  
 
2.5. The Diabetes Control and Complications Trial 
In 1993 a monumental clinical study was concluded based on data collected for 
10 years on the effects and treatments of Type 1 diabetes [74]. The study was conducted 
by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and 
incorporated findings from 1,441 volunteers from 29 medical centers in the U.S. and 
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Canada. At the time, the body of work collected from the 10-year study was the most 
comprehensive on diabetes performed to date and its findings drastically altered the 
clinical treatment of Type 1 diabetes. The DCCT generated several critical results based 
on the comparison between conventional insulin therapy consisting of one or two daily 
injections of regular insulin to intensive insulin therapy requiring smaller, more frequent 
injections, at least three per day, and frequent monitoring of glucose levels. These results 
indicated that significant reductions in retinopathy, nephropathy, and neuropathy in 
patients with Type 1 diabetes were observed in patients who used intensive insulin 
therapy versus that of conventional therapy [74, 76]. While the results were widely 
regarded as elementary to many people, the thorough and incontrovertible evidence of the 
study altered the mindset for physicians, educators, and insurance companies that by 
aggressively treating diabetes, the chronic long-term effects can be greatly reduced in 
addition to the acute effects.  
 
2.6. Alternative Insulin Delivery Methods 
In general, all peptide and protein drugs must be administered subcutaneously 
or intravenously. Since the discovery of insulin, many non-invasive methods of insulin 
delivery have been thoroughly investigated. However, to date, no feasible alternative 
modes of delivery have achieved enough success to replace subcutaneous administration. 
Current delivery by injection is taxing on the patient who must continuously monitor 
their blood glucose and self-administer insulin. Non-compliance to this dosing regimen is 
common. Also, because it is challenging, treatment with insulin is often seen as a last 
resort for Type 2 diabetics even though data suggests that early prescription is beneficial 
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[34]. The investigation of alternative routes for insulin delivery is driven by the desire to 
simplify the administration of insulin and potentially reduce the levels of non-compliance 
currently seen with insulin therapy. The greatest challenge for all approaches to oral 
insulin delivery is achieving a high bioavailability when compared with subcutaneous 
delivery. The following discussion reviews the different delivery routes considered for 
delivery and their benefits and drawbacks. 
 
2.6.1. Pulmonary Delivery of Insulin 
Pulmonary insulin has significant potential as an alternative route for insulin 
delivery. The rate of insulin absorption and onset, however, makes it only applicable to 
replace postprandial insulin requirements not basal insulin requirements. Nonetheless, the 
potential to replace all but a single basal insulin injection have made it very appealing to 
diabetic patients and studies have shown that many would prefer pulmonary insulin to 
injection [81, 82]. To date, it is the most successful alternative to subcutaneous injection 
for insulin is the pulmonary route, and in 2006, an inhaled dry powder insulin 
formulation from Nektar and Pfizer was approved by the FDA for the treatment of 
diabetes under the name Exubera® [82, 83].  
The delivery of insulin to the lungs has several distinct advantages. The lungs 
have a large surface area (100-140 m2), have a relatively high permeability, and are 
highly vascular [84, 85]. Each of these factors contributes significantly to the rapid 
absorption of insulin from the lungs. Insulin can be absorbed efficiently without the 
addition of absorption enhancers or enzyme inhibitors, so side effects generally 
associated with such treatments are non-existent. For the greatest amount of absorption 
 24
into the bloodstream, inhaled insulin should reach the alveolar or deep lung areas. The 
optimal particle size is 1.5-2.5 μm; larger particles are largely deposited in the upper 
lungs, while smaller particles are mostly exhaled [82, 84, 85]. The pharmacokinetics of 
this delivery system shows a more rapid onset of insulin action and more rapid clearance 
than that of subcutaneous injection of regular human insulin. With the addition of a small 
amount of chelating agent or absorption enhancer the rate of absorbance and onset is 
faster even than current short-acting insulin analogs, though toxicity is a concern [86]. 
When absorbed from the lungs, insulin enters the circulation bypassing the first-pass 
hepatic clearance, giving it a slightly longer pharmacodynamic profile than endogenous 
insulin [87]. 
The major drawbacks to pulmonary insulin delivery are that the bioavailability 
is still only 9-22 % that of subcutaneously injected insulin and that improper inhalation 
technique can cause large variations in administration, causing potentially dangerous 
administration levels [84]. Because of the lower bioavailability, large quantities of insulin 
are required when compared to injection, making inhalable insulin significantly more 
expensive. Due to these drawbacks, heavy criticism of current products for pulmonary 
insulin delivery has been experienced and new products are being developed. In fact, as 
of October 17, 2007, Pfizer announced that it will no longer produce or market Exubera 
because it failed to gain acceptance among patients and physicians [88]. Efforts still 
continue in the development of an improved type of inhalable insulin delivery system. 
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2.6.2. Transdermal Delivery of Insulin 
Transdermal insulin delivery would allow similar insulin absorption as current 
subcutaneous delivery without the pain associated with injection. The major challenges 
are that the skin is relatively impermeable to large, hydrophilic molecules such as insulin 
due primarily to the intracellular lipid layer of the stratum corneum (SC) [85]. One 
approach to transdermal delivery is through the use of micro or nanoneedles. They can 
permeate the skin in the same fashion as a standard needle with very low levels of 
associated pain. The direct disruption of the SC greatly increases the permeability of 
insulin and has been reported to have negligible pain [89]. A significant hypoglycemic 
response has been seen in tests with diabetic hairless rats in which the microneedles were 
inserted to puncture the skin and then an insulin solution was applied at the site of 
treatment [90]. A second approach to transdermal delivery is iontophoresis which uses 
electrical charge to disrupt the SC and propel insulin into the skin. This technique 
generally required pretreatment of the delivery site and still only delivered very little 
insulin into the bloodstream [85, 91]. Low-frequency ultrasound, or sonophoresis, has 
also been explored as a method for transdermal insulin delivery. This technique uses 
sound waves to disrupt the SC thus increasing the permeability of insulin. In a study 
performed with pigs, a drop in blood glucose was evident; however it required 60 
minutes of treatment, an unreasonably long time for a patient to try to use this method 
[92]. Photomechanical waves or laser-generated stress has also been investigated for 
transdermal insulin delivery [93]. A hypoglycemic response was exhibited in tests with 
diabetic rats, but similarly to sonophoretic approaches, it required a long time to dose. 
Each technique for transdermal insulin delivery has had only limited success. All 
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approaches require extended exposure to topical insulin solutions and the variability in 
dosing and occurrence of skin irritation make it unlikely that transdermal insulin delivery 
will become standard practice. 
 
2.6.3. Nasal Delivery of Insulin 
The delivery of insulin to the nasal cavity has been investigated due to its 
convenience, large absorptive surface, and high vascularity [94]. Drug absorption by the 
nasal mucosa is generally rapid and directly enters the systemic circulation, bypassing the 
first-pass hepatic clearance. However the low absorption of insulin, mucociliary 
clearance, and presence of proteolytic enzymes make this approach challenging [85, 94]. 
The major approaches to nasal delivery use permeation enhancers, mucoadhesive 
materials, enzyme inhibitors, or a combination of these methods. Permeation enhancers 
have a tendency to damage the nasal mucosa and may present a significant challenge for 
any long-term use of nasally delivered insulin. Nonetheless, studies in which insulin 
formulations were delivered along with didecanoly-L-α-phosphatidylcholine (DDPC), an 
absorption enhancer, had bioavailabilities of 8.3-13.2 % compared to intravenous 
injection [95]. The hypoglycemic effect in these studies had lower variability and faster 
onset than subcutaneous injection. Another popular approach to nasal insulin delivery is 
through the use of chitosan, a positively charged polysaccharide [96-98]. The study by 
Dyer et. al. used chitosan in solution, as a dry powder, and grafted to nanoparticles to 
deliver insulin. Each approach succeeded in producing a hypoglycemic effect in vivo, 
with the highest bioavailability of 17.0 % for insulin delivered with chitosan powder [98].  
Enzyme inhibitors have also been investigated for nasal insulin delivery, though the 
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degree of absorption of insulin does not exceed that of other absorption enhancing 
methods [94].  Nasal insulin delivery has significant promise; but higher bioavailability 
levels are necessary for it to succeed in becoming a standard practice.  
 
2.6.4. Other Delivery Routes for Insulin 
Other routes of delivery for insulin that have been investigated are rectal, 
ocular, vaginal, buccal, and oral. A number of studies evaluating rectal insulin delivery 
systems have been performed due to the lack of enzymatic degradation. However, low 
absorption (4-10 %) persists and it does not seem to represent an acceptable alternative 
route [85]. Both ocular [99] and vaginal [100] insulin delivery similarly have achieved 
only limited absorption levels and severe local adverse reactions indicate that they offer 
little opportunity for insulin delivery [85, 101]. Buccal or sublingual delivery systems 
have generated a significant amount of attention due to the ease of administration, low 
proteolytic activity, and high vascularization [102-105]. The challenges include the thick, 
multilayered structure of the buccal and sublingual mucosa and the constant flow of 
saliva. A Canadian company specializing in buccal drug delivery, Generex, currently 
produces Oral-Lyn™ which delivers insulin via the buccal route [106]. The product is 
only intended for those who have pre-diabetes or Type 2 diabetes as an insulin therapy to 
slow the progression of the disease. For each of these routes investigated designs use 
nanoparticles, permeation enhancers, mucoadhesion, or a combination of these to 
overcome these barriers. Of the routes discussed in this section, oral insulin delivery has 
generated the largest body of research. A review of oral insulin will be discussed later in 
this chapter. 
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2.6.5. Artificial Pancreas 
One other major area of research for insulin delivery is the development of an 
artificial pancreas. The premise behind the artificial pancreas is that it would be able to 
dose insulin to a patient in response to endogenous glucose levels. The first approach is to 
have an insulin pump connected to a real-time glucose monitoring system in a feedback 
control loop. The benefit of this design is that it can use pump technology currently being 
used for CSII therapy. Alternatively, implantable pumps have been investigated for future 
designs [107]. The largest challenge to this type of artificial pancreas is maintaining 
rapid, accurate, and consistent monitoring of the endogenous blood glucose levels which 
can provide continuous or near-continuous glucose determination [107, 108]. Most 
glucose monitors use optical or electrochemical changes induced by glucose in the 
presence of immobilized glucose oxidase as the means of detection [108-112]. 
Traditional implanted sensor designs require direct contact with whole blood using 
intravenous catheters. Newer monitoring techniques use interstitial fluid to detect 
glucose. These sensors generally require multiple daily calibrations using whole blood 
from finger prick samples due to potential changes in enzymatic activity in the sensor and 
build up of tissue from a foreign body response [107, 113]. An alternative glucose 
monitor uses the optical characteristics of a synthetic hydrogel receptor called 
phenylboronic acid [114]. The measurement of glucose is based on the swelling of the 
hydrogel material in response to glucose concentration which imparts a change in the 
modulation of light diffracted through the material. The benefit of this material is that the 
binding of glucose is completely reversible (as opposed to glucose oxidase which 
converts glucose to gluconic acid) and the sensitivity is generally maintained longer than 
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traditional glucose monitors. However, the measurements are highly sensitive to 
interstitial pH and the rate of change is rather slow compared to conventional glucose 
meters.  
A second type of artificial pancreas is referred to as a bio-hybrid or bio-artificial 
pancreas. This design utilizes natural pancreatic β-cells which are encapsulated in some 
sort of semi-permeable membrane such that glucose and insulin can diffuse through it, 
but the cells are protected from immunological detection and destruction [115-117]. The 
premise is that following implantation the natural function of pancreatic β-cells has a 
more intricate action than what is currently modeled by artificial means. Direct 
transplantation of pancreatic tissue requires the use of immune suppressive drugs for the 
remaining lifetime of the individual. Immunoisolation of the cells would remove this 
treatment, the major drawback of current pancreas transplant methods. Bio-hybrid 
pancreas designs can be either intravascular or extravascular. Intravascular systems are 
grafted directly to a blood vessel similar to the way that natural tissues may be. However, 
decreased insulin secretion with time due to cell death and surgical risk of implantation 
and extrication are major drawbacks [117]. Extravascular systems avoid the risks of 
intravascular because they are implanted into tissue without direct access to the 
bloodstream. However, there is a delay in the response of the cells due to diffusive 
restrictions of glucose in the interstitial fluids. Also, over time the fibrous encapsulation 
of the implant further reduces the flux of glucose and pancreatic secretions into and out 
of the bio-hybrid pancreas [115, 117]. 
A third approach utilizes glucose-responsive biomaterials as the platform of the 
artificial pancreas. In most cases the biomaterial responds to glucose by biodegradation 
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[118], by swelling changes [119, 120], competitive binding of glucose for glycosylated 
insulin on concanavalin A [121, 122], or by sol-gel transition [123] such that insulin 
trapped in the material is released. These approaches are promising when performed in 
vitro, but their in vivo applications have had limited success. The designs are inherently 
limited for long-term use because they cannot be replenished. Only intermittent 
administration of a bioresorbable, glucose-responsive material could be applicable for 
this approach, though significant challenges still exist. 
 
2.7. Oral Insulin Delivery and its Challenges  
The growth of the development of protein and peptide drugs has increased 
significantly in recent years due to the ability to create them using recombinant 
techniques. In general these drugs require parenteral delivery, as is currently the case for 
insulin. Oral delivery is perhaps the most enticing alternative to parenteral delivery due to 
the general acceptance of orally administered drugs. However, oral delivery arguably 
represents the most challenging route of insulin delivery and it continues to be the “holy 
grail” of insulin therapy. These challenges are due primarily to proteolytic degradation 
and limited absorption of insulin in the gastrointestinal tract. Overcoming each of these 
enzymatic and physical barriers has been investigated using a multitude of approaches. 
The following sections will discuss the pathway, potential benefits, challenges, and 
approaches related to the oral delivery of insulin. 
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2.7.1. Physiology of the Gastrointestinal Tract 
In order to design an approach to orally delivered insulin, the physiology of the 
gastrointestinal (GI) tract should be well understood. A drawing of the entire human GI 
tract can be seen in Figure 2.3. Sequentially, the GI tract includes the mouth, esophagus, 
stomach, duodenum, jejunum, ileum, colon, rectum, and anus. It exists primarily to 
transport water and nutrients into the body. Most nutrients required for human are present 
as solid material composed of macromolecules, which makes them nearly impermeable 
across cell membranes. Therefore, the function of the GI tract is to physically and 
chemically break down food in a process generically referred to as digestion [124]. The 
absorption of digested material from the GI tract varies widely and is dependent on the 
physiochemical characteristics of the material. The rate of nutrient absorption can vary 
greatly depending on whether it is hydrophobic or hydrophilic, or if it has a specific 
mechanism for facilitated or active transport into the bloodstream [125]. The efficiency 
of nutrient absorption is quite high and there is significant excess capacity of surface area 
and enzymatic activity in the GI tract. This was crucial for the survival of humans in 
ancient times when food may not have been plentiful. However, in modern times, 
especially in developed nations, this efficient nutrient absorption may contribute 
significantly to high rates of obesity [125]. The GI tract also serves an important role for 
excretion from the body. This is important not only for non-absorbable foods, but also for 
materials which cannot exit the body through alternative means. The critical 
characteristic of the GI tract is the defensive structure of the tissues. The GI tract exists as 
a single tube with an inner (apical) surface that is in continuity with the outside of the 
body, making it a potential pathway for toxic or invading molecules, viruses, or bacteria 
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can enter the body [126]. For drug delivery, this easy access to the GI tract is exploited to 
administer therapeutic molecules. However, the physiology of the GI tract has several 
layers of resistance to uncontrolled absorption that persist throughout its entirety such as: 
polarized epithelial cells joined by tight junctions, a mucosal boundary layer, and the 
largest concentration of lymphocytes in the body.  
The epithelial cells in the GI tract, collectively referred to as the epithelium, 
form a single cell thick membrane which represents the first layer encountered by an 
ingested material. It is at this layer that the where the distinction is made for absorption or 
rejection of nutrients. The epithelial cells are polarized, distinguishing between the apical 
and basolateral (blood-side) membranes. The surface area of the epithelium is greatly 
increased by the structure of these cells as seen in Figure 2.4. They are folded into many 
finger-like projections of the tissue called villi [125]. The villi are approximately 0.6-1.0 
mm in length, 0.2-0.4 mm wide, and spaced approximately 15-40 μm apart [127]. This 
makes the surface of the GI tract appear to be rough and folded. On a smaller scale, the 
apical surface of these individual epithelial cells is covered with projections of the cell 
membrane called microvilli which are approximately 1-2 μm long, 50-100 nm wide, and 
spaced 18-24 nm apart [124, 128].  
Beneath the epithelium, on the basolateral side, is the basement membrane 
which lies atop the lamina propria and muscularis mucosa. The lamina propria contains 
the majority of the nerve endings and blood vessels and the muscularis mucosa controls 
villi movement. These layers, along with the epithelium, make up what is referred to as 
the mucosa [124, 125]. Beneath the mucosa is a grouping of nervous tissue meant to 
carry information to and from the GI tract called the submucosa. Beneath the submucosa 
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are several layers of muscle tissue oriented either around or along the GI tract which is 
meant to either squeeze the diameter of the GI tube or propel its contents along, 
depending on the muscular orientation.  
Movement of the GI is controlled by the enteric nervous system based on the 
signals generated by chemoreceptors and mechanoreceptors and is not voluntarily 
controlled [126]. There are several different types of digestive tube movements present in 
the GI tract. Peristalsis is the forward propulsion of lumenal contents by a controlled 
wave of muscle contractions [124, 126]. Segmentation is a type of tube movement in 
which a simultaneous contraction of non-adjacent areas of the digestive tube occurs. This 
generally happens exclusively in the small intestines and the purpose is to mix the chyme 
with digestive enzymes as it is moved back and forth [124]. Mass peristalsis is the 
simultaneous contraction of several adjacent segments of the intestine and is usually 
associated with bowel movements. All motor movements of the contents of the GI tract 
are lubricated by a large amount of mucus and saliva. Glandular secretion of saliva 
produces between 1 and 1.5 liters each day [126]. Further down the GI tract, mucosal 
secretions cover the epithelium. The composition of the secretions changes from the 
stomach to the small intestines and the large intestines, but in all cases it is composed of a 
mixture of water, glycoproteins, and digestive enzymes. This mucus serves several 
purposes: it lubricates the lining of the GI tract, prevents the majority of diffusion of 
macromolecules to the surface of the epithelium prior to digestion, provides a 
concentrated digestive surface near sites of absorption, and provides a concentrated 
boundary layer for the transport of signals to and from the epithelium [126]. 
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2.7.1.1. Absorption in the Gastrointestinal Tract 
For many years research on the transport of proteins and peptides from the GI 
tract was focused exclusively on short peptide chains of one, two, or three amino acids. 
More recently, however, whole proteins have been found to enter intestinal epithelial 
cells. Absorption of proteins and peptides across the epithelial layer of the GI tract can 
take place through several different pathways as seen in Figure 2.5: paracellular transport, 
active transport, receptor-mediated endocytosis, diffusive transport, and pinocytosis 
[129]. Paracellular transport is the movement of a drug or solute between adjacent cells to 
cross the epithelial membrane. Passive transcellular transport is the movement of a drug 
or solute through a cell or cell membrane from the apical to basolateral side, or vice 
versa. Receptor-mediated transport is a process through which a ligand is internalized 
from the extracellular fluids by endocytosis following its binding to a receptor on the cell 
surface [130]. Pinocytosis is a type of non-specific endocytosis in which extracellular 
fluids and incorporated solutes are internalized by pinching off a section of the plasma 
membrane [131, 132]. The resulting endosome then fuses with lysosomes and the 
contents are degraded by intracellular enzymes. Pinocytosis is non-specific in that it not 
initiated by a ligand from the extracellular fluids. It represents a very small amount of 
protein absorption in intestinal epithelial cells and will not be discussed in detail [129]. 
Paracellular transport of proteins between epithelial cells occurs most often 
when the intercellular connection between the two cells is disrupted. The strong 
connection between epithelial cells is stabilized by a number of different types of bonds 
as is seen in Figure 2.6. Tight junctions (TJ), or zona occludens, are the closest 
intercellular bond to the apical surface of epithelial cells and are the first barrier to 
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paracellular transport. They are also the least permeable membrane for paracellular 
transport of proteins because they generally exclude all solutes with a molecular radius 
greater than 11-15 Å [133, 134]. Tight junctions are formed by several transmembrane 
proteins which connect intercellularly to one another between cells in the extracellular 
space. Their intracellular domains bind to the actin filaments which constitute the cell 
cytoskeleton. The transmembrane proteins present in TJs are occludin, claudin, and 
junctional adhesion molecule (JAM) [135, 136]. The concentration of highly hydrophobic 
residues in the extracellular regions of these bonds suggests that hydrophobic interactions 
stabilize the tight junctions [137].  Intracellular proteins associated with TJs are Zona 
Occludens (ZO) 1, 2, and 3, which are part of the family of proteins referred to as the 
Membrane Associated Guanine Kinases (MAGUK). The ZO proteins bind to the 
transmembrane proteins through the interaction of a PDZ binding motif which is present 
on both proteins [138]. Both ZO-2 and ZO-3 form dimers with ZO-1, but not with each 
other. The ZO-1 and ZO-2 proteins are the F-actin binding proteins which allow them to 
connect the intercellular bonds formed by transmembrane proteins with the actin-based 
cytoskeleton of the epithelial cells [138, 139]. Paracellular transport through the TJ is the 
primary pathway for the absorption of hydrophilic proteins from the GI tract which have 
very low absorption and lack active transport mechanisms, such as insulin. In recent 
years, modulation of the TJs has been investigated with some success as will be discussed 
later.  
Other intercellular bonds exist between epithelial cells which can inhibit 
paracellular transport. Adherins junctions (AJ), located just beneath the TJs, form 
intercellular bonds in a circumferential pattern around epithelial cells [137, 138]. Their 
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function is not as clear as that of TJs because the cell membranes are 15-20 nm apart at 
AJs, compared to only 1.1-1.5 nm at TJs. They likely contribute to strengthening TJs and 
may serve a regulatory function for coordinating multicellular processes [138]. 
Desmosomes represent another form of intercellular bonds in epithelial cells. They are 
located medially on the intercellular surfaces between adjacent epithelial cells and their 
purpose is to strengthen the physical connection between adjacent cells providing 
mechanical strength to tissues [140]. They do so without preventing the passage of 
solutes through the extracellular space between epithelial cells. Desomosomes are formed 
by the desmosome filament complex, which forms a fibrous connection of desmosomal 
adhesion molecules connected to the cytoskeletal filaments of the cells. One other 
connection between cells in the epithelium is gap junctions. They are small, reinforced 
openings connecting the cytosol of adjacent cells which provide a portal to electrical 
current, ions, and small molecules [141]. They are primarily used for signaling and are 
neither a barrier to paracellular transport nor a source of significant physical strength 
between epithelial cells. Adherins junctions, desmosomes, and gap junctions are all 
important to the function and maintenance of the epithelial cell layer, but because the 
most restricting feature for protein transport is the tight junctions, paracellular drug 
delivery research generally focuses on tight junctions and their temporary modification. 
Active transport is a mechanism of transepithelial transport coupled to an 
exergonic process such as the movement of ions or breakdown of ATP. In the epithelial 
cells of the intestine actively transport molecules include amino acids, oligopeptides, bile 
acids, water-soluble vitamins, monocarboxylic acids, phosphate, and carbohydrates 
[142]. Each of these materials exists as part of the lumen of the intestine due to the 
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digestion of food or from exocrine releases of the pancreas, liver, or endothelium. The 
transporters have potential to provide a pathway for peptide and protein absorption across 
the epithelial wall of the intestine [143-148]. One oligopeptide transporter in particular, 
PepT1, has been thoroughly investigated and due to its broad substrate specificity and 
high level of expression in the small intestine. It has been utilized to increase the 
intestinal absorption of peptide-mimetic molecules such as β-lactam antibiotics, 
angiotensin converting enzyme inhibitors, the antiviral drug valacyclovir, and the 
anticancer drug bestatin [149]. Transporters for bile acids are also of great interest 
because they are the largest molecules which are actively transported from the GI tract 
and represent transport capacities of as high as 10-20 g/day with > 95 % absorption 
efficiency [133, 150-153]. While results of conjugated drug transfer across epithelial cells 
using either PepT1 or bile acid transporters is promising, most of the work has been 
performed with very short peptide chains only. Transport of large peptides and proteins 
through these channels will most likely not be possible.  
Receptor-mediated endocytosis is an active transport mechanism in which a 
ligand initiates the endocytosis of the ligand-receptor complex along with a small amount 
of extracellular fluids [66]. The endocytotic vesicle is generally much smaller than that of 
pinocytotic vesicles, but protein uptake by receptor-mediated endocytosis occurs much 
more frequently and represents roughly 100-1000 times that of non-specific pinocytosis 
[154]. The internalized vesicle, also referred to as an endosome, follows a number of 
different pathways depending on the signal cascade initiated by the active receptor [155]. 
The endosome can fuse with intracellular lysosomes and be degraded by enzymes. 
Alternatively, the ligand can be disassociated from its receptor in the endosome such that 
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the receptor returns to the cell surface and the ligand is not degraded but incorporated by 
the cell. A third outcome is that the ligand is unidirectionally transported across the 
epithelial cell through a process called transcytosis. This is of particular interest for the 
purposes of protein delivery by oral delivery because it has the potential to actively 
transport large molecules across the epithelium of the intestine in tact and specifically 
release it into the bloodstream. Only a few receptor-mediated transcellular transport 
mechanisms have been identified [155]. Immunoglobulins in the neonatal intestine 
actively transport maternal antibodies through this method. More applicable for drug 
delivery are vitamin B12, transferrin, dietary lectins, viruses, various bacteria, and certain 
toxins which enter epithelial cells via receptor-mediated endocytosis. In the case of 
viruses, bacteria, and toxins, the end result of internalization is infection and apoptosis of 
the cell. Vitamin B12, transferrin, and dietary lectins, however, all are absorbed by the 
epithelium to be utilized by the body. Macromolecular and even nanoparticle drug 
delivery via receptor-mediated endocytosis is a promising route for oral protein delivery 
and significant research efforts have been made to investigate its potential [155-158]. 
Another means of absorption is the GI tract is via diffusive transport. There are 
two theoretical pathways of diffusive transport across epithelial cells: paracellular and 
transcellular. Diffusive paracellular transport is the movement of a molecule along the 
lipid bilayer of the cell membrane. In order to follow this path, the diffusing solute must 
be highly lipophilic and roughly 4 Å in size, so this is generally not considered a 
reasonable pathway for proteins [129]. Transcellular diffusive transport is the movement 
of a molecule through and across the cell membrane. The factors that influence 
transcellular diffusive transport are molecule size and lipophilicity. It generally occurs 
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when a highly hydrophobic regions of a protein or attached fatty acid chain is inserted 
into the cell membrane. Macromolecular proteins such as insulin, however, are generally 
too large to easily diffuse across cell membranes and this route of absorption has a low 
efficiency.  
 
2.7.1.2. Pathway for Orally Delivered Proteins 
The pathway for ingested food and the physiological response of the GI tract is 
well understood and characterized. After food is chewed and swallowed, it enters the 
stomach from the esophagus through one of two sphincters on either side of the stomach. 
The lower esophageal sphincter is at the union of the esophagus and the stomach. It is 
this muscle that keeps acidic stomach contents from flowing backward into the 
esophagus; the failure of it to do so is what leads to acid reflux. Once in the stomach, 
orally administered food or drugs are mixed and churned with gastric fluids until gastric 
emptying.  
Gastric emptying occurs in a controlled fashion according to signals received by 
the stomach. Under normal circumstances, the stomach empties about 200 kcal/h into the 
small intestines, although this can vary significantly [125]. Therefore, the stomach can 
serve the function of a mixer or homogenizer as well as a reservoir for yet to be digested 
foods. The emptying of the stomach is controlled by the pyloric sphincter, or pylorus 
[159]. This is a muscle which surrounds the opening from the stomach to the duodenum. 
When the stomach is filled with a meal, the muscle is contracted, restricting the flow of 
particles greater than 1-2 mm in size to the duodenum [125]. The residence time of an 
orally delivered meal depends directly on the amount and type of food detected by the 
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stomach. A larger meal of solid food requires significantly longer than a liquid or highly 
hydrated foods. The signals for gastric emptying are believed to be related to the 5-
hydroxytryptamine (5-HT) receptors where 5-HT1 receptors reduce it and 5-HT3 
receptors induce it [160]. There are some drugs and chemicals which affect gastric 
emptying. Nitric oxide has been reported to induce gastric emptying while certain opioids 
reduce it [125]. Synthetic drugs can also induce gastric emptying and are sometimes 
utilized when GI motility is reduced such as occurs in gastroparesis [161]. The transfer of 
chyme from the stomach to the intestine is critical for GI function because the majority of 
absorption of nutrients and water occurs in the small intestine. 
The small intestine is referred as such due to its relatively smaller diameter 
when compared to the large intestine. In reality, however, the small intestine has a much 
larger surface area due to its length (~20 ft.) compared to the large intestine (~4.5 ft.) and 
the high concentration of folds in the tissue [128]. It also plays a much larger role in 
nutrient absorption that the large intestine [125]. The small intestine is separated into 
three sections: duodenum, jejunum, and ileum, descending from the stomach to the large 
intestine. The duodenum is the most proximal region of the small intestine and also the 
shortest at roughly 12 inches long. The remainder of the small intestine is composed of 
the jejunum (~8 ft.) and ileum (~12 ft.) [128]. Because the small intestine represents the 
majority of absorption of the GI tract, it is critical for orally administered drugs. It is also 
the location of the majority of potential active and receptor-mediated transport pathways 
for oral protein delivery. The ileum contains a unique concentration of lymphatic tissues 
concentrated into groups called Peyer’s patches. Lymphocytes lie directly beneath a 
follicle-associated epithelium (FAE) that is different than the majority of the epithelial 
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membrane in the small intestine. The FAE contains a high amount of M-cells which 
express only minimal mucosal covering, limited microvilli, and increased lumenal 
absorption by pinocytosis [162-164]. These cells offer unique absorption pathways for 
oral vaccine delivery as well as proteins which can exist in the lymphatic system. 
Because of the vast array and high level of absorption mechanisms, most research 
investigating the oral delivery of proteins focuses on improving the absorption of 
therapeutic proteins in the small intestine.  
The large intestine, also referred to as the colon, is the final length of the GI 
tract prior to excretion. Its general purpose is to serve as a storage area for waste material 
and absorption of excess water [125]. Several drug delivery techniques target colonic 
uptake of proteins because of the significant reduction in proteolytic enzymes or to treat 
local diseases such as irritable bowel syndrome, Crohn’s disease, colorectal cancer, 
amebiasis, and ulcerative colitis [165-168]. Other benefits of colonic protein delivery are 
the increased response of the epithelium to absorption enhancers, increased lymphoid 
tissue for delivery of antibodies to the immune system, and sustained residence time for 
absorption. The colon is inhabited by 400-500 types of  bacterial microflora which have a 
total live population of 1014 organisms compared to 1013 eukaryotic cells in the human 
body [168]. The digestive behavior of these bacteria contributes to the metabolism and 
absorption of carbohydrates and proteins. One of the primary digestion products in the 
large intestines are short chain fatty acids, which are readily absorbed by transporters in 
the large intestine. Other peptide and amino acid transporters are also present in the large 
intestine such as the PepT1 transporter.  
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2.7.2. Rationale for Oral Insulin Delivery 
Oral insulin delivery would provide an easy and convenient method of delivery 
and likely improve patient compliance, a large issue for current parenteral delivery [85]. 
With an easy administration method, doctors and patients would likely be more inclined 
to start insulin therapy before the disease becomes advanced or use it for Type 2 diabetics 
who often resist starting intensive insulin therapy [37]. Detractors cite low 
bioavailability, potentially high cost and high protein requirement, potential side effects, 
and poor reproducibility as significant difficulties which make oral insulin delivery 
unlikely for the future [169]. So what are the potential benefits for oral insulin delivery 
which justify its continued and growing research?  
When nutrients are absorbed from the gastrointestinal tract, primarily in the 
small intestines, they immediately enter the portal circulation and undergo first-hepatic 
pass metabolism [126]. For many drugs, bypassing first-pass metabolism is desired to 
reduce the clearance of the drug from the bloodstream. For insulin, however, this delivery 
route would mimic the physiological pathway of endogenous insulin produced from the 
pancreas [68]. In the postprandial state, the interaction of insulin and glucose with the 
liver is the most critical for maintaining euglycemic levels [170]. First of all, in a healthy 
individual, the majority of ingested glucose is taken up by splanchnic tissue (the liver) 
[68]. In order to do so, insulin must be bound to the surface receptors in the liver. 
Following oral delivery, the first potential site for insulin action is in the liver. Second, 
the presence of insulin at these receptors is critical to initiate glycogenesis and glycolysis, 
and inhibit gluconeogenesis and glycogenolysis. Each of these processes are important 
steps in maintaining healthy circulating glucose concentrations. A schematic of the action 
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of insulin on glucose can be seen in Figure 2.2. Third, the sensitivity of the liver is much 
greater than that of muscle tissues and it responds very quickly to the presence of insulin 
[68]. Thus, a more rapid hypoglycemic effect is seen from insulin in the portal vein than 
from insulin delivered parenterally reducing the risk of postprandial hyperglycemia. 
Fourth, the residence time of insulin on insulin receptors in the liver is significantly less 
than that of muscle and adipose tissues [171]. This reduces the risk of sustained 
hypoglycemia induced by extended hyperinsulinemic reactivity in peripheral tissues. 
Finally, one of the most common problem among Type 2 diabetics is insulin resistance in 
the liver [172]. These patients require high insulin levels (~100 μU/ml) in the portal 
circulation to affect hepatic glucose production [173]. Insulin concentrations at this level 
can be safely utilized by the liver, but if circulating plasma insulin concentrations were 
that high in the general circulation, as would be the case for subcutaneously delivered 
insulin, a severe hypoglycemic episode would occur. Therefore, orally administered 
insulin has the potential to treat both Type 1 and Type 2 diabetics in a pharmacokinetic 
route similar to that of native endogenous insulin production. 
 
2.7.3. Enzymatic Barrier 
For oral delivery of traditional small molecule pharmaceuticals, the largest 
concern is digestion in the stomach and bond cleavage due to very low pH. For 
macromolecules, the presence of lipases and peptidases represent serious challenges in 
maintaining the integrity of the molecular structure. Proteins delivered orally are digested 
into smaller peptides or individual amino acids prior to their absorption primarily by 
pepsin in the stomach and pancreatic enzymes such as trypsin, α-chymotrypsin, and 
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elastase in the small intestine [174]. In the stomach, the primary materials secreted by the 
stomach are mucus, hydrochloric acid (HCl), intrinsic factor, pepsinogen, and a group of 
regulatory peptides which stimulate gastric secretion upon the ingestion of food [125, 
126, 175]. The mixture of food and secretions is referred to as chyme. The most 
important of these gastric secretions to orally delivered drugs are HCl and pepsinogen, 
which is enzymatically converted to pepsin in the presence of HCl. The low pH of the 
stomach can induce the hydrolytic breakdown of several different ingested species. 
Additionally pepsin, which is most active at low pH levels and deactivated at pH > 5, can 
cleave the amino bond of phenylalanine, tryptophane, and tyrosine amino acid residues 
[66]. Further digestion of food and drugs takes place further down the GI tract as 
described in the following section.  
 
2.7.3.1. Lumenal Enzymes from Pancreatic and Hepatic Secretion 
Pancreatic and hepatic secretions into the lumen of the intestine are critical for 
natural digestion. Understanding their role in metabolism is critical to design an oral 
delivery method for insulin. While endocrine secretions of the pancreas are important for 
controlling circulating insulin and glucose levels, exocrine pancreatic secretions into the 
GI tract are critical for normal digestive function. This secretion into the duodenum 
imparts an array of changes on the chyme of the small intestine. The most important of 
these secreted substances for digestion are the pancreatic proteases including: trypsin, α-
chymotrypsin, elastase, carboxypeptidase A, and carboxypeptidase B [174]. Also 
generated and release from the pancreas are amylolytic enzymes, lipases, nucleases, and 
secretory modulating species [125].  
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The release of pancreatic and hepatic secretions into the duodenum is controlled 
by the hepatopancreatic sphincter. The stimulus for the opening and closing of the port is 
dependent on a hormone called cholecystokinin, or CCK [124, 126]. Cholecysokinin is 
synthesized and stored in the endocrine cells in the duodenum. It triggers contracting the 
gall bladder, relaxing of the hepatopancreatic sphincter, and slow gastric motility and 
emptying, thus giving duodenal enzymes more time to digest the chyme before sending it 
lower in the intestine [125]. The release of CCK is modulated according to competitive 
binding of the CCK-releasing peptide (CCK-RP) which is normally present in the lumen 
of the duodenum. In the absence of food, trypsin digests CCK-RP rapidly and it cannot 
initiate CCK release. When food is present, however, CCK-RP is not digested as rapidly, 
it triggers CCK release which in turn initiates exocrine hepatic and pancreatic secretion 
into the duodenum.  
Pancreatic enzymes represent a very large challenge to any macromolecular 
drug entering the duodenum in the chyme from the stomach. Without some way of 
resisting degradation, the digestion of proteins, starches, or nucleotides is likely to take 
place to a large degree due to these enzymes. One other important chemical which is 
released by pancreatic secretion is bicarbonate ion. Ductular cells line the ducts of the 
pancreas which concentrate its exocrine products. When they are stimulated they also 
transport bicarbonate ions into the pancreatic juice as it passes along the ducts, making it 
highly alkaline. When combined with the acidic chyme exiting the stomach upon 
secretion, it has a neutralizing effect which occurs over a very short length of the GI tract 
[125]. The neutralization of the chyme is critical because the activity of the five major 
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pancreatic peptidases is optimal at pH ~ 7 [174]. This rapid pH change can also be 
exploited for potential routes of oral protein delivery.  
Concomitant to the release of pancreatic material is the bile produced from the 
liver. Bile is a lipid rich solution produced by the liver which facilitates the elimination of 
hydrophobic substrates from the body as well as promoting the absorption of long-chain 
fatty acids and fat soluble vitamins [125]. It consists of micelles formed from the 
combination of bile salts with phosphatidylcholine. The two main hepatic ducts transport 
bile the liver to the gall bladder which serves as a reservoir until it can be secreted [124]. 
The common bile duct then connects the gall bladder to the pancreatic duct at the outlet 
to the duodenum at the hepatopancreatic sphincter. The effect of bile on peptide and 
protein drug delivery is primarily for the absorption of lipophilic materials such as lipids 
and lipoproteins. Their presence is important for the delivery of hydrophobic proteins and 
peptide drugs but is not applicable to insulin. Transport mechanisms of bile salts can also 
be utilized for protein drug delivery.  
 
2.7.3.2. The Brush-Border Membrane and Intracellular Enzymes 
The second important groups of enzymes that are part of the enzymatic barrier 
to oral insulin delivery are those which are located along the absorptive pathway of orally 
delivered drugs. These enzymes are located in three sub-cellular locations in epithelial 
cells: the brush-border, the cytoplasm, and the lysosomes [176]. The primary degradation 
of proteins in sub-cellular regions of epithelial cells occurs on their apical surface by 
brush-border enzymes. The brush-border is the surface of composed of the microvilli of 
epithelial cells covered with the mucous/glycocalyx layer which consists of mucous, 
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glycoproteins, and enzymes. In all pathways for protein absorption following oral 
administration the drug must pass through the brush-border region of the epithelium. 
Brush-border enzymes include amino-exopeptidases, carboxy-exopeptidases, and 
endopeptidases which cleave bonds and the N-terminus, C-terminus, and at particular 
internal sites of amino acid chains, respectively [174, 176]. They range in specificity, but 
in concert they have the potential to degrade whole proteins to short peptide sequences. 
They tend to be anchored to the cell membrane by a hydrophobic anchor with a large 
extracellular hydrophilic component responsible for the enzymatic activity of the protein 
[176]. Not all orally delivered proteins are equally susceptible to hydrolysis by brush-
border enzymes, however. Insulin, for instance, exhibits very limited degradation after 24 
hours of exposure to brush-border enzymes [177]. The presence of proline in the amino 
acid sequence may be critical to the digestion of proteins by brush-border enzymes in the 
intestines. Several dietary proteins contain large amounts of proline and their efficient 
degradation is important for healthy GI function [176].  
Cytoplasmic enzymes tend to be ubiquitous in nature and are intended to 
hydrolyze di- and tripeptides which are absorbed by surface transporters [178]. These 
enzymes are not active toward large peptide molecules and do not present a significant 
source of protein degradation. Lysosomal proteases mostly consist of cathepsins, exo- 
and endopeptidases which can degrade proteins upon their incorporation into the 
lysosome [179]. 
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2.7.4. Physical Barrier 
The second major challenge to oral insulin delivery is the physical barrier of the 
intestinal epithelium. A thick mucous/glycocalyx layer covers the lumenal side of the 
intestines which serves several functions to GI function. Water can account for up to 95 
% of the weight of this layer with the remainder being composed of glycoproteins, 
proteoglycans, glycolipids, and inorganic salts [180, 181]. The mucous and glycocalyx 
layers have thicknesses of 5-10 and 0.1-0.5 μm, respectively. One function is to protect 
the apical epithelial surface from microbial and foreign materials. The 
mucous/glycocalyx layer also lubricates the lumen of the intestine to facilitate the 
movement of chyme. For protein drug delivery, the most important feature of the 
mucous/glycocalyx layers is the reduced access to the surface of epithelial cells. The 
diffusion rate of large molecules greater than approximately 5000 Da is severely reduced 
by the mucous and glycocalyx [133]. Larger molecules may not be effectively degraded 
by brush-border enzymes and this layer keeps the majority of them in the lumen where 
they can be degraded by pancreatic peptidases. On the other hand, the mucous layer on 
epithelial cells can also be exploited for drug delivery as will be discussed later. Another 
important feature of the physical barrier is the impermeability of the epithelial layer to 
protein transport. The reason for this feature is defensive in nature to exclude other 
macromolecular species such as bacteria and viruses which may enter the GI tract. The 
structure of the epithelial layer is discussed previously in this chapter. Overcoming the 
physical barrier is an important factor for oral insulin delivery.  
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2.8. Approaches for Oral Insulin Delivery 
Researchers have investigated a plethora of methods in attempts to deliver 
insulin orally. Generally the techniques attempt to address one or both the enzymatic 
barrier and the physical barrier of the GI tract. Common approaches to overcome the 
enzymatic barrier include enzyme inhibitors [174, 182, 183], prodrug strategies [133, 
184, 185], and protein encapsulation [186-188]. Approaches for overcoming the physical 
barrier include carrier-mediated uptake [144, 189-191], receptor-mediated transcytosis 
[132, 142, 192], and permeation enhancement [134, 137, 193]. Often times, efforts to 
modify the absorption of the protein drugs through enzymatic or physical modification 
are coupled with polymeric delivery vehicles which improve the targeting of these 
techniques. Each approach has various degrees of success; however none have been able 
to create high levels of bioactivity to make oral protein delivery a reality. The following 
is a brief review of methods and results achieved in attempts to deliver insulin and other 
proteins orally. 
 
2.8.1. Enzyme Inhibitors 
Inhibiting the action of enzymes greatly reduces the loss of proteins in the 
gastric and intestinal environments. There are two main considerations for enzyme 
inhibition. First, the multitude of enzymes in the lumen, brush-border, and intracellular 
environments make a single approach difficult. Second, by altering the proteolytic 
activity of the GI tract, natural digestive processes are modified which may induce 
significant side effects. The enzymatic barrier for the oral absorption of individual 
proteins varies from one to another because certain enzymes may or may not readily 
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degrade them. The enzymes of the GI tract are well characterized, so a systematic 
evaluation of the degradation of each therapeutic protein can be performed in vitro and in 
vivo [183]. Discovery of the individual enzymatic barrier for a single protein allows for 
the use of specialized protein inhibitors which are intended to only disrupt the activity of 
particular enzymes. Examples of enzyme inhibitors include pepsinostreptin, aprotinin, 
chymastatin, elastatinal, EDTA, chitosan-EDTA, soybean or basic pancreatic trypsin 
inhibitor, amastatin, puromycin, bestatin, phosphinic acid dipeptide analogues, and 
enterostatin [133, 183, 194, 195]. Often enzyme inhibitors are co-administered or 
maintained in close proximity to the protein to be delivered. In a study performed by 
Plate et. al., a delivery system including pancreatic and soybean trypsin inhibitor 
immobilized into polymers was able to maintain high insulin retention levels in the 
presence of trypsin, α-chymotrypsin, and elastase [196]. Another approach utilized citric 
acid and aminopeptidase inhibitor as protease inhibitors release concomitantly with a 
model peptide drug [174]. A similar design used aprotinin as the enzyme inhibitor [194]. 
Other approaches to use enzyme inhibitors do so by covalently attaching them to the 
protein thus using a combination of enzyme inhibition and prodrug strategies to address 
the enzyme barrier [197-199]. 
 
2.8.2. Permeation Enhancers 
With the exception of proteins that are transported across the epithelial cell 
membrane by active or receptor-mediated transport, hydrophilic proteins generally must 
be absorbed through paracellular pathways. Several small peptide drugs are believed to 
be absorbed by this route including octreotide, vasopressin analogue desmopressin, and 
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thyrotropin releasing hormone [200]. Most proteins, however, are too large and too 
hydrophilic to be readily absorbed through the TJ of epithelial cells. Paracellular 
transport can be increased in the intestine through the use of permeation or absorption 
enhancing materials. Generally, these chemicals disrupt the TJ of the epithelial cell layer 
which constitutes the largest barrier to passive paracellular drug absorption [193]. Three 
primary mechanisms have been identified to increase transport through the TJ of 
epithelial layers: membrane perturbation by interaction with membrane lipids or proteins, 
decreasing the non-protein thiol content in the membrane, and complexation of 
extracellular Ca2+ ions which facilitate TJ formation [133]. A wide variety of intestinal 
absorption enhancers have been investigated including bile salts, dimethyl-β-
cyclodextrin, chitosan, hydrochloride, sodium lauryl sulfate, nafamostat, bacitracin, 
capric acid, taurodeoxycholic acid, glycyrrhizic acid, and zona occludens toxin [138, 195, 
201-204].  
Often the paracellular absorption enhancers are used in addition to enzyme 
inhibitors. Two studies by Takeyama et. al. and Komada et. al. demonstrated that 
enzymatic insulin degradation was inhibited by the absorption enhancer nafamostat [205, 
206]. Radwan et. al. demonstrated a similar result with glycyrrhizic acid [204]. A 
variation of permeation enhancers involves covalent attachment of the therapeutic 
molecule to the delivery agent through prodrug strategies. Clement et. al. demonstrated 
that the covalent attachment of a 7-9 unit length of polyethylene glycol and a hydrophilic 
hexyl alkyl chain to the lysine B29 residue of insulin to form hexyl insulin 
monoconjugate-2 (HIM2) increased the enzymatic resistance of insulin as well as 
increasing its permeation across a modeled intestinal epithelium using Caco-2 cells [207]. 
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When disrupting the TJ of intestinal epithelial cells care must be taken to only 
cause minimal and reversible loss of the TJ for increased drug transport as extended 
opening greatly increases the potential for paracellular transport of other large species 
such as viruses, bacteria, mycoplasma, and E-Coli [138, 208]. Several disease states are 
directly or partially induced by loss of TJ integrity such as Crohn’s disease, ankylosing 
spondylitis, Type 1 diabetes, and certain types of cancer [208]. Therefore, increased 
paracellular transport via tight junction modulation offers potential for increased protein 
uptake from the GI tract, but problems may be encountered in chronic diseases which 
require long-term and frequent dosing. 
 
2.8.3. Prodrug Systems 
Prodrugs are pharmacological substances which are modified from their normal 
form such that they have a different molecular structure which alters the biological action 
of the substance [133, 209]. Insulin analogs are sometimes referred to as insulin prodrugs. 
Prodrugs can also involve the covalent conjugation of a chemical species to the drug 
which directly alters its absorption, distribution, metabolism, and excretion (ADME) 
behavior [210]. Prodrugs have been investigated for use with both traditional and protein 
and peptide drugs for many parenteral and non-parenteral delivery methods [133, 211-
216]. Specifically for oral delivery of insulin, prodrug strategies generally attempt to 
address one or both the enzymatic and physical barriers of the intestinal epithelium. 
Prodrugs differ from traditional enzyme inhibitors and permeation enhancers because 
their action is immediately concentrated in close proximity to the therapeutic protein due 
to covalent modification. In some cases this modification is reversible such that upon 
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exposure to lumenal, brush-border, or intracellular enzymes the prodrug is reduced to the 
native form of the substance. Other protein prodrugs maintain the integrity of the 
covalent modification even in the presence of enzymes. Common approaches involving 
prodrugs for oral delivery include modifying the N-terminus or C-terminus of proteins 
such that they can’t be degraded by amino- or carboxypeptidases, conjugating actively 
transported compounds, reducing immunogenicity of the protein, or reducing hepatic and 
renal clearance. Two research groups have used prodrug strategies on the platelet 
fibrinogen receptor antagonist (GP IIb/IIIa) such that its absorption increased up to 20 
times that of the parent peptide [211, 217]. Prodrugs utilizing single amino acid 
modifications have exhibited increased intestinal permeability for L-α-methyldopa and 
bisphosphonates [216]. Sinha et. al. utilize a prodrug strategy to target drug delivery to 
the colon [168]. By conjugation with bonds which are specifically cleaved by the 
microflora of the large intestine, release of the biologically active substrate could be 
exclusively targeted to the colon. Not all investigated prodrug strategies have succeeded, 
however. Work by Kondo et. al. indicated that while the oral absorption of an ester-type 
prodrug GP IIb/IIIa was increased in mice, the efflux was also increased negating the 
increased absorption rates [214].  
Another type of protein prodrug involves the conjugation of polyethylene glycol 
(PEG). The conjugation of PEG, also known as PEGylation, has been shown to reduce 
enzymatic degradation, increase circulation time, and increase the solubility of 
therapeutic protein and peptide drugs [218-222]. PEGylation has been studied with many 
drugs such as: adenosine deamidase, bovine liver catalase, uricase, collagen, human 
growth hormone, nerve growth factor, trypsin, and insulin [223]. PEG is highly 
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biocompatible, has been found to be nontoxic, and is approved by the U.S. FDA for use 
in drugs, foods, and cosmetics [224]. It is a readily available polymer species and can be 
made in many different forms including single chains, branched chains, dendrimers and 
star polymers. The molecular weights are easily controlled to various lengths from only 
three or four repeat units to molecular weights well over 1 million Da. Further, the 
chemistry of the end groups for PEG is easily modified to make it reactive toward any 
one of a number of species. Because of these benefits, PEGylated proteins have garnered 
significant interest in recent research. In fact, several PEGylated proteins have been 
commercialized including granulocyte colony stimulating factor, alpha interfereon 2b and 
2a, and human growth hormone [225].  
 
2.8.4. Active Transport and Receptor-Mediated Endocytosis 
Facilitated absorption by active transport and receptor-mediated endocytotic 
pathways are other promising techniques for oral protein delivery. As discussed above, 
transmembrane transporters are primarily utilized for peptide or peptidometric drugs 
which low molecular weights (<1000 Da). Large proteins generally cannot be absorbed 
using these transporters. Therefore, absorption by receptor-mediated endocytosis is more 
often investigated to increase the absorption of perorally administered proteins [184, 226, 
227]. This mechanism usually requires conjugation of the ligand to the protein either 
directly or using a spacer to ensure endocytosis of the therapeutic substance. Many 
endocytosed materials, however, directly shuttle the endosome to digestive lysosomes for 
hydrolysis of the ligand and/or receptor [132]. Some ligands exist which specifically 
induce the unidirectional transcytosis of endocytosed material from apical to basolateral 
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membranes of intestinal epithelial cells. The two which have been most investigated are 
transferrin and cobalamin (Vitamin B12).  
Transferrin (Tf) is an iron transporting glycoprotein with a molecular weight of 
~82 kDa which is expressed primarily in the mucosa of the GI tract. It is relatively stable 
in the GI environment and digestion of the protein by α-chymotrypsin does not affect the 
biological action of the protein with its receptor [156]. It has a high binding affinity for 
iron which induces the binding of Tf with the transferrin receptor (TfR) on epithelial cells 
[155, 156]. The Tf-TfR complex is then internalized by endocytosis of a clathrin coated 
pit formed by the concentration of activated TfR receptors [66]. The endosome then is 
transcytosed to the basolateral side of the epithelial cell at which point the ligand is 
released along with iron into the bloodstream. Several groups have investigated the 
potential for oral delivery of Tf-conjugated insulin to the bloodstream [156, 192, 228, 
229]. Each study exhibited increased transport of insulin across in vitro models of the 
intestinal epithelium using Caco-2 cells. Xia et. al. [228] and Lim et. al. [156] also 
showed a hypoglycemic effect of Tf-insulin conjugated insulin following oral 
administration to streptozotocin-induced diabetic rats.  
Another receptor-mediated material investigated for oral insulin delivery is 
cobalamin, or vitamin B12 (VB12). It is a naturally occurring vitamin normally bound to 
food in the regular human diet. The process of VB12 absorption in the intestine is well 
established [175, 230-233]. Upon digestion by gastric enzymes, VB12 is released from 
food and is bound to haptocorrin (HC), a naturally secreted protein present in the saliva 
[234]. After passing the bile duct in the duodenum, HC bound to VB12 is degraded in the 
intestinal lumen by trypsin and α-chymotrypsin. Free VB12 is then bound to intrinsic 
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factor (IF), a glycoprotein weighing ~ 45 kDa which is secreted in the stomach [232, 
235]. The binding of IF to VB12 is blocked in the stomach by HC, but IF is has a much 
higher binding affinity for VB12 than degraded HC and replaces it in the duodenum by 
competitive binding. The IF-VB12 travels down to the intestinal tract with minimal loss 
where it can be actively endocytosed after binding to the intrinsic factor receptor (IFR). 
The distribution of IFR varies along the small intestine with the majority presiding in the 
lower jejunum and ileum [230, 233]. Once inside the epithelial cell, the IF-VB12 complex 
is broken down by an unknown method and VB12 is exocytosed bound to transcobalamin 
II (TC II), a basolateral exocrine receptor of epithelial cells [236]. Typically, the 
endosome formed during endocytosis is about 200 nm in diameter [155]. Such a large 
space could easily accommodate the ligand as well as any drug complex that may be 
attached to it.  
Russell-Jones et. al. have shown that it is possible to covalently attach VB12 to 
several different peptides and hormones [155, 237]. In doing so, they were able to 
significantly increase the transport of covalently attached erythropoietin and 
granuclocyte-colony stimulating factor across the intestinal epithelium of rats. One major 
limitation of utilizing VB12 as a vehicle for oral protein delivery is the natural saturability 
of the transport mechanism. Generally, the amount of VB12 in the human diet exceeds the 
biological need 4-fold [175]. Prodrugs of VB12-conjugates and the IF-VB12-conjugate 
exhibit a reduced binding affinity for IF and IFR, respectively [236]. Competitive binding 
of this material would greatly reduce the amount of VB12 prodrugs which would be 
absorbed without significant changes in diet. Also, only about 1 mg of VB12 is absorbed 
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daily, so potency of the drug is critical. Nonetheless, exploiting this pathway for oral 
protein delivery is a promising alternative to parenteral delivery. 
 
2.8.5. Lipid Based Delivery Systems 
Another commonly investigated system to overcome the barriers to oral protein 
delivery is lipid based delivery systems. These designs use lipids, bile salts, cholesterol, 
or a combination thereof to encapsulate a protein in one of several 3-dimentional 
configurations. By separating the orally delivered protein from the surrounding 
environment by a lipid layer, the enzymatic degradation is greatly reduced. The design of 
lipid based systems attempt to utilize the natural tendency of the amphiphilic molecules 
to coalesce in an organized manner. The most common designs investigated are micelles 
and liposomes (a.k.a. vesicles). These two approaches are easily distinguished from one 
another based on the organization of the lipids as seen in Figure 2.7. This organization is 
based on the hydrophobic/hydrophilic interaction of the molecules in aqueous 
environments. Micelles are spherical collections of lipids in which the hydrophilic head 
of the lipid forms the exterior shell of the sphere and the internal phase consists of the 
hydrophobic chains [66]. This system is a unilamellar design because there is only a 
single layer of lipids required to stabilize the structure. Liposomes are bilamellar 
spherical organizations of lipids in which a lipid bilayer forms around an aqueous core 
[130]. The structure of the shell of a liposome is similar to that of the lipid bilayer of cell 
membranes. In oral protein delivery, the most important distinction between the two 
designs is the contents of the center of the sphere. The center of a micelle is highly 
hydrophobic in nature whereas the center of a liposome is aqueous, thus each design can 
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only be used for the corresponding type of protein drug. Micelles are typically used for 
the delivery of hydrophobic drugs, but since most protein and peptide drugs are 
hydrophilic, they are infrequently used.  
Liposomal delivery of proteins to the GI tract has been investigated by a 
number of research groups due to their aqueous core and similarity to the cell membrane 
[238-240]. Several critical findings were similar throughout these studies. The primary 
method of absorption was found to be pinocytosis in the Peyer’s patches primarily 
located in the ileum. The Peyer’s patches have high concentrations of absorptive M-cells. 
Absorption in M-cells has been reported to increase with increasing hydrophobicity 
[241], making liposomes ideal candidates. As the size of the liposomes increased, their 
absorption efficiencies and the bioavailability of the model drug both decreased. 
Therefore, the smallest possible size liposome would be desired. However, because 
liposomes are bilamellar, they are difficult to make and stabilize in sizes as small as that 
of micelles. Two major obstacles to oral protein delivery using liposomes are their 
instability in the GI tract and their tendency to leak their contents due to the transient 
nature of the lipid bilayer [129]. The instability of liposomes is due to several factors. 
First, their structure is only maintained to a great deal in dilute aqueous environments. 
When concentrated, liposomes have a tendency to aggregate and in the process may 
become too large to be absorbed in the Peyer’s patches. Second, the outer lipid bilayer 
may be disrupted by the presence of bile salts and lipases present in the GI tract [242]. 
Even if only briefly compromised the stability of the liposome can easily be lost. A 26 % 
loss of insulin incorporated in a model liposome was exhibited when it was stored at 4 °C 
for 3 days [243]. This leakiness would make accurate dosing difficult because protein 
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content would be unknown even after only 3 days. Nonetheless, liposomes continue to be 
actively investigated [244] due to their high level of absorption from Peyer’s patches. 
Much work is also being done in a liposome-mimetic polymer particle as will be 
discussed below. 
 
2.9. Polymeric Systems for Oral Insulin Delivery 
Over the last 30 years, a very large body of work has been generated 
investigating the potential of polymeric delivery systems for oral protein delivery. These 
polymeric systems attempt to address the challenges of the GI tract through various 
methods. All techniques protect the protein from proteolytic enzymes in the GI tract 
and/or facilitate the uptake of the protein. There are a number of delivery designs using 
polymers including micro- and nanoparticles, biodegradable systems, bioadhesive 
systems, and hydrogels. Each of these designs has the common feature of entrapping or 
encapsulating the protein. The most-significant benefits to using polymers for oral protein 
delivery are their customizability, low cost, and high availability. Because the amount of 
research for all designs and proteins is so large, the discussion of polymeric oral protein 
delivery systems in this work will focus on insulin.  
 
2.9.1. Micro- and Nanoparticles 
Polymeric particles to encapsulate insulin have been designed on both the 
micrometer and nanometer scale. The structures of these particles vary significantly 
based on the incorporation mechanism used. They can be broadly separated into two 
groups: micro- or nanocapsules and micro- or nanospheres. Capsules utilize a body-and-
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shell design in which the drug is contained within the center of a particle which is 
surrounded by a polymeric shell. Spheres do not have this feature and the distribution of 
the polymers and drug can be dispersed throughout the particle. A diagram of the 
common designs of polymeric capsules and spheres is shown in Figure 2.8. The 
polymeric particle design is a good method in addressing a few barriers to oral protein 
delivery. First, by physically separating the protein from the chyme of the GI tract, 
lumenal enzymes cannot attack the protein until it is released from the particle. Second, 
the transport of a single micro- or nanoparticle to the bloodstream represents the transport 
of many individual protein molecules.  
The most common design for micro- or nanocapsules has similar structural 
designs as liposomes utilizing hydrophilic-hydrophobic-hydrophilic tri-block copolymers 
to associate into the bilamellar structure. Xiong et. al used a more complicated design 
utilizing a block copolymer with polylactic acid (PLA), polyethylene oxide (PEO), and 
polypropylene (PPO) in a PLA-PEO-PPO-PEO-PLA configuration to make polymeric 
vesicles  of 30-100 nm [245]. The reason for the complexity of the block copolymer is 
that the center PEO-PPO-PEO tri-block copolymer is a commercial ready, FDA approved 
polymer sold under the brand name Pluronic®. The stability of these nanoparticles is 
greater than that of liposomes and the size of the particles can be controlled based on the 
molecular weight of the PLA hydrophilic blocks [245]. The PLA groups slowly degrade 
by hydrolytic degradation allowing for timed release of the drug release following oral 
dosing [246]. The polymeric vesicles were loaded with insulin by forming them in an 
insulin solution. The indirect method of loading was only able to incorporate 0.08 wt% of 
available insulin into the nanoparticles [247]. When these nanoparticles were delivered to 
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diabetic mice a hypoglycemic was exhibited for 24 hours indicating that insulin could be 
protected from enzymatic attack and still be absorbed as the biologically active protein 
[247]. However, the dosing levels in this study were at least 100-fold greater than that of 
subcutaneous injection of insulin, so the bioavailability of the protein remained very low. 
Another polymeric particle design was used by Furtado et. al. to make insulin containing 
microcapsules from a block copolymer of fumaric anhydride (FA) and sebacic anhydride 
(SA) [248]. They used a phase inversion technique which is used for the entrapment of a 
hydrophilic drug within a hydrophobic polymer shell [249]. A solution of insulin was 
added in a 1:100 volume ratio to a solution of 20:80 p(FA:SA) in petroleum ether while 
stirring. The spontaneous separation of the insulin-containing aqueous phase occurred 
and was stabilized by the p(FA:SA). The microparticles formed by this technique were 
quite stable and exhibited insulin release for at least 12 days [250]. The oral dosing of 
these particles, however, resulted in only minimal hypoglycemic effect in rats and dogs 
even at dosing levels of 250 IU/kg. This low bioavailability is most likely due to the slow 
rate of insulin release, the non-specific rate of release, and the large size of the particles 
expected to be transported across the intestinal epithelium. 
Polymeric particles as micro- or nanospheres can have two different 
constructions as seen in Figure 2.8. The most common particle synthesis method 
investigated utilizes a double emulsion technique. This technique, also referred to as a 
water-in-oil-in-water or W/O/W, first encapsulates protein in an aqueous solution within 
a non-aqueous solvent containing an emulsifier. The combination generally agitated such 
that the emulsion generates individual particles of nanometer dimensions. This first 
emulsion is then added to an aqueous phase containing a second emulsifier, often 
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polyvinyl alcohol (PVA). The non-aqueous solvent then evaporates at the water/air 
interface. After separating the particles from the emulsion solution, the particles consist 
of a solid hydrophobic polymer particle which contains one or more pockets of drug 
containing emulsions. Many W/O/W particles use hydrophobic polymers which degrade 
slowly for extended release in vivo. The W/O/W technique was used by Damgé et. al. for 
the oral delivery of insulin using poly(e-caprolactone) (PCL) as the hydrophobic block 
and poly(methacrylic acid) (PMMA) as the hydrophilic block [186]. The second 
emulsion was stabilized by PVA. The oral delivery of these particles to diabetic rats 
caused a sustained hypoglycemic effect for 8 hours. Again in these particles the dosing 
was quite high (50 or 100 IU/kg) for orally dosed rats indicating that the transport of 
insulin from the GI tract to the bloodstream was inefficient. A second polymeric sphere 
design utilizes spray drying techniques to create a drug containing particle. Briefly, an 
aqueous drug solution is dispersed in a non-aqueous polymer solution. The mixture is 
heated and nebulized in a spray such that both solvents rapidly evaporate leaving only the 
drug and polymer. This approach rarely creates particles of less than 5 μm, though, so it 
is rarely used in oral insulin delivery research [187].  
Each of the two designs for micro- or nanoparticles described above is useful in 
protecting proteins from lumenal enzymes. However, the number of particles which reach 
the bloodstream is low because of the inefficient, non-specific means of transport from 
the GI tract. To address this issue, a nanoparticle design which has vitamin B12 (VB12) 
conjugated to its surface has been investigated [251]. The absorption of the nanoparticle 
was mediated by the transcytosis of VB12 from the GI tract. By utilizing a nanoparticle 
design many insulin molecules can be transferred to the bloodstream for each VB12 
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ligand-receptor transport. The in vivo results for these particles caused a hypoglycemic 
effect in diabetic rats at doses of 10 and 20 IU/kg, the lowest doses of the nanoparticle 
designs discussed, and bioavailability as high as 29.4 % compared to subcutaneous 
injection [252]. This design seems promising, however the processing of the particles and 
insulin loading is an incredibly cumbersome process and would be very difficult to scale 
up to commercial scale. 
The additional challenge of overcoming the physical barrier for absorption has 
not been adequately researched with polymer particles to give a thorough discussion on 
approaches. Many polymeric micro- or nanoparticle research contends that the uptake of 
the particles from the GI tract via pinocytosis is sufficient for drug transport. The dosing 
levels, however, had to be at least 100-fold greater than that of subcutaneous dosing. The 
approach using VB12 is restricted by the very small amount of VB12 normally absorbed 
from the GI tract, competitive binding of the receptors with native VB12, and difficult 
processing of the particles. For these reasons, investigators have spent much more time 
researching other polymeric materials for oral protein delivery. 
 
2.9.2. Biodegradable Systems 
Polymeric materials have been developed and investigated for oral protein 
delivery which has unique properties of degradation when exposed to the GI tract. The 
earliest designs of biodegradable polymers were based on degradation of the polymer 
bonds based on the amount of time it was exposed to particular environments. An 
example of a time-based biodegradable polymer is a copolymer of poly(lactic acid) 
(PLA) with poly(glycolic acid) (PGA) [253-257]. Both polymers are hydrophobic and 
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can be used to make micro- or nanoparticles using methods described previously. More 
importantly, however, is the fact that the polymer bonds of each polymer are cleaved by 
hydrolysis. The bonds for PGA are degraded more quickly than that of PLA. The use of a 
copolymer allows for customization of the rate of degradation. These particles have been 
investigated somewhat for oral protein delivery systems, but the degradation times are 
generally quite long and unless the particle is absorbed in its entirety, much of the orally 
delivered dose would be passed before the drug is released. 
Other types of investigated biodegradable polymers for oral protein delivery are 
polysaccharides. Some of the most common polysaccharides researched are dextran and 
chitosan because they are well characterized, easily customizable, plentiful, and highly 
biocompatible. Dextran is a polysaccharide derived from glucose and chitosan is 
commercially produced from chitin, a material found in the exoskeleton of shellfish. The 
degradation of the particles is based on the natural digestion of polysaccharides by the GI 
tract. Sarmento et. al. used dextran sulfate with chitosan to make biodegradable 
nanoparticles for oral insulin delivery [258]. These particles exhibited the ability to 
maintain high insulin content through the stomach and release it in the small intestine in 
the presence of amylolytic enzymes [258]. A hypoglycemic response was seen following 
oral dosing of 50 or 100 IU/kg to diabetic rats from particles loaded with just over 2 wt% 
insulin. Similar to other designs, the dosing levels were quite high, though significant 
bioavailability was observed (5.6 %) due to the extended action of the hypoglycemic 
effect versus subcutaneous injection [259]. 
Another biodegradable polymer investigated for oral protein delivery is 
Eudragit® [260]. This material is made from poly(methacrylic acid) and can be used to 
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encapsulate many different materials. Its applicability for oral protein delivery lies in the 
fact that poly(methacrylic acid) is a weak acid with a pKa of ~ 4.8 [261]. When exposed 
to pH environments below this pH, the polymer is hydrophobic and insoluble in chyme. 
When in environments above this pH, the polymer is hydrophilic and soluble due to loss 
of hydrogen on the carboxylic acid side group. This pH dependent solubility can be 
utilized with Eudragit for oral protein delivery because of the large shift in pH that occurs 
in the duodenum. A Eudragit coated particle or pill will be impermeable to water and 
lumenal enzymes in the gastric environment. Upon exposure to the near neutral 
environment of the small intestine it dissolves and releases its contents. Several research 
groups have used Eudragit as a coating for protein delivery designs to ensure that they do 
not release their contents in the stomach [201, 260, 262]. This approach is good because 
it can ensure that gastric and early pancreatic enzymes do not degrade the orally delivered 
protein, but the transport of the protein across the intestinal epithelium is not increased 
when using Eudragit alone.  
 
2.9.3. Mucoadhesive Delivery Systems 
Another technique being investigated for enhanced transepithelial transport of 
proteins is the use of mucoadhesive polymers [263-265]. These materials preferentially 
bind to the mucus layer covering the epithelial cells. This is beneficial for oral protein 
delivery because it brings the protein within close proximity to the epithelial layer that it 
needs to cross in order to be absorbed into the bloodstream. Mucoadhesive polymers 
should also increase the residence time of the delivery system in the GI tract. If the 
protein is protected from enzymatic degradation, this could improve the percentage of 
 66
drug which reaches the bloodstream by reducing loss from fecal elimination. There are 
several theories of mucoadhesion which are used to describe the interaction [181]. 
Electronic theory suggests that the cause of binding is electron transfer between adhering 
surfaces causing the formation of an electrical double layer at their interface. Wetting 
theory states that the strength of a mucoadhesive bond is related to the surface energies of 
the two interacting surfaces. Absorption theory attributes mucoadhesion to van der 
Waal’s forces. Diffusion theory describes the interdiffusion of polymer chains with the 
glycoprotiens in mucus layers. Mechanical theory attributes mucoadhesion to the surface 
tension of the water and its penetration into irregularities in the surface of the binding 
material. Fracture theory relates the adhesive strength to the forces required to separate 
the two surfaces. This theory is different because it assumes fracture at the interface, 
when in fact the loss of mucoadhesion is generally due to loss of the cohesion of the 
mucus.  
The most commonly investigated mucoadhesive polymers include chitosan, 
poly(acrylic acid), poly(methacrylic acid), sodium alginate, and cellulose derivatives 
[181]. Several studies have used only mucoadhesion to promote the absorption of 
proteins [263, 264, 266]. One approach by Whitehead et. al. utilized unidirectional 
release from mucoadhesive patches to significantly improve the bioavailability of insulin 
when place in situ in the intestine of rats [263]. Other approaches use mucoadhesive 
polymers in concert with other materials investigated for oral protein delivery to improve 
the absorption of the protein. Combination of protease inhibitors with mucoadhesive 
polymers can address parts of both the enzymatic and physical barriers [196]. 
Alternatively, some mucoadhesive polymers can provide enzyme inhibition and/or 
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permeation enhancement through indirect modulation of the immediate surroundings 
[267]. The long-term effects of mucoadhesive materials are not yet determined. Concerns 
over potential buildup in the GI tract or toxicity must be addressed in future work with 
these materials.  
 
2.10. Hydrogels for Oral Protein Delivery 
Hydrogels are defined as water-swollen, crosslinked polymer structure 
produced by the reaction of one or more monomers [268]. In comparison to other 
synthetic biomaterials, they are widely considered to most closely resemble living tissue 
because of their high water content and soft texture [269]. Their consistency can range 
from nearly liquid materials that can flow through syringes to rubbery material with the 
stiffness of tissues such as cartilage and tendons. Their crosslinks can be stabilized by 
physical, covalent, ionic, hydrogen bonds, or ligand-receptor bonds. Because of their 
unique properties, their potential use is wide reaching for biomedical and drug delivery 
applications [269-273]. 
The use of hydrogel systems for drug delivery has been investigated for over 40 
years. They can be classified based on the nature of the polymer or side chain, the nature 
of the crosslinking, the physical structure of the network, natural or synthetic sources, and 
being composed of one or more monomers. The wide variety of materials which can be 
used to make hydrogels adds to their potential use for numerous applications. They can 
absorb up to thousands of times their dry weight in water and the swelling of these 
materials is a critical feature in their applicability for delivery of hydrophilic proteins 
[272]. When a hydrogel imbibes water, it can also incorporate solutes in that water, such 
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as proteins, into the polymeric network of the gel. In doing so, the hydrogel can be used 
as a delivery vehicle for these loaded proteins. Understanding the movement of water and 
soluble drugs into and out of hydrogels is based largely on their swelling characteristics.   
The swelling behavior of a hydrogel is mostly defined by the chemical nature of 
the polymer. As a hydrogel becomes more swollen there is an increased transport of 
water and drug through the polymer network [274]. A simplified picture of a hydrogel 
can be seen in Figure 2.9. The important parameters for hydrogel swelling are based on 
the density of the crosslinks and the polymer chain length in between those crosslinks. 
This length can be expressed as the average molecular weight between crosslinks, eM , 
or as the network correlation length or mesh size, ξ. The determination of each of these 
parameters is dependent on the swelling, polymerization, ionization, and number and type 
of crosslinks within the hydrogel. An explanation for one type of hydrogel is described in 
Chapter 4 and a very good review of hydrogel theory can be found in the reference by 
Brannon-Peppas [268].  
The swelling of some hydrogels is dependent not only on the intrinsic nature of 
the polymer, but on that of the surroundings also. Environmentally responsive hydrogels 
exhibit changes in swelling characteristics based on the conditions of the surroundings. 
They can be dependent on temperature, light, pH, ionic strength, pressure, electric 
current, or the presence of particular species such as glucose [275]. Of particular interest 
to oral protein delivery are pH-sensitive hydrogels. In a similar fashion as that of 
Eudragit, pH sensitive hydrogels can restrict release of encapsulated protein in the 
stomach due to the low pH levels and allow its release in the neutral environment of the 
small and large intestines. Several different pH responsive hydrogels have been 
 69
investigated for oral protein delivery [269, 275-277]. In addition to environmentally 
responsive swelling characteristics, hydrogels can also be formulated to be 
mucoadhesive, permeation enhancers, or enzyme inhibitors [272].  
 
2.11. Poly(methacrylic acid-g-ethylene glycol) 
A copolymer of poly(methacrylic acid) (PMAA) and poly(ethylene glycol) 
(PEG) has generated much of the research on oral protein delivery using pH responsive 
hydrogels, in particular for insulin delivery. In studies of uncrosslinked PMAA and PEG 
chains in solution, the two polymers were observed to complex to one another in acidic 
media while in neutral media the complexation did not occur [278]. The interpolymer 
association was deemed to be due to the hydrogen bonding between the protonated 
carboxylic acid group of PMAA and the ether groups in PEG. The weak acid PMAA 
polymer has a pKa of ~ 4.8. In solutions at pH levels below the pKa, PMAA is 
protonated and can form these hydrogen bonds. In solutions at pH levels above the pKa, 
PMAA becomes deprotonated and negatively charged. The hydrogen bonds formed 
between PMAA and PEG are then lost. This bond formation behavior is depicted in 
Figure 2.10. These results were later confirmed by Osada and Sato who also found that 
the complexation was disrupted in the presence of methanol and ethanol [279]. Hydrogels 
consisting of the two polymers have been made using PMAA as the backbone with PEG 
grafts polymerized into the PMAA backbone. This has been done by utilizing pre-made 
PEG chains with one terminal methacrylate group which can react with the propagating 
PMAA chain. The polymers are covalently crosslinked to form an insoluble polymer 
matrix by introducing short PEG chains with methacrylate groups at each end. In doing 
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so, hydrogels of P(MAA-g-EG) can be highly swollen in the presence of water, but never 
dissociate such that the polymers are completely dissolved.  
This material forms a copolymer network with water-filled nanopores which 
exhibits reversible, pH-dependent swelling behavior [271, 280-286]. The swelling occurs 
in a similar fashion as that seen for the two non-crosslinked polymers in solution. At low 
pH levels (pH < 4) the network complexes due to hydrogen bonds between the PMAA 
backbone and the pendant PEG ether groups. This complexation causes both macroscopic 
and microscopic changes to the hydrogel. At low pH levels the network collapses, 
making the hydrogel shrink and become stiffer. The polymer mesh size is reduced when 
P(MAA-g-EG) hydrogels are in the complexed state because of the hydrogen bonds 
which form temporary crosslinks in addition to the covalent crosslinks. In this complexed 
state, the hydrogel is unable to imbibe much fluid and solute transport through the 
network is severely limited [281, 286]. Upon exposure to more neutral environments (pH 
> 6), the PMAA backbone becomes deprotonated and the hydrogen bonds between 
PMAA and PEG are lost. Additionally, the PMAA groups become negatively charged 
causing the hydrogel to swell due to ionic repulsion.  
The use of P(MAA-g-EG) hydrogel for oral insulin delivery has shown 
significant promise in vitro and in vivo [282, 285, 287-292]. A high loading efficiency 
with insulin has been observed for P(MAA-g-EG) [293, 294]. Further, when highly 
complexed, P(MAA-g-EG) has exhibited high retention of insulin in low pH solutions 
[294]. The high loading efficiency and retention was most pronounced when the ratio of 
MAA:EG monomer groups was 1:1. In this ratio the complexation of the hydrogel was 
most pronounced [281, 286]. Another important factor for P(MAA-g-EG) is that the 
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transition between swelling states occurs over a pH range that is relevant for oral drug 
delivery, between the pH of the stomach (pH ~ 1-2) and the small intestine and colon (pH 
~ 6.4-7.2) [125]. In the acidic environment of the stomach the network collapses, 
trapping insulin. In the neutral environment of the lower intestine (pH ~ 6.4-7.2) the 
network swells, allowing insulin release. In vitro studies with the hydrogel have shown 
its ability to protect insulin from enzymatic degradation in a simulated gastric 
environment [292]. When exposed to an intestinal environment, the swelling of the 
hydrogel allows insulin release [284-286, 292]. This behavior allows insulin to released 
in areas of the small intestines where enzymatic activity is significantly lower. 
Additionally, when the hydrogel is in the intestinal environment, it has exhibited the 
ability to reduce enzymatic activity of several intestinal enzymes due in large part to 
steric hindrance of local enzymes and reduction of extracellular calcium ion, which is 
necessary for lumenal peptidases [284]. By reducing the degradation of insulin in both 
the complexed and uncomplexed state, the enzymatic barrier to oral insulin delivery is 
greatly lessened by P(MAA-g-EG). The hydrogel has also exhibited mucoadhesive 
characteristics [264, 287, 295] which provides localized release of insulin at the apical 
membrane of the intestinal epithelium. Another key feature of P(MAA-g-EG) for oral 
insulin delivery is its binding of extracellular calcium ions by the hydrogel. This can 
temporarily and reversibly disrupt the tight junctions of the intestinal enterocyte, 
promoting the absorption of insulin across the epithelial layer [286]. Thus, P(MAA-g-
EG) can address both the enzymatic and the physical barriers to oral insulin delivery.  
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Figure 2.1. The amino acid sequence of native human insulin 
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Figure 2.2. Metabolic and catabolic processes involving glucose 
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Figure 2.3. Schematic of the entire human gastrointestinal tract 
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Figure 2.4. The intestinal epithelium 
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Figure 2.5. Transepithelial pathways for protein drugs from the intestinal lumen to the 
bloodstream: (1) pinocytosis (2) paracellular transport (3) receptor-mediated trancytosis 
(4) active transport (5) passive transcellular transport 
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Figure 2.6. Structure of the tight junction in epithelial cells 
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Figure 2.7. Lipid based systems for oral protein delivery: (a) micelle and (b) liposome 
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Figure 2.8. Polymer based nanoparticle designs: (a) nanosphere from spray drying, (b) 
nanosphere from double emulsion, and (c) nanocapsule 
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Figure 2.9. Simplified diagram of a drug contained within a hydrogel network indicating 
the network mesh size, ξ, and the average molecular weight between crosslinks, eM  
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Figure 2.10. Interpolymer bonds between PMAA and PEG  
 
 
 
 
 
 
 
 
 82
2.12. References 
 
1. Pickup, J.C. and G. Williams, Eds., Textbook of Diabetes. 2 ed. Vol. 1. 1997, 
Malden, MA: Blackwell Science Ltd. 
2. Clark, M., Understanding Diabetes. 2004, Hoboken, NJ: John Wiley & Sons, Ltd. 
3. Dean, L., McIntyre, J., The Genetic Landscape of Diabetes. 2004, National 
Instititue of Diabetes and Digestive and Kidney Disease. 
4. Mokdad, A.H., et al., Prevalence of obesity, diabetes, and obesity-related health 
risk factors, 2001. Jama, 2003. 289(1): p. 76-9. 
5. National diabetes fact sheet: general information and national estimates on 
diabetes in the United States, 2003. Rev. ed. 2003, Centers for Disease Control 
and Prevention, U.S. Department of Health and Human Services: Atlanta, GA. 
6. Gestational Diabetes. 2007, American Diabetes Association. 
7. Ballinger, W.F. and P.E. Lacy, Transplantation of intact pancreatic islets in rats. 
Surgery, 1972. 72(2): p. 175-86. 
8. Dafoe, D.C. and L.E. Ratner, Pancreatico-renal composite transplant: a new 
technique designed to decrease pancreatic graft thrombosis. Clin Transplant, 
2005. 19(5): p. 690-3. 
9. Sansalone, C.V., et al., Surgical complications are the main cause of pancreatic 
allograft loss in pancreas-kidney transplant recipients. Transplant Proc, 2005. 
37(6): p. 2651-3. 
10. Ricordi, C., Islet transplantation: a brave new world. Diabetes, 2003. 52(7): p. 
1595-603. 
11. Fiorina, P. and A. Secchi, Pancreatic islet cell transplant for treatment of 
diabetes. Endocrinol Metab Clin North Am, 2007. 36(4): p. 999-1013; ix. 
12. Noguchi, H., et al., Immunosuppression for islet transplantation. Acta Med 
Okayama, 2006. 60(2): p. 71-6. 
13. Harris, M.I., Summary, in Diabetes in America, 2nd Edition, M.I. Harris, Editor. 
1995, National Institutes of Health: Bethesda, MD. 
 83
14. Weber, J., Changing Epidemiology of Obesity - Implications for Diabetes, in 
Obesity and Diabetes, A.H. Barnett, Kumar, Sudesh, Editor. 2004, John Wiley & 
Sons, Ltd: Hoboken, NJ. 
15. Kenny, S.J., Aubert, R. E., Geiss, L. S., Prevalence and Incidence of Non-Insulin-
Dependent Diabetes Mellitus, in Diabetes in America, 2nd Edition, M.I. Harris, 
Editor. 1995, The National Insitutes of Health: Bethesda, MD. 
16. Astrup, A. and N. Finer, Redefining type 2 diabetes: 'diabesity' or 'obesity 
dependent diabetes mellitus'? Obes Rev, 2000. 1(2): p. 57-9. 
17. Finucane, P., Popplewell, P., Diabetes Mellitus and Impaired Glucose Regulation 
in Old Age: The Scale of the Problem, in Diabetes in Old Age, 2nd Edition, P. 
Finucane, Sinclair, A. J., Editor. 2001, John Wiley & Sons Ltd.: Hoboken, NJ. 
18. Rewers, M., Hamman, R. F., Risk Factors for Non-Insulin-Dependent Diabets 
Mellitus, in Diabetes in America, 2nd Edition, M.I. Harris, Editor. 1995, The 
National Institutes of Health: Bethesda, MD. 
19. Powers, M., American Dietetic Association Guide to Eating Right When You 
Have Diabetes. 2003, Hoboken, NJ: John Wiley & Sons, Inc. 
20. Tupper, T. and G. Gopalakrishnan, Prevention of diabetes development in those 
with the metabolic syndrome. Med Clin North Am, 2007. 91(6): p. 1091-105, viii-
ix. 
21. Number of Adults with Diabetes by Diabetes Medication Status, United States, 
1997–2003. 2002, Centers for Disease Control and Prevention. 
22. Scemons, D., Are you up-to-date on diabetes medications? Nursing, 2007. 37(7): 
p. 45-9; quiz 49-50. 
23. Umpierrez, G.E., et al., Diabetes mellitus in the Hispanic/Latino population: an 
increasing health care challenge in the United States. Am J Med Sci, 2007. 
334(4): p. 274-82. 
24. Black, C., et al., Meglitinide analogues for type 2 diabetes mellitus. Cochrane 
Database Syst Rev, 2007(2): p. CD004654. 
25. Rambiritch, V., P. Naidoo, and N. Butkow, Dose-response relationships of 
sulfonylureas: will doubling the dose double the response? South Med J, 2007. 
100(11): p. 1132-6. 
 84
26. Servey, J.T., Alpha-glucosidase inhibitors may reduce the risk of type 2 diabetes. 
Am Fam Physician, 2007. 76(3): p. 374-5. 
27. Stumvoll, M., et al., Metabolic effects of metformin in non-insulin-dependent 
diabetes mellitus. N Engl J Med, 1995. 333(9): p. 550-4. 
28. Chaudhry, J., et al., Antihyperglycemic effect of a new thiazolidinedione analogue 
and its role in ameliorating oxidative stress in alloxan-induced diabetic rats. Life 
Sci, 2007. 80(12): p. 1135-42. 
29. Schwartz, A.V. and D.E. Sellmeyer, Effect of thiazolidinediones on skeletal health 
in women with Type 2 diabetes. Expert Opin Drug Saf, 2008. 7(1): p. 69-78. 
30. Eurich, D.T., et al., Benefits and harms of antidiabetic agents in patients with 
diabetes and heart failure: systematic review. Bmj, 2007. 335(7618): p. 497. 
31. O'Farrell, A.M., et al., Pharmacokinetic and pharmacodynamic assessments of the 
dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, 
single- and multiple-dose studies in healthy subjects. Clin Ther, 2007. 29(8): p. 
1692-705. 
32. Yamazaki, K., et al., Comparison of efficacies of a dipeptidyl peptidase IV 
inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal 
tolerance tests and the effects of their combination in mice. J Pharmacol Sci, 
2007. 104(1): p. 29-38. 
33. Saudek, C.D., Rubin, Richard R., Shump, Cynthia S., Johns Hopkins Guide to 
Diabetes : For Today and Tomorrow. 1997, Baltimore, MD: The Johns Hopkins 
University Press. 
34. Nolte, M.S., Karam, John H., Pancreatic Hormones & Anitdiabetic Drugs, in 
Basic and Clinical Pharmacology, 10th Edition, B.G. Katzung, Editor. 2007, 
McGraw-Hill: New York. 
35. Haas, L.B., Optimizing insulin use in type 2 diabetes: role of basal and prandial 
insulin in long-term care facilities. J Am Med Dir Assoc, 2007. 8(8): p. 502-10. 
36. Spellman, C.W., Insulin therapy for maximal glycemic control in type 2 diabetes 
mellitus. J Am Osteopath Assoc, 2007. 107(7): p. 260-9. 
37. Campos, C., Treating the whole patient for optimal management of type 2 
diabetes: considerations for insulin therapy. South Med J, 2007. 100(8): p. 804-
11. 
 85
38. Sanger, F. and H. Tuppy, The amino-acid sequence in the phenylalanyl chain of 
insulin. I. The identification of lower peptides from partial hydrolysates. Biochem 
J, 1951. 49(4): p. 463-81. 
39. Sanger, F., E.O. Thompson, and R. Kitai, The amide groups of insulin. Biochem 
J, 1955. 59(3): p. 509-18. 
40. Sanger, F., L.F. Smith, and R. Kitai, The disulphide bridges of insulin. Biochem J, 
1954. 58(330th Meeting): p. vi-vii. 
41. Sanger, F. and E.O. Thompson, The amino-acid sequence in the glycyl chain of 
insulin. II. The investigation of peptides from enzymic hydrolysates. Biochem J, 
1953. 53(3): p. 366-74. 
42. Sanger, F. and E.O. Thompson, The amino-acid sequence in the glycyl chain of 
insulin. I. The identification of lower peptides from partial hydrolysates. Biochem 
J, 1953. 53(3): p. 353-66. 
43. Sanger, F. and E.O. Thompson, The amino-acid sequence in the glycyl chain of 
insulin. Biochem J, 1952. 52(1): p. iii. 
44. Sanger, F. and H. Tuppy, The amino-acid sequence in the phenylalanyl chain of 
insulin. 2. The investigation of peptides from enzymic hydrolysates. Biochem J, 
1951. 49(4): p. 481-90. 
45. King, K.M. and G. Rubin, A history of diabetes: from antiquity to discovering 
insulin. Br J Nurs, 2003. 12(18): p. 1091-5. 
46. Bliss, M., The Discovery of Insulin. 1982, Edinburgh, England: Paul Harris 
Publishing. 
47. Davis, S.N., Insulin, Oral Hypoglycemic Agents, and the Pharmacology of the 
Endocrine Pancreas, in Goodman and Gilman's - The Pharmacological Basis of 
Therapeutics, 11 ed., L.L. Brunton, Ed., Editor. 2006, McGraw-Hill. 
48. Heller, S., P. Kozlovski, and P. Kurtzhals, Insulin's 85th anniversary--An 
enduring medical miracle. Diabetes Res Clin Pract, 2007. 78(2): p. 149-58. 
49. King, K.M., A history of insulin: from discovery to modern alternatives. Br J 
Nurs, 2003. 12(19): p. 1137-41. 
50. Ladisch, M.R. and K.L. Kohlmann, Recombinant human insulin. Biotechnol Prog, 
1992. 8(6): p. 469-78. 
 86
51. Bell, D.S., Insulin therapy in diabetes mellitus: how can the currently available 
injectable insulins be most prudently and efficaciously utilised? Drugs, 2007. 
67(13): p. 1813-27. 
52. Vajo, Z. and W.C. Duckworth, Genetically engineered insulin analogs: diabetes 
in the new millenium. Pharmacol Rev, 2000. 52(1): p. 1-9. 
53. Brange, J. and A. Volund, Insulin analogs with improved pharmacokinetic 
profiles. Adv Drug Deliv Rev, 1999. 35(2-3): p. 307-335. 
54. Oiknine, R., M. Bernbaum, and A.D. Mooradian, A critical appraisal of the role 
of insulin analogues in the management of diabetes mellitus. Drugs, 2005. 65(3): 
p. 325-40. 
55. Aventis receives FDA approval of its rapid-acting insulin analogue Apidra. 2007, 
Aventis Pharmaceuticals Inc. 
56. Robinson, D.M. and K. Wellington, Insulin glulisine. Drugs, 2006. 66(6): p. 861-
9. 
57. Heise, T., et al., Insulin glulisine: a faster onset of action compared with insulin 
lispro. Diabetes Obes Metab, 2007. 9(5): p. 746-53. 
58. Drejer, K., The bioactivity of insulin analogues from in vitro receptor binding to 
in vivo glucose uptake. Diabetes Metab Rev, 1992. 8(3): p. 259-85. 
59. Goldman-Levine, J.D. and K.W. Lee, Insulin detemir--a new basal insulin 
analog. Ann Pharmacother, 2005. 39(3): p. 502-7. 
60. Russell-Jones, D.L., Insulin detemir and basal insulin therapy. Endocrinol Metab 
Clin North Am, 2007. 36 Suppl 1: p. 7-13. 
61. Porcellati, F., et al., Comparison of pharmacokinetics and dynamics of the long-
acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a 
double-blind, randomized, crossover study. Diabetes Care, 2007. 30(10): p. 2447-
52. 
62. Kurtzhals, P., et al., Correlations of receptor binding and metabolic and 
mitogenic potencies of insulin analogs designed for clinical use. Diabetes, 2000. 
49(6): p. 999-1005. 
 87
63. Hansen, B.F., et al., Sustained signalling from the insulin receptor after 
stimulation with insulin analogues exhibiting increased mitogenic potency. 
Biochem J, 1996. 315 ( Pt 1): p. 271-9. 
64. Slieker, L.J., et al., Modifications in the B10 and B26-30 regions of the B chain of 
human insulin alter affinity for the human IGF-I receptor more than for the 
insulin receptor. Diabetologia, 1997. 40 Suppl 2: p. S54-61. 
65. Ciaraldi, T.P., et al., Effects of the long-acting insulin analog insulin glargine on 
cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin 
Endocrinol Metab, 2001. 86(12): p. 5838-47. 
66. Nelson, D.L., Cox, M. M., Lehninger Principles of Biochemistry, 3rd Edition. 
2000, New York: Worth Publishers. 
67. Volund, A., Conversion of insulin units to SI units. Am J Clin Nutr, 1993. 58(5): 
p. 714-5. 
68. Arbit, E., The physiological rationale for oral insulin administration. Diabetes 
Technol Ther, 2004. 6(4): p. 510-7. 
69. Duckworth, W.C., R.G. Bennett, and F.G. Hamel, Insulin degradation: progress 
and potential. Endocr Rev, 1998. 19(5): p. 608-24. 
70. Bliss, M., Resurrections in Toronto: the emergence of insulin. Horm Res, 2005. 
64 Suppl 2: p. 98-102. 
71. Hayward, R.A., et al., Starting insulin therapy in patients with type 2 diabetes: 
effectiveness, complications, and resource utilization. Jama, 1997. 278(20): p. 
1663-9. 
72. Harris, M.I., et al., Racial and ethnic differences in glycemic control of adults 
with type 2 diabetes. Diabetes Care, 1999. 22(3): p. 403-8. 
73. Turner, R.C., et al., Glycemic control with diet, sulfonylurea, metformin, or 
insulin in patients with type 2 diabetes mellitus: progressive requirement for 
multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) 
Group. Jama, 1999. 281(21): p. 2005-12. 
74. DCCT, The effect of intensive treatment of diabetes on the development and 
progression of long-term complications in insulin-dependent diabetes mellitus. N 
Engl J Med, 1993. 329(14): p. 977-86. 
 88
75. Cherrington, A.D., et al., Physiological consequences of phasic insulin release in 
the normal animal. Diabetes, 2002. 51 Suppl 1: p. S103-8. 
76. Jeandidier, N. and S. Boivin, Current status and future prospects of parenteral 
insulin regimens, strategies and delivery systems for diabetes treatment. Adv 
Drug Deliv Rev, 1999. 35(2-3): p. 179-198. 
77. Norgaard, K., A nationwide study of continuous subcutaneous insulin infusion 
(CSII) in Denmark. Diabet Med, 2003. 20(4): p. 307-11. 
78. Thompson, J.S. and W.C. Duckworth, Insulin pumps and glucose regulation. 
World J Surg, 2001. 25(4): p. 523-6. 
79. White, R.D., Insulin pump therapy (continuous subcutaneous insulin infusion). 
Prim Care, 2007. 34(4): p. 845-71. 
80. Lee, S.W., R. Im, and R. Magbual, Current perspectives on the use of continuous 
subcutaneous insulin infusion in the acute care setting and overview of therapy. 
Crit Care Nurs Q, 2004. 27(2): p. 172-84. 
81. Royle, P., et al., Inhaled insulin in diabetes mellitus. Cochrane Database Syst 
Rev, 2004(3): p. CD003890. 
82. Setter, S.M., et al., Inhaled dry powder insulin for the treatment of diabetes 
mellitus. Clin Ther, 2007. 29(5): p. 795-813. 
83. Crotty, S. and S.L. Reynolds, The new insulins. Pediatr Emerg Care, 2007. 
23(12): p. 903-5; quiz 906-7. 
84. Patton, J.S., J.G. Bukar, and M.A. Eldon, Clinical pharmacokinetics and 
pharmacodynamics of inhaled insulin. Clin Pharmacokinet, 2004. 43(12): p. 781-
801. 
85. Owens, D.R., B. Zinman, and G. Bolli, Alternative routes of insulin delivery. 
Diabet Med, 2003. 20(11): p. 886-98. 
86. Hussain, A. and F. Ahsan, State of insulin self-association does not affect its 
absorption from the pulmonary route. Eur J Pharm Sci, 2005. 25(2-3): p. 289-98. 
87. Brain, J.D., Inhalation, deposition, and fate of insulin and other therapeutic 
proteins. Diabetes Technol Ther, 2007. 9 Suppl 1: p. S4-S15. 
88. Simons, J., How the Exubera Debacle Hurts Pfizer, in Fortune. 2007. 
 89
89. Kaushik, S., et al., Lack of pain associated with microfabricated microneedles. 
Anesth Analg, 2001. 92(2): p. 502-4. 
90. Martanto, W., et al., Transdermal delivery of insulin using microneedles in vivo. 
Pharm Res, 2004. 21(6): p. 947-52. 
91. Kanikkannan, N., J. Singh, and P. Ramarao, Transdermal iontophoretic delivery 
of bovine insulin and monomeric human insulin analogue. J Control Release, 
1999. 59(1): p. 99-105. 
92. Park, E.J., J. Werner, and N.B. Smith, Ultrasound mediated transdermal insulin 
delivery in pigs using a lightweight transducer. Pharm Res, 2007. 24(7): p. 1396-
401. 
93. Lee, S., et al., Photomechanical transdermal delivery of insulin in vivo. Lasers 
Surg Med, 2001. 28(3): p. 282-5. 
94. Hinchcliffe, M. and L. Illum, Intranasal insulin delivery and therapy. Adv Drug 
Deliv Rev, 1999. 35(2-3): p. 199-234. 
95. Pontiroli, A.E., Peptide hormones: Review of current and emerging uses by nasal 
delivery. Adv Drug Deliv Rev, 1998. 29(1-2): p. 81-87. 
96. Zhang, X., et al., Nasal absorption enhancement of insulin using PEG-grafted 
chitosan nanoparticles. Eur J Pharm Biopharm, 2007. 
97. Yu, S., et al., Nasal insulin delivery in the chitosan solution: in vitro and in vivo 
studies. Int J Pharm, 2004. 281(1-2): p. 11-23. 
98. Dyer, A.M., et al., Nasal delivery of insulin using novel chitosan based 
formulations: a comparative study in two animal models between simple chitosan 
formulations and chitosan nanoparticles. Pharm Res, 2002. 19(7): p. 998-1008. 
99. Lee, Y.C. and S.H. Yalkowsky, Ocular devices for the controlled systemic 
delivery of insulin: in vitro and in vivo dissolution. Int J Pharm, 1999. 181(1): p. 
71-7. 
100. Degim, Z., et al., Rectal and vaginal administration of insulin-chitosan 
formulations: an experimental study in rabbits. J Drug Target, 2005. 13(10): p. 
563-72. 
101. Lee, Y.C., et al., Review on the systemic delivery of insulin via the ocular route. 
Int J Pharm, 2002. 233(1-2): p. 1-18. 
 90
102. Senel, S. and A.A. Hincal, Drug permeation enhancement via buccal route: 
possibilities and limitations. J Control Release, 2001. 72(1-3): p. 133-44. 
103. Junginger, H.E., J.A. Hoogstraate, and J.C. Verhoef, Recent advances in buccal 
drug delivery and absorption--in vitro and in vivo studies. J Control Release, 
1999. 62(1-2): p. 149-59. 
104. Luo, Y., et al., Study on a nanoparticle system for buccal delivery of insulin. Conf 
Proc IEEE Eng Med Biol Soc, 2005. 5: p. 4842-5. 
105. Pozzilli, P., et al., Biokinetics of buccal spray insulin in patients with type 1 
diabetes. Metabolism, 2005. 54(7): p. 930-4. 
106. Generex, Oral-lyn product information. 2008, 
http://www.generex.com/products/oral-lyn/. 
107. Hanazaki, K., Y. Nose, and F.C. Brunicardi, Artificial endocrine pancreas. J Am 
Coll Surg, 2001. 193(3): p. 310-22. 
108. Lim, M.W. and T.P. Fan, A "pancreatic tooth" design best accommodates the 
limitations of current artificial pancreas technology. Med Hypotheses, 2007. 
69(4): p. 741-5. 
109. Tohda, K. and M. Gratzl, A microscopic, continuous, optical monitor for 
interstitial electrolytes and glucose. Chemphyschem, 2003. 4(2): p. 155-60. 
110. Woderer, S., et al., Continuous glucose monitoring in interstitial fluid using 
glucose oxidase-based sensor compared to established blood glucose 
measurement in rats. Anal Chim Acta, 2007. 581(1): p. 7-12. 
111. Wentholt, I.M., et al., Comparison of a needle-type and a microdialysis 
continuous glucose monitor in type 1 diabetic patients. Diabetes Care, 2005. 
28(12): p. 2871-6. 
112. Kono, T., et al., Pancreatic polypeptide administration reduces insulin 
requirements of artificial pancreas in pancreatectomized dogs. Artif Organs, 
2005. 29(1): p. 83-7. 
113. Ratner, B.D., Hoffman, A. S., Schoen, F. J., Lemons, J. E., Biomaterials Science. 
1996, San Diego: Academic Press. 
114. Worsley, G.J., et al., Continuous blood glucose monitoring with a thin-film 
optical sensor. Clin Chem, 2007. 53(10): p. 1820-6. 
 91
115. Silva, A.I., et al., An overview on the development of a bio-artificial pancreas as a 
treatment of insulin-dependent diabetes mellitus. Med Res Rev, 2006. 26(2): p. 
181-222. 
116. Hirotani, S., et al., A bio-artificial endocrine pancreas for the treatment of 
diabetes. Transplant Proc, 1998. 30(2): p. 485-9. 
117. Hou, Q.P. and Y.H. Bae, Biohybrid artificial pancreas based on macrocapsule 
device. Adv Drug Deliv Rev, 1999. 35(2-3): p. 271-287. 
118. Kashyap, N., et al., Design and evaluation of biodegradable, biosensitive in situ 
gelling system for pulsatile delivery of insulin. Biomaterials, 2007. 28(11): p. 
2051-60. 
119. Miyata, T., et al., Preparation of reversibly glucose-responsive hydrogels by 
covalent immobilization of lectin in polymer networks having pendant glucose. J 
Biomater Sci Polym Ed, 2004. 15(9): p. 1085-98. 
120. Matsumoto, A., R. Yoshida, and K. Kataoka, Glucose-responsive polymer gel 
bearing phenylborate derivative as a glucose-sensing moiety operating at the 
physiological pH. Biomacromolecules, 2004. 5(3): p. 1038-45. 
121. Liu, F., et al., Glucose-induced release of glycosylpoly(ethylene glycol) insulin 
bound to a soluble conjugate of concanavalin A. Bioconjug Chem, 1997. 8(5): p. 
664-72. 
122. Cheng, S.Y., J. Gross, and A. Sambanis, Hybrid pancreatic tissue substitute 
consisting of recombinant insulin-secreting cells and glucose-responsive material. 
Biotechnol Bioeng, 2004. 87(7): p. 863-73. 
123. Kim, J.J. and K. Park, Modulated insulin delivery from glucose-sensitive hydrogel 
dosage forms. J Control Release, 2001. 77(1-2): p. 39-47. 
124. Layman, D.P., Physiology Demystified. 2004, Blacklick, OH: McGraw-Hill. 
125. Barrett, K.E., Gastrointestinal Physiology. 2006, New York: McGraw-Hill. 
126. Pasley, J.N., USMLE Road Map: Physiology. 2003, New York: McGraw-Hill. 
127. Goldberg, H.I., et al., In vivo demonstration of small intestinal villi in dogs and 
monkeys using radiographic magnification. Radiology, 1982. 142(1): p. 53-8. 
128. Netter, F.H., Netter's Atlas of the Human Body. 2006, Hauppauge, NY: Barrons. 
 92
129. Wang, W., Oral protein drug delivery. J Drug Target, 1996. 4(4): p. 195-232. 
130. Saltzman, W.M., Drug Delivery: Engineering Principles for Drug Therapy. 2001, 
Oxford: Oxford University Press. 
131. Beck, F. and R.M. Williams, Pinocytosis in the neonate mammalian small 
intestine. J Anat, 1969. 104(Pt 1): p. 174-5. 
132. Liu, J. and J.I. Shapiro, Endocytosis and signal transduction: basic science 
update. Biol Res Nurs, 2003. 5(2): p. 117-28. 
133. Sood, A. and R. Panchagnula, Peroral route: an opportunity for protein and 
peptide drug delivery. Chem Rev, 2001. 101(11): p. 3275-303. 
134. Salama, N.N., N.D. Eddington, and A. Fasano, Tight junction modulation and its 
relationship to drug delivery. Adv Drug Deliv Rev, 2006. 58(1): p. 15-28. 
135. Puthenedam, M., et al., Modulation of tight junction barrier function by outer 
membrane proteins of enteropathogenic Escherichia coli: role of F-actin and 
junctional adhesion molecule-1. Cell Biol Int, 2007. 31(8): p. 836-44. 
136. Lapierre, L.A., The molecular structure of the tight junction. Adv Drug Deliv 
Rev, 2000. 41(3): p. 255-64. 
137. Anderson, J.M. and C.M. Van Itallie, Tight junctions and the molecular basis for 
regulation of paracellular permeability. Am J Physiol, 1995. 269(4 Pt 1): p. 
G467-75. 
138. Miyoshi, J. and Y. Takai, Molecular perspective on tight-junction assembly and 
epithelial polarity. Adv Drug Deliv Rev, 2005. 57(6): p. 815-55. 
139. Nusrat, A., et al., Tight junctions are membrane microdomains. J Cell Sci, 2000. 
113 ( Pt 10): p. 1771-81. 
140. Garrod, D. and M. Chidgey, Desmosome structure, composition and function. 
Biochim Biophys Acta, 2007. 
141. Larsen, W.J., Biological implications of gap junction structure, distribution and 
composition: a review. Tissue Cell, 1983. 15(5): p. 645-71. 
142. Tsuji, A. and I. Tamai, Carrier-mediated intestinal transport of drugs. Pharm 
Res, 1996. 13(7): p. 963-77. 
 93
143. Kunta, J.R. and P.J. Sinko, Intestinal drug transporters: in vivo function and 
clinical importance. Curr Drug Metab, 2004. 5(1): p. 109-24. 
144. Thwaites, D.T. and C.M. Anderson, H+-coupled nutrient, micronutrient and drug 
transporters in the mammalian small intestine. Exp Physiol, 2007. 92(4): p. 603-
19. 
145. Terada, T. and K. Inui, Gene expression and regulation of drug transporters in 
the intestine and kidney. Biochem Pharmacol, 2007. 73(3): p. 440-9. 
146. Terada, T. and K. Inui, Peptide transporters: structure, function, regulation and 
application for drug delivery. Curr Drug Metab, 2004. 5(1): p. 85-94. 
147. Rubio-Aliaga, I. and H. Daniel, Mammalian peptide transporters as targets for 
drug delivery. Trends Pharmacol Sci, 2002. 23(9): p. 434-40. 
148. Maubon, N., et al., Analysis of drug transporter expression in human intestinal 
Caco-2 cells by real-time PCR. Fundam Clin Pharmacol, 2007. 21(6): p. 659-63. 
149. Nozawa, T., et al., Enhanced intestinal absorption of drugs by activation of 
peptide transporter PEPT1 using proton-releasing polymer. J Pharm Sci, 2003. 
92(11): p. 2208-16. 
150. Swaan, P.W., et al., Enhanced transepithelial transport of peptides by conjugation 
to cholic acid. Bioconjug Chem, 1997. 8(4): p. 520-5. 
151. Kramer, W., Gunther, W., Enhsen, A., Eugen, F., Hoffman, A., Neckermann, G., 
Gerrit, S., Urmann, M., Modified bile acids as carriers for peptides and drugs. J 
Control Release, 1997. 46(1-2): p. 17-30. 
152. Kamath, A.V., I.M. Darling, and M.E. Morris, Choline uptake in human intestinal 
Caco-2 cells is carrier-mediated. J Nutr, 2003. 133(8): p. 2607-11. 
153. Alrefai, W.A. and R.K. Gill, Bile acid transporters: structure, function, 
regulation and pathophysiological implications. Pharm Res, 2007. 24(10): p. 
1803-23. 
154. Steinman, R.M., et al., Endocytosis and the recycling of plasma membrane. J Cell 
Biol, 1983. 96(1): p. 1-27. 
155. Russell-Jones, G.J., The potential use of receptor-mediated endocytosis for oral 
drug delivery. Adv Drug Deliv Rev, 2001. 46(1-3): p. 59-73. 
 94
156. Lim, C.J. and W.C. Shen, Comparison of monomeric and oligomeric transferrin 
as potential carrier in oral delivery of protein drugs. J Control Release, 2005. 
106(3): p. 273-86. 
157. Kavimandan, N.J., et al., Synthesis and characterization of insulin-transferrin 
conjugates. Bioconjugate Chemistry, 2006. 17(6): p. 1376-1384. 
158. Russell-Jones, G.J., L. Arthur, and H. Walker, Vitamin B12-mediated transport of 
nanoparticles across Caco-2 cells. Int J Pharm, 1999. 179(2): p. 247-55. 
159. Camilleri, M., et al., Human gastric emptying and colonic filling of solids 
characterized by a new method. Am J Physiol, 1989. 257(2 Pt 1): p. G284-90. 
160. Smith, A.J., et al., 5-Hydroxytryptamine contributes significantly to a reflex 
pathway by which the duodenal mucosa protects itself from gastric acid injury. 
Faseb J, 2006. 20(14): p. 2486-95. 
161. Decktor, D.L., et al., Effect of metoclopramide, bethanechol and the 
cholecystokinin receptor antagonist, L-364,718, on gastric emptying in the rat. 
Eur J Pharmacol, 1988. 147(2): p. 313-6. 
162. Higgins, L.M., et al., In vivo phage display to identify M cell-targeting ligands. 
Pharm Res, 2004. 21(4): p. 695-705. 
163. Brayden, D.J. and A.W. Baird, Apical membrane receptors on intestinal M cells: 
potential targets for vaccine delivery. Adv Drug Deliv Rev, 2004. 56(6): p. 721-6. 
164. Brayden, D.J., Jepson, M. A., Baird, A. W., Intestinal Peyer's patch M cells and 
oral vaccine targeting. Drug Discov Today, 2005. 10(17): p. 1145-1157. 
165. Yang, L., J.S. Chu, and J.A. Fix, Colon-specific drug delivery: new approaches 
and in vitro/in vivo evaluation. Int J Pharm, 2002. 235(1-2): p. 1-15. 
166. Tozaki, H., et al., Chitosan capsules for colon-specific drug delivery: 
improvement of insulin absorption from the rat colon. J Pharm Sci, 1997. 86(9): 
p. 1016-21. 
167. Chourasia, M.K. and S.K. Jain, Pharmaceutical approaches to colon targeted 
drug delivery systems. J Pharm Pharm Sci, 2003. 6(1): p. 33-66. 
168. Sinha, V.R. and R. Kumria, Microbially triggered drug delivery to the colon. Eur 
J Pharm Sci, 2003. 18(1): p. 3-18. 
 95
169. Brange, J., Langkjaer, L., Insulin Formulation & Delivery, in Protein Delivery: 
Physical Systems, L.M. Sanders, Editor. 1997, Kluswer Academic Publishers: 
Hingham, MA. 
170. Ferrannini, E., et al., The role of fractional glucose extraction in the regulation of 
splanchnic glucose metabolism in normal and diabetic man. Metabolism, 1980. 
29(1): p. 28-35. 
171. Moore, M.C., A.D. Cherrington, and D.H. Wasserman, Regulation of hepatic and 
peripheral glucose disposal. Best Pract Res Clin Endocrinol Metab, 2003. 17(3): 
p. 343-64. 
172. Lebovitz, H.E. and M.A. Banerji, Treatment of insulin resistance in diabetes 
mellitus. Eur J Pharmacol, 2004. 490(1-3): p. 135-46. 
173. Nathan, D.M., Clinical practice. Initial management of glycemia in type 2 
diabetes mellitus. N Engl J Med, 2002. 347(17): p. 1342-9. 
174. Langguth, P., et al., The challenge of proteolytic enzymes in intestinal peptide 
delivery. Journal of Controlled Release, 1997. 46(1-2): p. 39-57. 
175. Festen, H.P., Intrinsic factor secretion and cobalamin absorption. Physiology and 
pathophysiology in the gastrointestinal tract. Scand J Gastroenterol Suppl, 1991. 
188: p. 1-7. 
176. Erickson, R.H., Peptide Metabolism at Brush-Border Membranes, in Peptide-
based drug design, controlling transport and metabolism, M.D.a.G.L.A. Taylor, 
Editor. 1995, American Chemical Society: Washington, DC. p. 23-45. 
177. Stephenson, S.L. and A.J. Kenny, Metabolism of neuropeptides. Hydrolysis of the 
angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar 
membranes. Biochem J, 1987. 241(1): p. 237-47. 
178. Peters, T.J., The subcellular localization of di- and tri-peptide hydrolase activity 
in guinea-pig small intestine. Biochem J, 1970. 120(1): p. 195-203. 
179. Ciechanover, A., Intracellular protein degradation: from a vague idea thru the 
lysosome and the ubiquitin-proteasome system and onto human diseases and drug 
targeting. Exp Biol Med (Maywood), 2006. 231(7): p. 1197-211. 
180. Morishita, M., et al., In situ ileal absorption of insulin in rats: effects of 
hyaluronidase pretreatment diminishing the mucous/glycocalyx layers. Pharm 
Res, 2004. 21(2): p. 309-16. 
 96
181. Smart, J.D., The basics and underlying mechanisms of mucoadhesion. Adv Drug 
Deliv Rev, 2005. 57(11): p. 1556-68. 
182. Shah, R.B., A. Palamakula, and M.A. Khan, Cytotoxicity evaluation of enzyme 
inhibitors and absorption enhancers in Caco-2 cells for oral delivery of salmon 
calcitonin. J Pharm Sci, 2004. 93(4): p. 1070-82. 
183. Bernkop-Schnurch, A., The use of inhibitory agents to overcome the enzymatic 
barrier to perorally administered therapeutic peptides and proteins. J Control 
Release, 1998. 52(1-2): p. 1-16. 
184. Steffansen, B., et al., Intestinal solute carriers: an overview of trends and 
strategies for improving oral drug absorption. Eur J Pharm Sci, 2004. 21(1): p. 3-
16. 
185. Han, H.K. and G.L. Amidon, Targeted prodrug design to optimize drug delivery. 
AAPS PharmSci, 2000. 2(1): p. E6. 
186. Damgé, C., P. Maincent, and N. Ubrich, Oral delivery of insulin associated to 
polymeric nanoparticles in diabetic rats. J Control Release, 2007. 117(2): p. 163-
170. 
187. Delie, F. and M.J. Blanco-Príeto, Polymeric particulates to improve oral 
bioavailability of peptide drugs. Molecules, 2005. 10: p. 65-80. 
188. Leobandung, W., et al., Preparation of stable insulin-loaded nanospheres of 
poly(ethylene glycol) macromers and N-isopropyl acrylamide. J Control Release, 
2002. 80(1-3): p. 357-63. 
189. Pang, K.S., Modeling of intestinal drug absorption: roles of transporters and 
metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos, 2003. 
31(12): p. 1507-19. 
190. Foster, N. and B.H. Hirst, Exploiting receptor biology for oral vaccination with 
biodegradable particulates. Adv Drug Deliv Rev, 2005. 57(3): p. 431-50. 
191. Ronnestad, I., et al., Oligopeptide transporter PepT1 in Atlantic cod (Gadus 
morhua L.): cloning, tissue expression and comparative aspects. J Exp Biol, 
2007. 210(Pt 22): p. 3883-96. 
192. Shah, D. and W.C. Shen, Transcellular delivery of an insulin-transferrin 
conjugate in enterocyte-like Caco-2 cells. J Pharm Sci, 1996. 85(12): p. 1306-11. 
 97
193. Salamat-Miller, N. and T.P. Johnston, Current strategies used to enhance the 
paracellular transport of therapeutic polypeptides across the intestinal 
epithelium. Int J Pharm, 2005. 294(1-2): p. 201-16. 
194. Larionova, N.V., et al., Biodegradable cross-linked starch/protein microcapsules 
containing proteinase inhibitor for oral protein administration. Int J Pharm, 1999. 
189(2): p. 171-8. 
195. Hussain, A., et al., Absorption enhancers in pulmonary protein delivery. J Control 
Release, 2004. 94(1): p. 15-24. 
196. Plate, N.A., et al., Mucoadhesive polymers with immobilized proteinase inhibitors 
for oral administration of protein drugs. Biomaterials, 2002. 23(7): p. 1673-7. 
197. Marschutz, M.K. and A. Bernkop-Schnurch, Oral peptide drug delivery: polymer-
inhibitor conjugates protecting insulin from enzymatic degradation in vitro. 
Biomaterials, 2000. 21(14): p. 1499-507. 
198. Bernkop-Schnurch, A. and A. Scerbe-Saiko, Synthesis and in vitro evaluation of 
chitosan-EDTA-protease-inhibitor conjugates which might be useful in oral 
delivery of peptides and proteins. Pharm Res, 1998. 15(2): p. 263-9. 
199. Bernkop-Schnurch, A., A. Krauland, and C. Valenta, Development and in vitro 
evaluation of a drug delivery system based on chitosan-EDTA BBI conjugate. J 
Drug Target, 1998. 6(3): p. 207-14. 
200. Pauletti, G.M., Gangwar, S., Knipp, G. T., Nerurkar, M. M., Okumu, F. W., 
Tamura, K. Siahaan, T. J., Borchardt, R. T., Structural requirements for intestinal 
absorption of peptide drugs. J Control Release, 1996. 41(1-2): p. 3-17. 
201. Hosny, E.A., H.I. Al-Shora, and M.M. Elmazar, Oral delivery of insulin from 
enteric-coated capsules containing sodium salicylate: effect on relative 
hypoglycemia of diabetic beagle dogs. Int J Pharm, 2002. 237(1-2): p. 71-6. 
202. Uchida, T., et al., Preparation and characterization of insulin-loaded acrylic 
hydrogels containing absorption enhancers. Chem Pharm Bull (Tokyo), 2001. 
49(10): p. 1261-6. 
203. Shah, P., et al., Modulation of ganciclovir intestinal absorption in presence of 
absorption enhancers. J Pharm Sci, 2007. 96(10): p. 2710-22. 
 98
204. Radwan, M.A. and H.Y. Aboul-Enein, The effect of absorption enhancers on the 
initial degradation kinetics of insulin by alpha-chymotrypsin. Int J Pharm, 2001. 
217(1-2): p. 111-20. 
205. Komada, F., K. Okumura, and R. Hori, Fate of porcine and human insulin at the 
subcutaneous injection site. II. In vitro degradation of insulins in the 
subcutaneous tissue of the rat. J Pharmacobiodyn, 1985. 8(1): p. 33-40. 
206. Takeyama, M., et al., Enhanced bioavailability of subcutaneously injected insulin 
by pretreatment with ointment containing protease inhibitors. Pharm Res, 1991. 
8(1): p. 60-4. 
207. Clement, S., et al., Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in 
type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes 
Technol Ther, 2002. 4(4): p. 459-66. 
208. Cereijido, M., et al., New diseases derived or associated with the tight junction. 
Arch Med Res, 2007. 38(5): p. 465-78. 
209. Garnett, M.C., Targeted drug conjugates: principles and progress. Adv Drug 
Deliv Rev, 2001. 53(2): p. 171-216. 
210. Hou, T., et al., ADME evaluation in drug discovery. 6. Can oral bioavailability in 
humans be effectively predicted by simple molecular property-based rules? J 
Chem Inf Model, 2007. 47(2): p. 460-3. 
211. Saitoh, H. and B.J. Aungst, Prodrug and analog approaches to improving the 
intestinal absorption of a cyclic peptide, GPIIb/IIIa receptor antagonist. Pharm 
Res, 1997. 14(8): p. 1026-9. 
212. Biessen, E.A., et al., Design of a targeted peptide nucleic acid prodrug to inhibit 
hepatic human microsomal triglyceride transfer protein expression in 
hepatocytes. Bioconjug Chem, 2002. 13(2): p. 295-302. 
213. Sharma, S.K., et al., Sustained tumor regression of human colorectal cancer 
xenografts using a multifunctional mannosylated fusion protein in antibody-
directed enzyme prodrug therapy. Clin Cancer Res, 2005. 11(2 Pt 1): p. 814-25. 
214. Kondo, C., et al., Lack of improvement of oral absorption of ME3277 by prodrug 
formation is ascribed to the intestinal efflux mediated by breast cancer resistant 
protein (BCRP/ABCG2). Pharm Res, 2005. 22(4): p. 613-8. 
 99
215. Pauletti, G.M., et al., Improvement of oral peptide bioavailability: 
Peptidomimetics and prodrug strategies. Advanced Drug Delivery Reviews, 
1997. 27(2-3): p. 235-256. 
216. Ezra, A., et al., A peptide prodrug approach for improving bisphosphonate oral 
absorption. J Med Chem, 2000. 43(20): p. 3641-52. 
217. Weller, T., et al., Orally active fibrinogen receptor antagonists. 2. Amidoximes as 
prodrugs of amidines. J Med Chem, 1996. 39(16): p. 3139-47. 
218. Veronese, F.M., Peptide and protein PEGylation: a review of problems and 
solutions. Biomaterials, 2001. 22(5): p. 405-17. 
219. Veronese, F.M. and G. Pasut, PEGylation, successful approach to drug delivery. 
Drug Discov Today, 2005. 10(21): p. 1451-8. 
220. Roberts, M.J., M.D. Bentley, and J.M. Harris, Chemistry for peptide and protein 
PEGylation. Adv Drug Deliv Rev, 2002. 54(4): p. 459-76. 
221. Greenwald, R.B., et al., Effective drug delivery by PEGylated drug conjugates. 
Adv Drug Deliv Rev, 2003. 55(2): p. 217-50. 
222. Bailon, P. and W. Berthold, Polyethylene glycol-conjugated pharmaceutical 
proteins. Pharmaceutical Science & Technology Today, 1998. 1(8): p. 352-356. 
223. Hinds, K.D. and S.W. Kim, Effects of PEG conjugation on insulin properties. 
Adv Drug Deliv Rev, 2002. 54(4): p. 505-30. 
224. Fuertges, F. and A. Abuchowski, The Clinical Efficacy of Poly(Ethylene Glycol)-
Modified Proteins. Journal of Controlled Release, 1990. 11(1-3): p. 139-148. 
225. Veronese, F.M. and J.M. Harris, Introduction and overview of peptide and protein 
pegylation. Adv Drug Deliv Rev, 2002. 54(4): p. 453-6. 
226. Stoll, B.R., et al., A mechanistic analysis of carrier-mediated oral delivery of 
protein therapeutics. J Control Release, 2000. 64(1-3): p. 217-28. 
227. Valuev, L.I., et al., A biospecific polymeric carrier for polypeptide drugs. Russian 
Chem Bull, Int Ed., 2004. 53(11): p. 2611-2616. 
228. Xia, C.Q., J. Wang, and W.C. Shen, Hypoglycemic effect of insulin-transferrin 
conjugate in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther, 2000. 
295(2): p. 594-600. 
 100
229. Kavimandan, N.J., E. Losi, and N.A. Peppas, Novel delivery system based on 
complexation hydrogels as delivery vehicles for insulin-transferrin conjugates. 
Biomaterials, 2006. 27(20): p. 3846-54. 
230. Booth, C.C., et al., The site of absorption and tissue distribution of orally 
administered 56Co-labelled vitamin B12 in the rat. Br J Haematol, 1957. 3(3): p. 
253-61. 
231. Seetharam, B. and D.H. Alpers, Cellular uptake of cobalamin. Nutr Rev, 1985. 
43(4): p. 97-102. 
232. Seetharam, B., et al., Normal and abnormal physiology of intrinsic factor 
mediated absorption of cobalamin (vitamin B12). Indian J Biochem Biophys, 
1991. 28(5-6): p. 324-30. 
233. Hagedorn, C.H. and D.H. Alpers, Distribution of intrinsic factor-vitamin B12 
receptors in human intestine. Gastroenterology, 1977. 73(5): p. 1019-22. 
234. Russell-Jones, G.J., Oral delivery of therapeutic proteins and peptides by the 
viatmin B12 uptake system, in Peptide based drug design: Controlling transport 
and metabolism, M.D.a.G.L.A. Taylor, Editor. 1995, American Chemical Society: 
Washington, D.C. 
235. Seetharam, B., et al., Intestinal uptake and release of cobalamin complexed with 
rat intrinsic factor. Am J Physiol, 1985. 248(3 Pt 1): p. G326-31. 
236. Alsenz, J., et al., Oral absorption of peptides through the cobalamin (vitamin 
B12) pathway in the rat intestine. Pharm Res, 2000. 17(7): p. 825-32. 
237. Russell-Jones, G.J., Oral delivery of therapeutic proteins and peptides by the 
vitamin B12 uptake system, in Peptide-Based Drug Design: Controlling Transport 
and Metabolism, G.L. Amidon, Editor. 1995, American Chemical Society: 
Washington, D.C. p. 181-198. 
238. DiBiase, M.D., Morrel, E. M., Oral Delivery of Microencapsulated Proteins, in 
Protein Delivery: Physiacal Systems, L.M. Sanders, Editor. 1997, Kluwer 
Academic Publishers: Hingham, MA. 
239. Martin, C., et al., Cholesterol-bile salt vesicles as potential delivery vehicles for 
drug and vaccine delivery. Int J Pharm, 2005. 298(2): p. 339-43. 
240. Zasadzinski, J.A., Novel approaches to lipid based drug delivery. Biomaterials, 
1997. 2(3): p. 345-349. 
 101
241. Eldridge, J.H., Hammond, C. J., Meubroek, J. A., Staas, J. K., Gilley, R. M., Tice, 
T. R., Controlled vaccine release in the gut associated lymphoid tissues: orally 
administered biodegradable microspheres target the Peyer's patches. J Control 
Release, 1990. 11(205-214). 
242. Patel, H.M., Transcytosis of drug carriers carrying peptides across epithelial 
barriers. Biochem Soc Trans, 1989. 17(5): p. 940-2. 
243. Arrieta-Molero, J.F., et al., Orally administered liposome-entrapped insulin in 
diabetic animals. A critical assessment. Horm Res, 1982. 16(4): p. 249-56. 
244. Degim, I.T., et al., Oral administration of liposomal insulin. J Nanosci 
Nanotechnol, 2006. 6(9-10): p. 2945-9. 
245. Xiong, X.Y., Tam, K. C., Synthesis and aggregation behavior of Pluronic 
F127/poly(lactic acid) block copolymers in aqueous solutions. Macromolecules, 
2003. 36(26): p. 9979-9985. 
246. Xiong, X.Y., Tam, K. C., Hydrolygic degradation of Pluronic F127/poly(lactic 
acid) block copolymer nanoparticles. Macromolecules, 2004. 37(9): p. 3425-
3430. 
247. Xiong, X.Y., et al., Vesicles from Pluronic/poly(lactic acid) block copolymers as 
new carriers for oral insulin delivery. J Control Release, 2007. 120(1-2): p. 11-7. 
248. Furtado, S., et al., Oral delivery of insulin loaded poly(fumaric-co-sebacic) 
anhydride microspheres. Int J Pharm, 2008. 347(1-2): p. 149-55. 
249. Mathiowitz, E., et al., Biologically erodable microspheres as potential oral drug 
delivery systems. Nature, 1997. 386(6623): p. 410-4. 
250. Furtado, S., et al., Subcutaneous delivery of insulin loaded poly(fumaric-co-
sebacic anhydride) microspheres to type 1 diabetic rats. Eur J Pharm Biopharm, 
2006. 63(2): p. 229-36. 
251. Chalasani, K.B., et al., A novel vitamin B12-nanosphere conjugate carrier system 
for peroral delivery of insulin. J Control Release, 2007. 117(3): p. 421-9. 
252. Chalasani, K.B., et al., Effective oral delivery of insulin in animal models using 
vitamin B12-coated dextran nanoparticles. J Control Release, 2007. 122(2): p. 
141-50. 
 102
253. Carino, G.P., J.S. Jacob, and E. Mathiowitz, Nanosphere based oral insulin 
delivery. J Control Release, 2000. 65(1-2): p. 261-9. 
254. Cui, F.D., et al., Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral 
delivery. J Pharm Sci, 2007. 96(2): p. 421-7. 
255. Kwon, Y.M., et al., In situ study of insulin aggregation induced by water-organic 
solvent interface. Pharm Res, 2001. 18(12): p. 1754-9. 
256. Li, Y.-P., et al., PEGylated PLGA nanoparticles as protein carriers: synthesis, 
preparation and biodistribution in rats. Journal of controlled release, 2001. 71: p. 
203-211. 
257. Sahana, D.K., et al., PLGA nanoparticles for oral delivery of hydrophobic drugs: 
Influence of organic solvent on nanoparticle formation and release behavior In 
Vitro and In Vivo using estradiol as a model drug. J Pharm Sci, 2007. 
258. Sarmento, B., et al., Development and characterization of new insulin containing 
polysaccharide nanoparticles. Colloids Surf B Biointerfaces, 2006. 53(2): p. 193-
202. 
259. Sarmento, B., et al., Oral bioavailability of insulin contained in polysaccharide 
nanoparticles. Biomacromolecules, 2007. 8(10): p. 3054-60. 
260. Jain, D., D.K. Majumdar, and A.K. Panda, Insulin loaded eudragit L100 
microspheres for oral delivery: preliminary in vitro studies. J Biomater Appl, 
2006. 21(2): p. 195-211. 
261. Brandrup, J., Immergut, E. H., Grulke, E. A., Abe, A., Bloch, D. R., ed. Polymer 
Handbook (4th Edition). 4 ed. 1999, John Wiley & Sons. 
262. Jain, D., A.K. Panda, and D.K. Majumdar, Eudragit S100 entrapped insulin 
microspheres for oral delivery. AAPS PharmSciTech, 2005. 6(1): p. E100-7. 
263. Whitehead, K., Z. Shen, and S. Mitragotri, Oral delivery of macromolecules using 
intestinal patches: applications for insulin delivery. J Control Release, 2004. 
98(1): p. 37-45. 
264. Sahlin, J.J. and N.A. Peppas, Enhanced hydrogel adhesion by polymer 
interdiffusion: use of linear poly(ethylene glycol) as an adhesion promoter. J 
Biomater Sci Polym Ed, 1997. 8(6): p. 421-36. 
 103
265. Goto, T., et al., Gastrointestinal transit and mucoadhesive characteristics of 
complexation hydrogels in rats. Journal of Pharmaceutical Sciences, 2006. 95(2): 
p. 462-469. 
266. Krauland, A.H., D. Guggi, and A. Bernkop-Schnurch, Oral insulin delivery: the 
potential of thiolated chitosan-insulin tablets on non-diabetic rats. J Control 
Release, 2004. 95(3): p. 547-55. 
267. Lee, Y.H., et al., Impact of regional intestinal pH modulation on absorption of 
peptide drugs: oral absorption studies of salmon calcitonin in beagle dogs. Pharm 
Res, 1999. 16(8): p. 1233-9. 
268. Brannon-Peppas, L. and R.S. Harland, Absorbent Polymer Technology. 1990, 
New York: Elsevier Science Publishers. 278. 
269. Gupta, P., K. Vermani, and S. Garg, Hydrogels: from controlled release to pH-
responsive drug delivery. Drug Discov Today, 2002. 7(10): p. 569-79. 
270. Lowman, A.M. and N.A. Peppas, Hydrogels, in Encyclopedia of Controlled Drug 
Delivery, E. Mathiowitz, Editor. 1999, John Wiley & Sons. p. 397-418. 
271. Peppas, N.A., et al., Hydrogels in pharmaceutical formulations. Eur J Pharm 
Biopharm, 2000. 50(1): p. 27-46. 
272. Hoffman, A.S., Hydrogels for biomedical applications. Adv Drug Deliv Rev, 
2002. 54(1): p. 3-12. 
273. Peppas, N.A., et al., Physicochemical foundations and structural design of 
hydrogels in medicine and biology. Annu Rev Biomed Eng, 2000. 2: p. 9-29. 
274. Peppas, N.A., Controlling Protein Diffusion in Hydrogels, in Trends and Future 
Perspectives in Peptide and Protein Drug Delivery, V.H. Lee, Hashida, M., 
Mizushima, Y., Editor. 1995, CRC Press: Boca Raton, FL. p. 23-37. 
275. Qiu, Y. and K. Park, Environment-sensitive hydrogels for drug delivery. Adv 
Drug Deliv Rev, 2001. 53(3): p. 321-39. 
276. Podual, K., F.J. Doyle, 3rd, and N.A. Peppas, Dynamic behavior of glucose 
oxidase-containing microparticles of poly(ethylene glycol)-grafted cationic 
hydrogels in an environment of changing pH. Biomaterials, 2000. 21(14): p. 
1439-50. 
 104
277. Mahkam, M., Using pH-sensitive hydrogels containing cubane as a crosslinking 
agent for oral delivery of insulin. J Biomed Mater Res B Appl Biomater, 2005. 
75(1): p. 108-12. 
278. Antipina, A.D., Baranovsky, V. Y., Papisov, I. M., Kabanov, V. A., Equilibrium 
peculiarities in the complexing of polymeric acids with polyethylene glycol. 
Vysokomol. Soyed., 1972. A14: p. 941-949. 
279. Osada, Y., Sato, M., Thermal equilibrium of the intermacromolecular complexes 
of polycarboxylic acids realized by cooperative hydrogen bonding. J Poly Sci, 
Poly Let Ed, 1976. 14: p. 129-134. 
280. Lowman, A.M., et al., Oral delivery of insulin using pH-responsive complexation 
gels. J Pharm Sci, 1999. 88(9): p. 933-7. 
281. Lowman, A.M. and N.A. Peppas, Analysis of the complexation/decomplexation 
phenomena in graft copolymer networks. Macromolecules, 1997. 30(17): p. 4959-
4965. 
282. Peppas, N.A., Devices based on intelligent biopolymers for oral protein delivery. 
Int J Pharm, 2004. 277(1-2): p. 11-7. 
283. Peppas, N.A., et al., Poly(ethylene glycol)-containing hydrogels in drug delivery. 
J Control Release, 1999. 62(1-2): p. 81-7. 
284. Yamagata, T., et al., Characterization of insulin protection properties of 
complexation hydrogels in gastric and intestinal enzyme fluids. J Control Release, 
2006. 112(3): p. 343-9. 
285. Kim, B. and N.A. Peppas, In vitro release behavior and stability of insulin in 
complexation hydrogels as oral drug delivery carriers. Int J Pharm, 2003. 266(1-
2): p. 29-37. 
286. Madsen, F. and N.A. Peppas, Complexation graft copolymer networks: swelling 
properties, calcium binding and proteolytic enzyme inhibition. Biomaterials, 
1999. 20(18): p. 1701-8. 
287. Morishita, M., et al., Mucosal insulin delivery systems based on complexation 
polymer hydrogels: effect of particle size on insulin enteral absorption. J Control 
Release, 2004. 97(1): p. 115-24. 
 105
288. Peppas, N.A. and N.J. Kavimandan, Nanoscale analysis of protein and peptide 
absorption: insulin absorption using complexation and pH-sensitive hydrogels as 
delivery vehicles. Eur J Pharm Sci, 2006. 29(3-4): p. 183-97. 
289. Ichikawa, H. and N.A. Peppas, Novel complexation hydrogels for oral peptide 
delivery: in vitro evaluation of their cytocompatibility and insulin-transport 
enhancing effects using Caco-2 cell monolayers. J Biomed Mater Res A, 2003. 
67(2): p. 609-17. 
290. Besheer, A., et al., Loading and mobility of spin-labeled insulin in physiologically 
responsive complexation hydrogels intended for oral administration. J Control 
Release, 2006. 111(1-2): p. 73-80. 
291. Morishita, M., et al., Novel oral insulin delivery systems based on complexation 
polymer hydrogels: single and multiple administration studies in type 1 and 2 
diabetic rats. J Control Release, 2006. 110(3): p. 587-94. 
292. Perakslis, E., A. Tuesca, and A. Lowman, Complexation hydrogels for oral 
protein delivery: an in vitro assessment of the insulin transport-enhancing effects 
following dissolution in simulated digestive fluids. J Biomater Sci Polym Ed, 
2007. 18(12): p. 1475-90. 
293. Nakamura, K., et al., Oral insulin delivery using P(MAA-g-EG) hydrogels: effects 
of network morphology on insulin delivery characteristics. J Control Release, 
2004. 95(3): p. 589-99. 
294. Morishita, M., et al., Elucidation of the mechanism of incorporation of insulin in 
controlled release systems based on complexation polymers. J Control Release, 
2002. 81(1-2): p. 25-32. 
295. Peppas, N.A. and J.J. Sahlin, Hydrogels as mucoadhesive and bioadhesive 
materials: a review. Biomaterials, 1996. 17(16): p. 1553-61. 
 
 106
CHAPTER 3: RESEARCH GOALS 
 
The overall goal of this research is to investigate the potential for oral insulin 
delivery using complexation hydrogels composed of poly(methacrylic acid – g – ethylene 
glycol) (P(MAA-g-EG)) hydrogels. Previous work with this material has clearly 
identified its potential application for oral insulin delivery, but several specific 
characteristics of the material remain unknown. Insulin has been unique in this preceding 
work in its ability to be incorporated in the hydrogel network with very high efficiency 
when compared to other proteins or dextrans. One of the most important aspects of this 
work is to investigate the interaction between insulin and P(MAA-g-EG). In doing so, the 
network characteristics of the hydrogel are determined and correlated to the in vitro 
behavior with insulin. 
Additionally, the application of P(MAA-g-EG) loaded with insulin and insulin 
conjugated with polyethylene glycol (PEG) is investigated in vivo in rats. The purpose of 
the investigation with a PEG modified insulin species is two-fold: to investigate how it 
affects the protein-hydrogel interaction in support of earlier work and to improve the 
potential application in vivo against the enzymatic barrier in the GI tract. The specific 
aims of this work are: 
 
Specific Aim # 1: To synthesize a series of P(MAA-g-EG) hydrogels, modifying and 
characterizing the network properties by altering the amount of difunctional PEG and 
monomer concentration present during polymerization 
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Specific Aim # 2: To perform loading and release studies from each polymer formulation 
with regular human insulin and insulin glargine to examine the mechanism of insulin 
uptake and release from P(MAA-g-EG) hydrogels in vitro 
 
Specific Aim # 3: To synthesize, purify, and characterize a site-specific PheB1 mono-
substituted PEG-insulin conjugate 
 
Specific Aim # 4: To examine the in vitro and in vivo behavior of the PEGylated insulin 
with P(MAA-g-EG) hydrogels 
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CHAPTER 4: SYNTHESIS AND NETWORK STRUCTURE 
CHARACTERIZATION OF P(MAA-g-EG) HYDROGELS 
 
4.1.  Introduction 
Hydrogels hold significant promise for protein and peptide drug delivery. The 
biocompatibility of both synthetic and natural hydrogels is due to their ability to imbibe 
large amounts of water. When used for the delivery of water soluble drugs the motility of 
the water through the hydrogel is paramount for determining the effectiveness of the 
delivery system. The relationship between hydrogel pore size and the size of the water 
borne drug is very important. For rigid materials, the diffusion of a solute is greatly 
inhibited moving through pores with diameters less than one order of magnitude greater 
than that of the dynamic radius of the diffusing solute [1]. In the case of hydrogels, 
however, such scaling relationships are less easily determined due to the movement of the 
hydrated polymer chains. In a model described by Peppas [2], the diffusion rate of a 
protein through a hydrogel decreases dramatically as the ratio of protein size to pore size 
increases. In order to evaluate the feasibility of using P(MAA-g-EG) hydrogels for 
insulin delivery, it is important to understand the properties of the structure of the 
polymer network. 
The most important parameters defining the network structure of swollen 
hydrogels are the polymer volume fraction in the swollen state, υ2,s, average effective 
molecular weight of the polymer chain between crosslinks, eM , and network correlation 
length, or mesh size, ξ [3]. Mesh size is used to describe hydrogels with a crosslinked 
polymer backbone and is synonymous with pore size. A more detailed discussion of the 
calculations used to determine these values is provided in the discussion of this chapter. 
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The relationship between the hydrogel network characteristics and drug size is 
represented in Figure 4.1. In the case of P(MAA-g-EG) hydrogels, the network mesh size 
changes in response to the pH of the solution. At neutral pH levels the hydrogel swells to 
a great degree due to the lack of interpolymer complexation. Under these conditions, the 
MAA repeat units of the hydrogel backbone are negatively charged causing them to repel 
one another and they cannot form hydrogen bonds with the grafted PEG chains. In this 
state, the mesh size is sufficiently large to allow insulin to diffuse into and out of the 
network with minimal restriction. In acidic solutions, the hydrogel collapses into a highly 
complexed state. This is due to the protonation of the MAA repeat units of the hydrogel 
backbone which allows them to form hydrogen bonds with PEG as well as with other 
MAA groups. These hydrogen bonds form temporary crosslinks in addition to the 
covalent crosslinks introduced by difunctional PEG chains. Under these conditions, 
insulin release is severely reduced due to the drastic reduction in the network mesh size. 
P(MAA-g-EG) hydrogels with an equimolar ratio of ethylene glycol to methacrylic acid 
have exhibited the highest levels of interpolymer complexation due to hydrogen bonding 
between the two copolymers [4-6]. The same hydrogels repeatedly exhibited the highest 
efficiency of insulin retention [7, 8]. While each of these behaviors has been investigated, 
no attempt has been made to correlate the two. Therefore, in this work a series of 
P(MAA-g-EG) hydrogel formulations were polymerized and the network characteristics 
were determined for a range of pH levels relevant for oral insulin delivery. Additionally, 
modifications were made to the polymerization environment to impart network variation 
on the hydrogel formulations. By changing the amount of difunctional PEG or the 
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monomer weight fraction present during polymerization, the number and distribution of 
covalent crosslinks in the network was altered, irrespective of environmental pH.  
 
4.2. Materials and Methods 
 
4.2.1. Materials 
Methacrylic acid (MAA), dimethoxy propyl acetophenone (DMPA), 
Sigmacote® and ethanol were purchased from Sigma-Aldrich Chemical Co. (St. Louis, 
MO). In this study, quinone inhibitors in MAA monomer were removed by passing it 
through a column packed with DE-HIBIT 200 (Polysciences, Inc., Warrington, PA). 
Methacrylate terminated poly(ethylene glycol) monomethacrylate monomethyl ether 
1000 (PEGMA), and polyethylene glycol dimethacrylate 200 (PEGDMA) were 
purchased from Polysciences Inc. (Warrington, PA). The term crosslinker is used 
interchangeably for PEGDMA because its incorporation into the hydrogel imparts the 
covalently bonded crosslinks formed in the network. All chemicals were at least reagent 
grade.  
 
4.2.2. Synthesis of P(MAA-g-EG) Hydrogels 
Hydrogels of P(MAA-g-EG) were prepared by free-radical photopolymerization 
of MAA and PEGMA 1000. The MAA and PEGMA were mixed to yield a 1:1 ratio of 
MAA:EG units in the gel. The amount of EG units was assumed to be 22.7 moles per 
mole of PEGMA based on a molecular weight of the PEG chain of 1000 Da. Difunctional 
PEGDMA was then added to the solution in varying mol% based on the number of moles 
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of PEGDMA/total moles monomer (MAA and EG) in solution, as listed in Table 4.1. The 
mol% of PEGDMA investigated were 0.375, 0.75, 1.25, and 2.0 mol%. The monomers 
and crosslinker were placed into a 50 wt% mixture of ethanol in DI water and allowed to 
fully dissolve while stirring at 350 rpm for 30 minutes. The concentrations of the 
monomers were varied in this solution to alter the polymerization of the hydrogel by wt% 
(total weight of monomers/total weight of monomers and solvents), also described in 
Table 4.1. The wt% used for this study were 33, 50, and 66 wt%. The purpose of varying 
the mol% of PEGDMA and wt% of monomer was to alter the intrinsic crosslink density 
in the P(MAA-g-EG) formulations.  
A photoinitiator, DMPA, was used in the amount of 1 wt% of the monomers. 
The solution was stirred for approximately 15 minutes to ensure complete dissolution of 
the initiator. Nitrogen was gently bubbled through the solution to remove dissolved 
oxygen, a free radical scavenger, for 15 minutes. The reaction solution was pipetted 
between glass slides spaced 0.8 mm apart with Teflon spacers. The glass slides were 
previously treated with Sigmacote, a material which forms a thin covalently bonded 
coating on glassware to reduce its surface energy and making it water repellant. This 
minimized the hydrogel adhesion to the surface of the glass slides. Photopolymerization 
was initiated by UV light (Ultracure 100, Efos Inc. Buffalo, NY) at 1 mW/cm2 at 365 nm 
and allowed to react for 35 min. The polymerized hydrogel films were removed from the 
glass plates and rinsed for 1 week with deionized (DI) water (changed daily) to remove 
any unreacted monomer and remaining solvent. To ensure complete reaction of the 
monomers in the hydrogel, several samples were analyzed by Attenuated Total 
Reflectance – Fourier Transform Infrared spectroscopy (ATR-FTIR) measurements on a 
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Nicolet 560 (Madison, WI). The sample was examined as a hydrated hydrogel on a zinc 
selenide (ZnSe) crystal. The scanning resolution was set to 1 cm-1 with a total of 128 
scans per sample. 
 
4.2.3. Hydrogel swelling 
Swelling experiments were performed to measure the volume fractions of the 
polymer and water in the hydrogel. Discs with diameters of 14 mm were cut from the 
hydrogel films following the rinsing in DI water. The discs were then dried under 
vacuum for 2 days. The dried hydrogel discs were weighed in air and heptane to 
determine dry polymer volume using the buoyancy technique [8]. The experimental setup 
can be seen in Figure 4.2. The weight of the hydrogel is taken in a cup suspended above 
the heptane, then while completely submerged in heptane. The volume of the disc is 
determined according to the following equation: 
heptane
airinweightDischeptaneinweightDiscVolume ρ
−=   (Eqn. 4.1) 
The density of heptane at room temperature is 0.684 g/ml. Each disc was then isolated 
and placed into 20 mL of a phosphate buffered saline (PBS) solution adjusted to a 
specific pH. Ten pH levels were used at pH = 2.2, 2.7, 3.16, 3.71, 4.2, 4.7, 5.2, 5.6, 6.2, 
and 6.8. These values encompass the pH levels defined by the U.S. Pharmacopeia for 
gastric fluids at pH = 2.2 and for intestinal fluids at pH = 6.8 [9]. Each disc was allowed 
to swell over 48 hours, changing the buffer after 4 and 24 hours. The volume of the 
swollen disc was measured after swelling for 4, 24 and 48 hours. The polymer volume 
fraction of the hydrogel could be found by comparing the dry polymer volume to that of 
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the swollen polymer volume, assuming that any difference in volume was due to imbibed 
water, according to equation 4.2. 
QV
V
gel
p
s
1
gelswollenofvolume
polymerdryofvolume
,2 ===υ    (Eqn. 4.2) 
 
4.2.4. Mechanical Testing 
Rubber elasticity experiments were conducted to characterize the network 
structure of the swollen hydrogel. The rinsed hydrogel films were cut into strips roughly 
5 mm wide and a minimum of 30 mm long. These hydrogel strips were then swollen in 
PBS buffers at the same pH levels used for swelling experiments. They were allowed to 
swell for 48 hours, refreshing the buffer after 24 hours. The swollen sample dimensions 
were then measured with calipers prior to testing the tensile stress with a gauge length of 
20 mm. Each strip was stretched up to 15% strain at 10% strain per minute using an 
automated materials tensile testing system with a 5 N load cell (Instron Model 4442, Park 
Ridge, IL). The samples were tested at 37°C submerged in PBS at the same pH of the 
swelling buffer. A custom-made testing apparatus was used which made the effects of 
buoyancy negligible. A diagram of the setup can be seen in Figure 4.3. The reservoir 
buffer is maintained at 37 °C in a vacuum flask which is sealed and connected to the 
water bath by an air tight seal. This way the buffer from the water bath can be removed 
between samples using a vacuum created by the 3-way bulb so the temperature of the 
buffer can reach equilibrium at 37 °C and the hydrogel sample can be changed. The water 
bath itself is a tube which slides up and down the lower testing arm along a water tight 
washer to allow access to the grips which hold the sample in place. 
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4.2.5. Gel Permeation Chromatography 
The number average molecular weight of the linear polymer chains in the 
absence of crosslinks, nM , was determined using gel permeation chromatography 
(GPC). The polymers were synthesized by the same procedure described for P(MAA-g-
EG) hydrogels, except that all PEGDMA 200 was omitted to prevent covalent 
crosslinking of the polymers. After photopolymerization, the polymer was present as a 
highly viscous solution. These samples were not technically hydrogels, because at this 
point there were no crosslinks present in the polymer. Each solution was dispersed at a 
concentration of 1 mg/ml polymer in PBS based on the initial polymer fraction of the 
solution and dissolved overnight at 80°C. Once in solution, the samples were injected 
onto a Waters Ultrhydrogel Linear® column (Milford, MA) in PBS at pH = 7.4 with an 
isocratic flow of 0.7 mL/min. The eluent from the column was passed through a Waters 
410 refractive index detector (Milford, MA). The unknown values for nM  of the 
P(MAA-g-EG) samples were determined by comparing to PEG standards with known 
molecular weight and polydispersity indices. Because the backbone of the samples are 
MAA, the values measured were adjusted based on the discrepancy found when running 
MAA standards of known molecular weight and polydispersity as experimental samples 
against the PEG standards. 
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4.3. Results and Discussion 
 
4.3.1. Hydrogel Synthesis 
The FTIR spectrum of a polymerized P(MAA-g-EG) hydrogel is shown in 
Figure 4.4. Each of the hydrogel formulations exhibited a similar ATR-FTIR spectrum. 
The spectrum clearly exhibits the most prominent peaks of the copolymer with stretching 
at 2923, 1695, and 1082 cm-1, indicative of C-H, COOH, and C-O bonds, respectively. 
Absent is the stretching at 1490-1680 cm-1, which would be exhibited if unsaturated 
carbon-carbon double bonds were present from unreacted methacrylate groups. These 
results were taken after rinsing the hydrogel samples for 7 days in DI water. If any 
unreacted monomers were present after polymerization, this spectrum indicates that they 
were effectively removed by this washing method.  
The hydrogel polymerized with 0.375 mol% PEGDMA and 33 wt% monomer 
had such low mechanical strength that films could not be removed from the mold without 
destroying them, so they were discarded. The hydrogels with 0.75 mol% PEGDMA and 
33 wt% monomer and 0.375 mol% PEGDMA and 50 wt% monomer could be removed 
from the molds and used for insulin loading and release studies; however, they did not 
have enough mechanical integrity to be tested for swelling and mechanical data without 
destroying the hydrogel. The other 9 formulations were tested to the full extent of this 
study. The macroscopic behavior of the three samples described above is indicative that 
they did, in fact, have the lowest crosslink density, as was expected and presented in 
Table 4.1. Future references to individual hydrogel formulations use the numbers for the 
mol% of PEGDMA and wt% monomer represented as a ratio (e.g. 0.375/50). 
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4.3.2. P(MAA-g-EG) Swelling 
The value of υ2,s, the equilibrium polymer volume fraction of the swollen gel, 
and its inverse, Q, the equilibrium volume swelling ratio, is determined through 
equilibrium swelling experiments according to equation 4.2. These swelling 
measurements are indicative of the molecular changes occurring in the P(MAA-g-EG) 
hydrogel. Each hydrogel formulation exhibited the expected pH responsive swelling 
behavior. The values for υ2,s decreased with increasing pH. The results for two sample 
formulations can be seen in Figure 4.5. These formulations were polymerized with 0.75 
or 2.0 mol% PEGDMA with 66 wt% monomer and are referred to as 0.75/66 and 2.0/66.  
The largest change in υ2,s for these two samples occurred when the pH of the 
PBS was between 5.6 and 6.2. Each tested P(MAA-g-EG) formulation exhibit a similar 
pH dependent transition in the same range (data not shown). The inflection points of the 
curves indicate that the pKa of the hydrogel is roughly 5.8-6.0. This is dissimilar from 
previously reported values of the pKa of P(MAA-g-EG) hydrogels at pH = 4.8 [10, 11], 
which are based on the referenced value for the pKa of MAA. Some investigators 
concluded that the pKa of this material is at pH = 4.8 [8]. Others report findings that 
more closely match those presented in this study for pKa [6, 7, 12]. There is one 
particular difference in technique that could account for this variation. The hydrogel discs 
in this study were allowed to swell for 48 hours prior to determining the “equilibrium” 
swelling. In this study the hydrated discs may not have actually achieved equilibrium in 
the 48 hours allotted. Some previous methods measured the volume of each disc every 24 
hours until it changed by less than 5 % over a 48 hour period, such that the samples were 
actually at equilibrium. With that in mind, the reason that the hydrogels were only 
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swollen for 48 hours in this work is due to the intended application of the material for 
oral insulin delivery. Upon oral ingestion, the residence time of food in the stomach of 
humans is generally only 2-4 hours prior to gastric emptying into the small intestine [13, 
14]. The 48 hour swelling is roughly the amount of time that an ingested sample would 
remain within the entire gastrointestinal tract. Therefore, all hydrogel swelling was 
performed for only 48 hours.  
 
4.3.3. P(MAA-g-EG) Mechanical Testing 
The hydrogel mechanical testing exhibited similar characteristics as that of the 
swelling studies. For all formulations of P(MAA-g-EG) examined, the values for the 
normalized tensile modulus decreased with increasing pH. The results from two sample 
formulations are shown in Figure 4.6. The normalized tensile modulus, G, is described by 
the following equation: 
31
,221 s
G υαα
τ
−=       (Eqn. 4.3) 
The value for G is the same as the left side of Equation 4.4 multiplied by the equilibrium 
volume swelling ratio of the polymer (υ2,s) raised to the 1/3 power. This additional value 
normalizes the tensile stress based on the amount of polymer present based on swelling 
results in the one dimensional direction of the strain [15]. For the two results in Figure 
4.6, the greatest drop in G occurs between pH of 5.2 and 6.2. This transition point was 
seen for all formulations indicating the loss of interpolymer complexation between MAA 
and PEG chains with increasing pH across the pKa of the material. These results 
corroborate the swelling tests which exhibited a large change in behavior over the same 
pH range. 
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4.3.4. P(MAA-g-EG) Gel Permeation Chromatography 
This marks the first time in the investigation of P(MAA-g-EG) hydrogels in our 
lab that the values for nM  were determined experimentally using GPC. Previous 
characterization used theoretical calculations based on the polymerization kinetics 
described [8, 16]. By directly measuring the value for nM  using experimental techniques 
a more accurate model for the network properties of P(MAA-g-EG) hydrogels can be 
created.  
The results of the values found for the average molecular weight of the polymer 
in the absence of covalent crosslinks, nM , can be seen in Table 4.2. The values were a 
significantly higher than those previously reported based on theoretical calculations [6]. 
The molecular weights of the samples were measured against PEG standards and then 
adjusted based on PMAA standards run as unknown samples against the same PEG 
standards. All subsequent calculations requiring values for nM  used the average values 
listed in Table 4.2. The difference is given as the percentage decrease from the 
experimentally determined values for nM .  
The theoretical calculations for nM  make several assumptions which most 
likely account for the difference between experimental and theoretical values. Most 
importantly, theoretical values assume that the free radical polymerization is for a linear 
polymer chain. The polymer chains are linear, but the presence of the PEG grafts 
introduced by PEGMA significantly increases the actual molecular weight of the polymer 
chain. As the weight fraction of the monomers in solution decreases, the average 
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molecular weight also decreases and the effect of the PEG grafts becomes more 
prominent as shown by the higher variance from theoretical calculations.   
 
4.3.5. Network Modeling and Characterization 
By combining the results of the swelling, mechanical, and GPC testing, the 
network properties of P(MAA-g-EG) hydrogels can be modeled. The determination of  
eM  and ξ is described by Peppas and Merrell [17] in a model based on Flory’s theory of 
rubber elasticity [18]. The value for eM  is found from the following equation:  
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where τ is the tensile stress, ρ2,r is the density of the gel in the relaxed state, α is the 
normalized elongation of the sample,  
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υ2,r is the polymer volume fraction of the gel in the relaxed state, R is the ideal gas 
constant, and nM  is the average molecular weight of linear polymer chains in the 
absence of a crosslinker. The values for υ2,r were assumed to be 0.33, 0.5 and 0.67 for 
polymers made with 33, 50, and 67 wt% monomers, respectively. The mesh size of the 
polymer network is calculated using the value determined for eM  as, 
21
31
,2
2
⎟⎟⎠
⎞
⎜⎜⎝
⎛= −
o
en
s M
MClυξ       (Eqn. 4.6) 
in which Cn is the Flory characteristic ratio (PMAA = 14.6) [19], l is the carbon-carbon 
chain length (1.54 Å), and Mo is the molecular weight of the polymeric repeat unit. 
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Methacrylic acid was used as the monomer for this calculation because it is the backbone 
of P(MAA-g-EG) hydrogels. The mesh size is the simplest way to represent the structure 
of the hydrogel. For environmentally responsive hydrogels, the values of the 
characteristics used to describe the hydrogel change in response to the conditions of their 
surroundings. The amount of crosslinking in the hydrogel depends on both the covalent 
crosslinks and temporary hydrogen bond stabilized crosslinks. When highly complexed at 
low pH, the values of eM  and ξ are the lowest observed for each formulation due to the 
addition of the temporary crosslinks. When these bonds are lost a neutral pH levels, the 
values for eM  and ξ are the highest for each formulation and are only dependent the 
covalent crosslinks.  
Results for the effective molecular weight between crosslinks and the mesh size 
of two sample formulations are shown in Figure 4.7. These two formulations exhibit a pH 
dependent increase for both eM  and ξ with the largest change occurring between pH of 
5.6 and 6.2. This again suggests that the pKa of the P(MAA-g-EG) hydrogels is 5.8-6.0.  
The two formulations have average network mesh sizes of 8 and 10 nm at pH ≤ 4.7 for 
the samples polymerized with 2.0 and 0.75 mol% PEGDMA, respectively. The mesh 
sizes increased to 16 and 19 nm at pH = 6.8 with the greatest increase occurring between 
pH = 5.6 and 6.2 for the same formulations. The values of ξ for all formulations are 
represented in Figure 4.8. While the differences in swelling and mechanical 
characteristics were significantly affected by changes in the hydrogel formulations, this 
was not apparent for ξ. The reason for this is that the values for ξ are dependent on υ2,s to 
the -1/3 power and τ  to the 1/2 power. Therefore, changes in these values have a reduced 
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effect on ξ, which may be important when considering the use of this hydrogel for oral 
insulin delivery.  
 
4.4. Conclusions 
A total of eleven P(MAA-g-EG) hydrogel formulations were polymerized using 
UV light initiated polymerization. The polymerization was confirmed using ATR-FTIR 
following a 7 day rinsing process. Of the eleven formulations, nine were tested for 
hydrogel swelling and mechanical properties. The hydrogels exhibited pH responsive 
swelling in which they were minimally swollen by PBS buffer below pH = 5.2 and highly 
swollen above pH = 6.2. The values for υ2,s represent this swelling behavior. The 
apparent pKa of the material was 5.8-6.0 based on the inflection point of the chart for 
υ2,s. The normalized tensile moduli also exhibited a pH dependent decrease in value as 
the pH of the swelling buffer was increased through the apparent pKa of the hydrogel. 
The values for nM  determined by GPC were significantly larger than theoretical values 
used in previous investigations. Using the results from each of these experiments, eM  
and ξ were calculated. In the same fashion as the swelling and mechanical data, the 
values for eM  and ξ increased with increasing pH and exhibited a similar transition point 
based on pH. However, the characteristic length scale of the hydrogel mesh size did not 
vary greatly between each formulation.  
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Table 4.1. Formulations of polymerization conditions for the series of P(MAA-g-EG) 
hydrogels considered. Changes expected in the hydrogel network are indicated by the 
blue arrow. 
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Table 4.2. The effective molecular weight of P(MAA-g-EG) chains in the absence of 
covalent crosslinks determined by GPC (± S.D., n = 3) 
 
Monomer fraction Experimental Theoretical % difference
66 wt% 24930 ± 1160 16334 34.50% 
50 wt% 19370 ± 330 11550 40.40% 
33 wt% 16150 ± 750 8168 49.40% 
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Figure 4.1. Schematic of p(MAA-g-EG) hydrogel and its pH dependent swelling 
behavior 
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Figure 4.2. Hydrogel density determination using the buoyancy technique 
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Figure 4.3. Experimental setup for tensile testing of hydrated hydrogel strips in a custom 
made water bath at 37°C. 
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Figure 4.4. FTIR-ATR spectra of a polymerized, hydrated P(MAA-g-EG) hydrogel 
sample 
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Figure 4.5. Equilibrium polymer volume fraction for two P(MAA-g-EG) hydrogel 
formulations polymerized with 50 wt% monomer following 48 hours of swelling in PBS 
(± S.D., n = 3) 
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Figure 4.6. Normalized tensile moduli for two P(MAA-g-EG) hydrogel formulations 
polymerized with 50 wt% monomer following 48 hours of swelling in PBS (± S.D., n = 
3) 
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(b) 
Figure 4.7. (a) The modeled average effective molecular weight between crosslinks, 
eM , and (b) network correlation length, ξ, for two P(MAA-g-EG) hydrogel formulations 
polymerized with 50 wt% monomer (± S.D., n = 3) 
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Figure 4.8. The modeled network correlation length, or mesh size, ξ, for all formulations 
tested in swelling and tensile studies 
 
 
 132
4.5.  References 
 
1. Kathawalla, I.A. and J.L. Anderson, Pore size effects on diffusion of polystyrene 
in dilute solution. Ind Eng Chem Res, 1988. 27: p. 866-871. 
2. Peppas, N.A., Controlling Protein Diffusion in Hydrogels, in Trends and Future 
Perspectives in Peptide and Protein Drug Delivery, V.H. Lee, Hashida, M., 
Mizushima, Y., Editor. 1995, CRC Press: Boca Raton, FL. p. 23-37. 
3. Lowman, A.M. and N.A. Peppas, Hydrogels, in Encyclopedia of Controlled Drug 
Delivery, E. Mathiowitz, Editor. 1999, John Wiley & Sons. p. 397-418. 
4. Peppas, N.A., et al., Physicochemical foundations and structural design of 
hydrogels in medicine and biology. Annu Rev Biomed Eng, 2000. 2: p. 9-29. 
5. Morishita, M., et al., Elucidation of the mechanism of incorporation of insulin in 
controlled release systems based on complexation polymers. J Control Release, 
2002. 81(1-2): p. 25-32. 
6. Nakamura, K., et al., Oral insulin delivery using P(MAA-g-EG) hydrogels: effects 
of network morphology on insulin delivery characteristics. J Control Release, 
2004. 95(3): p. 589-99. 
7. Madsen, F. and N.A. Peppas, Complexation graft copolymer networks: swelling 
properties, calcium binding and proteolytic enzyme inhibition. Biomaterials, 
1999. 20(18): p. 1701-8. 
8. Lowman, A.M. and N.A. Peppas, Analysis of the complexation/decomplexation 
phenomena in graft copolymer networks. Macromolecules, 1997. 30(17): p. 4959-
4965. 
9. The United States Phamacopeia. The National Formulary. 20 ed. 1995, 
Rockville, MD: United States Phamacopeial Convention, Inc. 
10. Peppas, N.A. and N.J. Kavimandan, Nanoscale analysis of protein and peptide 
absorption: insulin absorption using complexation and pH-sensitive hydrogels as 
delivery vehicles. Eur J Pharm Sci, 2006. 29(3-4): p. 183-97. 
11. Blanchette, J. and N.A. Peppas, Cellular evaluation of oral chemotherapy 
carriers. J Biomed Mater Res A, 2005. 72A(4): p. 381-8. 
 133
12. Lopez, J.E. and N.A. Peppas, Effect of poly (ethylene glycol) molecular weight 
and microparticle size on oral insulin delivery from P(MAA-g-EG) 
microparticles. Drug Dev Ind Pharm, 2004. 30(5): p. 497-504. 
13. Proano, M., et al., Transit of solids through the human colon: regional 
quantification in the unprepared bowel. Am J Physiol, 1990. 258(6 Pt 1): p. 
G856-62. 
14. Camilleri, M., et al., Human gastric emptying and colonic filling of solids 
characterized by a new method. Am J Physiol, 1989. 257(2 Pt 1): p. G284-90. 
15. Treloar, R.G., The Physics of Rubber Elasticity, 2nd Edition. 1958, Oxford: 
Oxford University Press. 
16. Odian, G., Principles of Polymerization, 4th Edition. 2004, New York: John 
Wiley & Sons. 
17. Peppas, N.A. and E.W. Merrill, Crosslinked poly(vinyl Alcohol) hydrogels as 
swollen elastic networks. Journal of applied polymer science, 1977. 21(7): p. 
1763-1770. 
18. Flory, P.J., Principles of Polymer Chemistry. 1953, Cornell, NY: Cornell 
University Press. 688. 
19. Brandrup, J., Immergut, E. H., Grulke, E. A., Abe, A., Bloch, D. R., ed. Polymer 
Handbook (4th Edition). 4 ed. 1999, John Wiley & Sons. 
 
 134
CHAPTER 5: IN VITRO ELUCIDATION OF INSULIN UPTAKE AND RELEASE 
MECHANISM FROM P(MAA-g-EG) HYDROGELS 
 
5.1. Introduction 
Many studies have investigated the effectiveness for oral insulin delivery with 
P(MAA-g-EG) hydrogels based on the in vitro behavior of insulin release. While the first 
of these studies were performed nearly 10 years ago [1, 2], each subsequent study has 
repeated much of the same proof: insulin can be efficiently maintained within the 
hydrogel at low pH levels (pH < 3.2) and released upon exposure to neutral pH levels 
(pH > 6.5) [3-10]. This pH responsive behavior is the primary reason that P(MAA-g-EG) 
has potential for oral insulin delivery. However, none of these studies make any attempt 
to correlate the hydrogel network properties, namely the network mesh size, to the ability 
of the material to control insulin release. With the large body of research concerning this 
hydrogel, this information may be critical to be able to optimize the drug delivery system 
for insulin, as well as other potential protein and peptide drugs.  
As discussed in the conclusions of the preceding chapter, the network mesh size 
exhibited pH responsive changes with an apparent pKa of P(MAA-g-EG) at 5.8-6.0. The 
changes in the mesh size, however, were not as profound as expected and do not 
adequately explain the in vitro behavior which has been seen with these hydrogels. The 
hydrodynamic radius of insulin is between 1.3-2.7 nm, depending on its quaternary 
structure [11-13]. The hydrogel network mesh size is more than one order of magnitude 
larger than the hydrodynamic radius of insulin when completely uncomplexed at pH = 
6.8, allowing it to be released from the network. However, the network mesh size is also 
significantly larger than insulin at pH ≤ 4.7 for all of the P(MAA-g-EG) formulations 
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tested. According to the hydrogel diffusion model reported by Peppas [14], when the 
characteristic ratio of the hydrodynamic radius of insulin divided by the radius of the pore 
(referred to here as mesh size) is 0.25, the diffusion rate should be roughly 20% that of 
free diffusion in solution. Based on these values, insulin should be released to a great 
extent even when these hydrogels are highly complexed at pH levels below the pKa of 
the material. However, reported insulin retention efficiencies in P(MAA-g-EG) hydrogels 
remain near 100%, much higher than what is expected based on the network mesh size. 
This retention was not nearly as efficient for alternative model drugs [15]. This suggests 
that diffusion rates may only be partially responsible for insulin loading and release, and 
additional factors may be important to understand the in vitro behavior of the hydrogel 
with insulin.  
A greater understanding of the interaction between insulin and P(MAA-g-EG) 
hydrogels can be achieved by carefully examining the differences between native insulin 
and other protein drugs. Insulin glargine is an insulin analog in which a glycine replaces 
the native asparagine residue at the A21 residue and two arginine residues are attached to 
the C-terminus of the B chain [16]. This has the effect of shifting the isoelectric point (pI) 
of the molecule to from 5.2 for native human insulin to 6.7 for insulin glargine, making it 
the least soluble near neutral conditions. In solutions at pH levels below the pI, the 
protein is protonated and has a slight positive charge; in solutions at pH levels above the 
pI, the protein is deprotonated and has a slight negative charge. The purpose of this 
modification for clinical use is to make the protein crystallize following a subcutaneous 
bolus injection. The insulin glargine slowly dissolves into the bloodstream by zero order 
kinetics giving a very steady baseline level of insulin for at least 24 hours [16]. It is 
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currently produced by Sanofi-Aventis under the trade name Lantus®. For the purposes of 
this study, the shift in the pI allows the study of two insulin species with different 
ionization characteristics. If ionic interactions are the leading cause for insulin uptake and 
release from P(MAA-g-EG) then a difference in release profiles should be apparent 
between the pI levels of the two proteins. The major benefit of comparing insulin 
glargine to human insulin is that they are nearly identical with the one major difference of 
isoelectric point. They have nearly identical tertiary structure, they have nearly the same 
molecular weight and hydrodynamic radius, and since insulin glargine is derived from 
human insulin the changes were considered negligible for the purposes of this study. A 
side by side comparison of the two proteins is given in Table 5.1. 
The focus of this work was to examine the loading and release characteristics of 
insulin and insulin glargine with P(MAA-g-EG) using in vitro techniques. By combining 
these results with those of the network characteristics determined in Chapter 4, the 
threshold for insulin release should be able to be determined as a function of mesh size. 
Alternatively, if other interactions between P(MAA-g-EG) hydrogels and insulin are the 
driving cause for uptake and release of insulin from the hydrogel, that should also be 
apparent. 
 
5.2. Materials and Methods 
 
5.2.1. Materials 
Phosphate buffered saline (PBS), Sigmacote® ammonium bicarbonate 
(NH4HCO3), and acetonitrile were purchased from Sigma Aldrich (St. Louis, MO). 
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Spectrapor® 6 dialysis tubing was purchased from Fisher Scientific (Hampton, NH). 
Recombinant human insulin was purchased from Seracare Diagnositics (Milford, MA). 
Insulin glargine was purified from the pharmaceutical preparation of Lantus®, which was 
purchased from Sanofi Aventis (Bridgewater, NJ).  
 
5.2.2. Human Insulin Loading 
Insulin loading studies with recombinant human insulin were performed with all 
11 formulations of P(MAA-g-EG) described in Chapter 4 to make insulin loaded polymer 
(ILP) samples. Rinsed hydrogel films were dried under vacuum and then crushed into a 
fine powder first using a mill grinder followed by manual grinding with a mortar and 
pestle. The powder was passed through a sieve with a mesh size of 45 μm with gentle 
mixing. Hydrogel particles of this size exhibited the greatest amount of insulin absorption 
in vivo following ileal administration in rats [3].  
All of the glassware used for insulin loading was treated with Sigmacote® to 
prevent insulin adsorption on the glass wall. An insulin solution with a concentration of 
500 μg/mL in PBS at pH = 7.4 was prepared. The crushed P(MAA-g-EG) particles (140 
mg) were dispersed into 20 mL of the human insulin solution at 37°C and stirred at 300 
rpm. After 4 hours, 10 mL of 0.1M HCl was added to the solutions to collapse the 
hydrogel network. The collapsed hydrogel samples were recovered by filtration using 
filter paper with a 0.6 μm pore size and rinsed with 50 mL of 0.1 M HCl and 50 mL of 
DI-water to remove any surface bound protein. Each sample was then frozen and 
lyophilized to remove residual water. Samples were kept at -20°C until needed.  
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The total weight of insulin present was calculated using the concentration and 
the total volume of solution. Insulin incorporation efficiency was determined based on 
the ratio of insulin remaining in the wash solutions to the initial insulin in the loading 
solution. The weight fraction of insulin in a given ILP batch was then calculated based on 
the total amount of insulin loaded according to equation 5.1. 
%100
loadedinsulin  mgpolymer mg
loadedinsulin  mg  % loading ILP ×+=  (Eqn. 5.1) 
Aliquots of 0.2 ml of solution were taken using a 1 ml syringe with a 0.45 μm 
filter. In order to determine the insulin concentration in solution, reversed phase high 
performance liquid chromatography (RP-HPLC) was used. A mixture of water (mobile 
phase A) and acetonitrile (mobile phase B) with 0.1 % TFA (v/v) was used as the mobile 
phase on a Waters Spherisorb® C8 column (5 μm, 4.6 x 250 mm). Samples of 50 μl were 
injected to Waters 2695 separations module equipped with a 996 Photodiode Array 
detector (Milford, MA) at a 1 mL/min. A gradient from 35-65 % mobile phase B was run 
for 30 minutes. Concentrations were determined based on the area under the curve 
compared to insulin standards with detection at 214 nm. Average elution time was 6.5 
minutes.  
 
5.2.3.  Insulin Glargine Loading  
Prior to working with insulin glargine, it had to be isolated from the 
pharmacological preparation which included glycerol, zinc, m-cresol, and insulin 
glargine. Purification was performed by dialysis using a regenerated cellulose membrane 
with a molecular weight cutoff (MWCO) of 3500 Da against 0.01M NH4HCO3 for 2 
days. The protein crashed out of solution at the neutral pH and all other solutes were 
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removed. The dialysate was changed 3 times daily. The crystalline protein was removed 
from the dialysis membrane, frozen and lyophilized.  
The insulin glargine loading studies were performed using the lyophilized 
powder to make glargine insulin loaded polymer (GILP) in a similar method as regular 
human insulin loaded polymer samples. However, because the pI of insulin glargine is so 
close to the loading pH for native human insulin (pH = 7.4), the loading solution was 
maintained at pH = 9.5. The rest of the loading protocol remained the same as that for 
native human insulin. For the study with insulin glargine, only 4 hydrogel formulations 
were considered due to limited availability of the protein. The formulations considered 
were 0.75/33, 0.75/66, 2.0/33, and 2.0/66 where ratio indicates the mol% of 
PEGDMA/monomer weight% present during polymerization. These formulations were 
chosen because they represent a wide variation in crosslink density of P(MAA-g-EG) 
hydrogels. Insulin glargine concentrations were determined using RP-HPLC using the 
same mobile phases as that for native insulin with a gradient from 40-55 %B over 25 
minutes at a flow rate of 0.8 mL/min. The areas of the peaks with detection at 214 nm 
were compared with insulin glargine standards with an average elution time of 13 
minutes. 
 
5.2.4. Insulin Release Studies 
Release studies for human insulin were performed using jars treated with 
Sigmacote® to minimize insulin absorption. For each P(MAA-g-EG) formulation, 10 mg 
of ILP was dispersed into 20 mL PBS at 37 °C at pH = 2.7, 3.7, 4.7, 5.6, and 6.8. The 
solutions were stirred at 300 rpm and 0.2 mL aliquots were withdrawn using a syringe 
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equipped with a 0.45 μm syringe filter at set time intervals. To maintain a constant 
release volume and ensure complete maintenance of polymer suspended in solution, the 
0.2 ml samples were replaced with 0.2 ml of fresh PBS at the particular release pH by 
backflushing through the syringe filter. The protein concentration was determined using 
RP-HPLC as previously described, and insulin release was represented as the ratio of 
measured insulin release to the theoretical maximum insulin release. 
 
5.2.5. Insulin Glargine Release Studies 
Release studies for insulin glargine loaded polymer samples were performed 
using jars treated with Sigmacote®. The release studies with were performed at pH = 4.7, 
5.6, 6.2, 6.8 and 7.4. In this range the ionization of the analog should be distinct from that 
of native human insulin. Additional release studies had to be performed with native 
insulin at pH = 6.2 to supplement to previous results. Insulin glargine concentrations 
were determined using RP-HPLC as previously described.  
 
5.3. Results and Discussion 
 
5.3.1. Human Insulin Loading 
The average insulin loading efficiencies for each formulation of P(MAA-g-EG) 
considered are listed in Table 5.2. The values for insulin loading efficiency range from 
42.7 to 84.9 % of insulin from solution which is loaded into the hydrogel. For each 
column and row of Table 5.2, the loading efficiencies increase with increasing monomer 
wt% or with increasing PEGDMA present during polymerization of the hydrogel 
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formulation, though some of the differences are statistically insignificant. This trend was 
exhibited for all formulations to varying extents.  
The insulin loading efficiency of P(MAA-g-EG) tended to increase with 
increasing crosslink density. In comparing Tables 4.1 and 5.2, this is quite clear. These 
results indicate that the network structure of the hydrogel is important to the loading of 
insulin. In these tests, there was no apparent optimal crosslink density which appeared to 
maximize insulin loading; rather the greatest efficiency was obtained with the most 
highly crosslinked hydrogel formulation. The results of the insulin loading studies can be 
interpreted in two ways. The data suggests that there is a direct correlation between the 
network structure of P(MAA-g-EG) hydrogels and the amount of insulin which can be 
incorporated within the network. However, this does not explain why insulin is 
maintained within the hydrogel even when the network mesh size is significantly larger 
than the hydrodynamic radius of insulin. Alternatively, the data may suggest that higher 
crosslink density increases the interaction between insulin and P(MAA-g-EG). In doing 
so, an attractive force between the two efficiently binds the protein to the hydrogel. This 
would be a new result which could provide significant insight for future work with this 
material for oral insulin delivery. 
 
5.3.2. Insulin Glargine Loading 
Loading studies of insulin glargine were less extensive than those of human 
insulin due to the difficulty of obtaining significant amounts of the model protein. Four 
formulations were considered to cover a wide variety of crosslink densities. The 
formulations are listed in Table 5.3 with their respective average loading efficiencies. 
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Each hydrogel formulation exhibited varying loading efficiencies. The values ranged 
from 45.7 to 83.2 % of insulin glargine in the loading solution which was successfully 
incorporated into the hydrogels. Insulin glargine exhibited the same trend as human 
insulin in that the loading efficiencies increased with increasing monomer wt% and 
increasing mol% PEGDMA present during hydrogel polymerization. Again, the 
correlation between the network crosslink density and the loading of insulin glargine was 
apparent. This may give particularly meaningful results for this drug delivery system 
because insulin glargine is a variation of native insulin and therefore is inherently 
different in various characteristics. If the loading of insulin and insulin glargine is due to 
an interaction between the hydrogel and the protein, differences in the in vitro behavior 
should be seen. In either case, by carefully controlling the hydrogel characteristics, one 
can tailor the efficiency with which at least these two protein drugs can be loaded into 
P(MAA-g-EG) hydrogels. 
 
5.3.3. In Vitro Release Studies 
The release of human insulin from each insulin loaded polymer (ILP) 
formulation was first performed at pH = 2.7, 3.7, 4.7, 5.6, and 6.8. Based on the results, 
which are discussed below, a second in vitro study was performed with insulin glargine 
as well as insulin which focused more on the pH range which incorporates the ionic 
transition point of both the ionic hydrogel and the proteins. To do so, release studies were 
also performed at pH = 6.2.  
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5.3.3.1. Human Insulin Release Studies 
The release of human insulin was performed for all 11 formulations of ILP. The 
insulin maintained its chemical structure as is indicated in Figures 5.1 and 5.2. The 
retention time remains the same (Figure 5.1) and total absorbance spectrum (Figure 5.2) 
for an insulin standard in PBS was identical to that of insulin following incorporation and 
release from a P(MAA-g-EG) sample. The smaller peak and absorbance for the insulin 
released from the ILP is simply due to the reduced concentration of the sample. The 
insulin control sample used was left at 37 °C for several days in a shaker bath to induce 
some aggregation. The absence of the aggregate peak in Figure 5.1 for insulin released 
from P(MAA-g-EG) indicated that insulin aggregation did not occur due to loading and 
release in the hydrogels. Figure 5.3 displays the fractional release of insulin from two 
formulations used for examples of insulin release and are the same ones used in Chapter 
4: 0.75/66 and 2.0/66. The release of insulin is given as a fractional release based on the 
insulin incorporation efficiency of the tested sample. For both samples, the release of 
insulin does not exceed 20% until the pH of the release buffer is at 6.8. Nine of the eleven 
P(MAA-g-EG) formulations tested exhibited the same release behavior as the results for 
the examples shown in Figure 5.3. The two formulations that do not follow this trend are 
0.375/50 and 0.75/33, which had significant release of insulin at pH = 5.6 as well as 6.8 
over the three hour release study. These results will be discussed in more detail later. 
The most intriguing part of the results presented in Figure 5.3 is how rapidly the 
transition is between insulin being maintained to a great extent within the hydrogel to 
insulin release based on pH. This is especially true when considering the results of the 
network structure characterization described in Chapter 4. While the mesh size of each of 
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these two hydrogels does change between pH = 5.6 and pH = 6.8, they only increase to 
roughly twice the size of the highly complexed state of the hydrogel at lower pH levels. If 
there were no attractive or repulsive forces between the protein and the hydrogel, a mesh 
size change of this order should only increase the diffusion of the drug through the 
hydrogel slightly. However, the release of insulin from these two hydrogels occurs almost 
instantaneously at pH = 6.8. This suggests that at pH = 6.8, insulin is driven out of the 
hydrogel by repulsive forces rather than simple diffusion.  
When combined with the loading data, it appears that at pH levels below the 
pKa of the hydrogel, hydrogen bonds form between insulin and the hydrogel in a similar 
fashion as those responsible for its pH responsive swelling. Above the pKa of P(MAA-g-
EG), the hydrogen bonds are lost allowing insulin release. This result suggests that the 
same weak interactions which occur between MAA and PEG in the hydrogel may 
contribute significantly to insulin loading and release behavior in vitro and are crucial to 
its potential for oral insulin delivery. However, this does not explain why insulin appears 
to be driven from the hydrogel. One important point to consider is the fact that all 
proteins exhibit polarization and ionization in response to environmental pH. In the case 
of insulin, its isoelectric point (pI) has been reported at pH = 5.2 [17]. Above this pH, 
insulin becomes more deprotonated causing it to behave as an anionic molecule. 
Therefore, when the pH of the release buffer is above the ionic transition point for both 
insulin and P(MAA-g-EG) both materials are negatively charged. This ionic repulsion is 
likely the reason for the rapid release of insulin at pH = 6.8. 
To supplement the previous results, additional release studies were performed 
with four P(MAA-g-EG) hydrogel formulations which included release at pH = 6.2. With 
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this study, more information was gathered in the pH range which exhibits the largest 
change with respect to the interaction between the hydrogel and insulin. These results are 
shown in Figure 5.4. The pI of insulin and the pKa of P(MAA-g-EG) are displayed as 
vertical lines at pH = 5.2 and 5.8, respectively. Results at lower pH levels are omitted. 
The points represent the fractional release of insulin following 3 hours of dissolution in 
PBS at pH = 4.7, 5.6, 6.2, and 6.8. For three of the four formulations considered the 
release of insulin did not occur until the pH of the release buffer was above that of both 
the pI of insulin and the pKa of P(MAA-g-EG). Again, there is one exception to this rule 
with formulation 0.75/33. The results for this formulation are discussed later in this 
chapter. For the other three formulations considered, insulin release required that both the 
hydrogel and insulin were negatively charged for insulin release to exceed 20%. If this 
result is truly the behavior of this delivery system, and the result for formulation 0.75/33 
is the exception to the rule, then this represents a significant step in understanding how 
the release of insulin from P(MAA-g-EG) hydrogels can be tailored to suit the needs of a 
pH dependent system for oral insulin delivery.  
 
5.3.3.2. Insulin Glargine Release Studies 
The four P(MAA-g-EG) formulations used for in vitro work with insulin 
glargine are listed in Table 5.3. Their release profiles are shown in Figure 5.5. The 
fractional release is shown as cumulative release following 3 hours of dissolution in PBS 
at pH = 4.7, 5.6, 6.2, 6.8, and 7.4. The highest pH sample was added for insulin glargine 
due to its elevated pI at 6.7 with respect to native human insulin [18]. The pI for insulin 
glargine and pKa for P(MAA-g-EG) are indicated on the graph. Insulin glargine provides 
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a unique perspective when considered with P(MAA-g-EG) hydrogels because its pI is at 
a higher pH than that of the hydrogel, as opposed to insulin, which was at a lower pH.  
In contrast to insulin, the release of the insulin glargine did not exceed 20% 
until the release buffer was at pH = 6.2. If the release of the protein is driven by ionic 
repulsion, then it would not occur until both the protein and the hydrogel are negatively 
charged, at pH levels above the ionic transition points of both species. With insulin 
glargine, this is exactly what happened for the four formulations considered. Only when 
the PBS was at pH = 6.8, when insulin glargine carries a slight negative charge, did the 
majority of the protein come out of the hydrogel. In combination with the results for 
insulin release, these results strongly indicate that ionic repulsion is the driving force for 
the release of insulin and insulin glargine from P(MAA-g-EG) hydrogels.  
 
5.3.3.3. Insulin Release for Loosely Crosslinked Formulations 
The release of insulin from two P(MAA-g-EG) formulations did not follow the 
patterns which are discussed previously. The two formulations are 0.375/50 and 0.75/33. 
These two formulations were the most loosely crosslinked hydrogels of all those 
considered in this body of work. They exhibited the lowest loading efficiency and, 
because they were so delicate, could not be tested for network properties. Nonetheless, 
their in vitro behavior with insulin was unique from the other 9 formulations and they 
justify a more detailed analysis.  
The release of both of these formulations is shown in Figure 5.6. Three pH 
levels are represented here: pH = 4.7, 5.6, and 6.8. At pH = 4.7 the release of insulin was 
highly restricted for the duration of the 3 hour test, the same result as that seen for all 
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other P(MAA-g-EG) hydrogels. Similarly, at pH = 6.8 nearly 100% of insulin was 
released within 5 minutes and the total amount released did not increase. At pH = 5.6, 
however, the release of insulin progressed over the duration of the test for both 
formulations. The curves for this release profile appear to be what would be expected if 
the release was controlled by diffusion. This is likely due to the low polymer volume 
fraction of these two formulations. With the very low crosslink density, these hydrogels 
rely very heavily on hydrogen bonds to maintain their integrity. As the pH is increased 
through the pKa of the hydrogel, and hydrogen bonding is lost, the volume fraction of the 
hydrogels could drop below 5%, which was the lowest value for υ2,s seen in the swelling 
studies. In this case, interactions between the hydrogel and insulin would be significantly 
reduced and a release profile such as is seen in Figure 5.6 might be explained. The same 
behavior was not seen with insulin glargine at pH = 5.6, or even at pH = 6.2. This could 
be due to the fact that insulin glargine is much more strongly ionic in nature that native 
human insulin due to the addition of the arginine residues.  
 
5.4. Conclusions 
Insulin and insulin glargine were successfully loaded into various formulations 
of P(MAA-g-EG) hydrogels. For both insulin species, the loading efficiency increased 
with increasing crosslink density for the hydrogel. While this trend was clear, no 
optimum value was achieved which suggested a point of excessive crosslinking. The high 
efficiency of loading was not adequately explained by the characteristic mesh size with 
regard to diffusive limitations by the network. This indicated that insulin was bound 
within the hydrogel by attractive forces. The most likely bonds which could have formed 
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are hydrogen bonds which are also responsible for the complexation of the hydrogel at 
low pH levels. 
Insulin and insulin glargine loaded hydrogels were suspended in PBS at various 
pH levels to measure the release of the protein. In general, the release of the protein did 
not exceed 20 % until the pH or the release buffer was above both the pKa of P(MAA-g-
EG) and the pI of the incorporated insulin or insulin glargine, at which point the release 
occurred as a burst. Exceptions to this trend occurred for human insulin for the most 
loosely crosslinked formulations, but not for insulin glargine. These results lead to two 
major conclusions. First, the burst release of insulin at pH levels above the ionic 
transition points for the polymer and the protein indicated that insulin was propelled from 
the network due to ionic repulsion. Second, the apparent diffusive release of insulin at pH 
= 5.6 from the two most loosely crosslinked hydrogel formulations suggested that there 
was a critical polymer volume fraction necessary to effectively maintain the hydrogen 
bonds between P(MAA-g-EG) and insulin. At this point, however, these results are only 
an indication of this behavior and a thorough explanation for the interaction between 
P(MAA-g-EG) and protein drugs would require further investigation. 
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Table 5.1. A comparison between native human insulin and insulin glargine 
 
 Human Insulin Insulin Glargline 
Molecular Weight (Da) 5808 6063 
Structure Change None 
Glycine replaces 
AspA21 & two arginine 
residues at C-terminus 
of B chain 
Isoelectric Point (pI) 5.2 6.7 
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Table 5.2. Average insulin incorporation efficiencies for all P(MAA-g-EG) hydrogel 
formulations (± S.D., n = 3) 
 
 Monomer fraction (wt%) 
  33 wt% 50 wt% 66 wt% 
0.375% N/A 42.7 ± 25.3 76.6 ± 4.7 
0.75% 52.7 ± 7.0 76.7 ± 2.2 77.8 ± 0.3 
1.25% 67.3 ± 3.4 77.1 ± 1.8 81.9 ± 1.4 
PE
G
D
M
A
 (2
00
) (
m
ol
%
) 
2.00% 75.2 ± 3.6 82.0 ± 2.1 84.9 ± 0.9 
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Table 5.3. Average incorporation efficiencies for insulin glargine loading in four 
P(MAA-g-EG) hydrogel formulations (± S. D., n = 3) 
 
 Monomer fraction (wt%) 
 33 wt% 66 wt% 
0.750% 45.7  64.7 
PE
G
D
M
A
 (2
00
) 
(m
ol
%
) 
2.000% 61.9 83.2 
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Figure 5.1. RP-HPLC absorbance at 214 nm of native human insulin standard with 
insulin aggregate (top) and human insulin following uptake and release from an ILP 
sample (bottom) 
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Figure 5.2. Total absorbance spectra for (a) native human insulin standard and (b) human 
insulin following uptake and release from an ILP sample 
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Figure 5.3. Release of insulin from ILP samples of P(MAA-g-EG) formulations (a) 
0.75/66 and (b) 2.0/66 into PBS at various pH levels (+ S.D., n = 3) 
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Figure 5.4. Fractional insulin release following 3 hours of dissolution in PBS at 37°C (+ 
S.D., n = 3) 
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Figure 5.5. Fractional insulin glargine release following 3 hours of dissolution in PBS at 
37°C (+ S.D., n = 3) 
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Figure 5.6. Release of insulin from ILP samples of P(MAA-g-EG) formulations 0.75/33 
(closed symbols) and 0.375/50 (open symbols) into PBS at various pH levels (± S.D., n = 
3) 
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CHAPTER 6: SYNTHESIS AND CHARACTERIZATION OF PEGYLATED 
INSULIN 
 
6.1. Introduction 
One of the most difficult challenges to oral insulin delivery is maintaining the 
integrity of the protein against enzymatic degradation in the GI tract. In simulated testing, 
hydrogels of P(MAA-g-EG) have been able to successfully protect insulin through the 
most aggressive section of the stomach and duodenum to then release it in the jejunum 
[1-4]. Delivering insulin to the small intestine is important because of the lower 
enzymatic activity and the potential for absorption by the local tissues. These hydrogels 
exhibit additional characteristics which enhance their potential for oral insulin delivery. 
The mucoadhesive behavior of swollen P(MAA-g-EG) causes insulin to be released at 
the proposed site of absorption, near the apical surface of the epithelial cells in the small 
intestine which are covered by a thick mucous layer [5-7]. By releasing in this location 
insulin has a greater chance of absorption because it has shown low levels of enzymatic 
degradation in the presence of brush border peptidases [8]. Additionally, these hydrogels 
strongly bind Ca2+ ions from the intestinal lumen. This contributed to the reversible 
opening of the tight junctions between Caco-2 cells in an in vitro model of the intestinal 
epithelium as well as reduced the enzymatic activity of intestinal enzymes, which rely on 
extracellular Ca2+ to maintain their activity [9-12]. While all of these attributes of 
P(MAA-g-EG) benefit the design for oral insulin delivery, they are only significant when 
insulin is in close proximity to the hydrogel. Upon release, insulin may not immediately 
diffuse to the apical surface of the tissues in the intestine. Extended exposure to the GI 
tract, unless in the presence of P(MAA-g-EG), is likely to lead to the protein’s eventual 
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enzymatic degradation by lumenal enzymes. In order to improve the design of this 
delivery system and improve bioavailability of orally delivered insulin, the resistance of 
insulin to enzymatic degradation should be improved.  
There are several approaches to reduce environmental enzymatic activity.  
Several groups have proposed the co-administration of enzyme inhibitors with an orally 
delivered protein [13-16]. However, considerably reducing enzymatic activity in the GI 
tract could greatly affect natural digestion and lead to complications such as poor nutrient 
absorption, diarrhea, or even malnutrition [16, 17]. In order to reduce the proteolytic 
degradation of insulin with minimal effect to natural digestion the changes must be 
localized near the protein. One method of making the protein resistant to enzymatic 
attack is through PEGylation, the covalent conjugation of polyethylene glycol (PEG) to 
the molecule.  
PEGylation of proteins has several key benefits that are associated with the high 
biocompatibility of the polymer. PEGylation has been shown to decrease 
immunogenicity and antigenicity, improve solubility, and increase circulation time for 
proteins [18-20]. The most important effect for oral protein delivery is the reduced 
enzymatic degradation of PEGylated proteins [18-21]. The steric hindrance caused by the 
presence of PEG decreases the accessibility of proteolytic enzymes to sites for 
degradation on the polypeptide. For many proteins PEGylation can occur at many 
different locations on the protein sequence by a number of various chemical reactions. In 
the case of insulin, however, there are few potential sites for conjugation and it must be 
targeted to very specific locations on the protein in order to maintain its biological 
activity.  
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In work performed by Lindsay and Shall [22] the three amino groups of insulin 
were individually acetylated: the N-termini of the A and B chains and the lysine in the 
29th residue of the B chain. These sites will henceforth be referred to as GlyA1, PheB1, 
and LysB29 in this chapter. The amino acid sequence of insulin is given in Figure 6.1. 
Their study determined that upon modifying the GlyA1 residue that the bioactivity of 
insulin was significantly reduced. The bioactivity was maintained, however, after 
modification of the other two amino acids. Similar results were made by several studies 
performed by Baudys et. al. [23, 24] which showed that glycosylation with a low 
molecular weight glycoside at the GlyA1 residue reduced bioactivity. The same 
modification at PheB1 or LysB29 indicated full retention of bioactivity. For this reason, 
both the PheB1 and the LysB29 site have been targeted for insulin PEGylation in the past 
and there is still debate as to which location is more suitable.  
In this study the PheB1 was targeted for a mono-substituted PEG-insulin 
conjugate for several reasons. First, even though both LysB29 and PheB1 can be 
modified without reducing bioactivity of insulin, the bioactivity of insulin was 
significantly reduced for di-substituted insulin species in which both LysB29 and PheB1 
were PEGylated [23-25]. Second, while each site maintained similar biological activity 
levels, modification at the PheB1 site exhibited a greater reduction in the immunogenicity 
of the protein [26]. Third, PheB1 modification had a more pronounced effect on the 
stability of the protein when compared to LysB29 [23, 27]. Fourth, modifying the PheB1 
residue eliminates the ability of the protein to self-associate into 6 member hexamers. 
Insulin is only reactive as a monomer and if it forms dimers or hexamers it must 
dissociate in order to bind to the insulin receptor. Modifying the LysB29 site stops the 
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monomer from forming dimers, however, hexamers can still occur in a Zn2+ stabilized 
formation. Finally, the location of the PheB1 residue in the tertiary structure of insulin is 
on the opposite side of the protein as that of the binding site. This is clear in a space-
filled, 3-D rendering of the insulin monomer seen in Figure 6.2. In this figure, the white 
residues indicate the insulin receptor binding site, which includes GlyA1. The three 
highlighted residues are: GlyA1 (red), LysB29 (orange), and PheB1 (green). If the 
reduction in biological activity by PEG is due to steric hindrance, the modification of 
PheB1 should be less pronounced than LysB29 due to the relative proximity of LysB29 
to the receptor binding site. The major argument for modifying the LysB29 residue is that 
the synthesis of LysB29 modified insulin is easier and generally has a higher yield than 
PheB1 modification. However, due to the reasons listed above, the PheB1 residue was 
targeted for this work. 
The synthesis of PEGylated insulin has been achieved through a variety of 
ways. Until recently, however, most of those approaches did not attempt to target a 
particular amino acid for modification and relied on purification methods to separate the 
product mixtures. The technique used in this work was a modification of a protocol 
designed by Hinds et. al. which investigated insulin PEGylation with PEG groups of 750 
and 2000 Da [27]. In this work, the molecular weight of the PEG group investigated is 
5000 Da. The higher molecular weight should impart more of the beneficial effects of 
PEGylation on insulin, but it may cause a drop in bioactivity. This will be discussed and 
determined in Chapter 7. 
In order to target the PheB1 amino acid for PEG conjugation the other two sites 
with free amine groups had to be eliminated as potential sites for conjugation. In order to 
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do so, the protein was pre-treated with di-t-butyl dicarbonate (diboc), which can 
reversibly react with the free amine groups of a protein [28]. This reaction attaches 
extremely hydrophobic t-butyl (BOC) groups to the amino acids with which it reacts. 
When the protection reaction is performed in dimethyl sulfoxide (DMSO) with 
triethylamine (TEA) the GlyA1 and LysB29 are more reactive than PheB1 [24]. 
Although PheB1 is less probable to be modified with a BOC group, this reaction 
produces a number of side products. This protection is reversible, however, and if the 
side products are separated from the desired product they should be able to be recycled 
for use in subsequent batches. After reacting with diboc and purifying the desired 
product, the reaction with an amine reactive mPEG species is isolated to the single 
remaining free amine group of insulin at PheB1. After PEGylation the BOC groups can 
be removed and a mono-substituted mPEG-insulin conjugate is produced. In this work, 
the synthesis of PheB1-mPEG-insulin is described and characterized. 
 
6.2. Materials and Methods 
 
6.2.1. Materials 
Dimethyl sulfoxide (DMSO), triethylamine (TEA), trifluoroacetic acid (TFA) 
di-tert-butyl dicarbonate (diboc), acetonitrile ethanol amine, ethylenediaminetetraacetic 
acid (EDTA), tris, sodium chloride (NaCl), ammonium bicarbonate (NH4HCO3), 
hydrogen chloride (HCl), urea, dithiolthreitol (DTT), 2,5-dihydroxybenzoic acid (DHB), 
sinapic acid, α-cyano-4-hydroxycinnamic acid (CHCA), iodoacetamide, ammonium 
hydroxide, and acetic acid were purchased from Sigma Aldrich (St. Louis, MO). 
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Spectrapor® 6 regenerated cellulose dialysis tubing was purchased from Fisher Scientific 
(Hampton, NH). Recombinant human insulin was purchased from Seracare Diagnostics 
(Milford, MA). mPEG succinmidyl propionate 5000 (mPEG-SPA) was purchased from 
Nektar Therapeutics (Huntsville, AL). Immobilized TPCK Trypsin was purchased from 
Pierce Chemical Company (Rockville, IL) 
 
6.2.2. Synthesis of Di-BOC Insulin  
In order to target insulin PEGylation to only the PheB1 amino acid, the native 
protein was first modified such that the PEG conjugation did not occur at two other 
potential amino acid residues, GlyA1 and LysB29. To do this a solution of 500 mg  
insulin was made in 9.5 ml of DMSO and 0.5 ml TEA. Another solution with 41 mg 
diboc was made in 0.5 ml DMSO. Insulin and diboc were reacted in a 1:2 stoichiometric 
molar ratio to increase the yield of the properly protected insulin intermediate. The 
reaction of insulin with diboc reversibly alkylates free amine groups with a BOC 
protecting group.  
Once both reactants were completely dissolved, the solution with diboc was 
pipetted into the solution with insulin using a glass transfer pipette. A few drops of 
DMSO were then used to rinse the centrifuge vial with the solution originally containing 
diboc and added to the reaction solution. The solution was stirred at 60 rpm and the 
alkylation reaction was allowed to take place for 30 minutes at room temperature. After 
30 minutes, 25 μl of ethanol amine was added to the solution to quench any remaining 
unreacted diboc. The entire reaction mixture was then pipetted into 200 ml of acetone and 
1 drop of 6 M HCl was added to initiate precipitation of the protein. The reaction vial was 
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rinsed with a small amount of acetone to ensure complete transfer of the reaction product. 
The precipitate was removed by filtration using a 0.22 mm PVDF filter paper under 
vacuum until dry. To be sure that no further protein was in solution, several drops of 6 M 
HCl was added to the recovered filtrate. If any further precipitation occurred the solution 
was filtered a second time. The precipitate and filter paper were then placed into 30 ml of 
DI water. A small amount of DI water was used to rinse the filtration funnel. After 30 
minutes, the filter paper was removed, rinsed with water, and discarded. The remaining 
solution was then dialyzed against DI water in a 3500 MWCO membrane overnight to 
remove residual acetone, unreacted diboc, and ethanol amine.  
The crude product from the reaction between diboc and native human insulin 
was purified using ion exchange chromatography (IEC), more specifically cation 
exchange chromatography. Urea and acetic acid was added to the solution recovered 
from dialysis to make a 7M urea and 1 M acetic acid solvent. This was the starting 
mobile phase of the IEC purification. When doing this, the total volume of the solution 
increased greatly, so the amount of urea and acetic acid necessary were based on an 
increase in volume of 50%. The purification was performed using Fast Protein Liquid 
Chromatography (FPLC) (GE Healthcare, Piscataway, NJ). A gradient elution profile 
was used with two mobile phases: buffer A contained 7M urea, 1M acetic acid, and 0.01 
M NaCl, buffer B contained 7M urea, 1M acetic acid and 0.3M NaCl. The gradient was 
performed from 0 – 60 %B over 80 column volumes using either a SP FF 16/10 cation 
exchange column (GE Healthcare, Piscataway, NJ) at a flow rate of 2 ml/min for large 
volume samples or a Mono S 5/50 cation exchange column (GE Healthcare) at a flow 
rate of 0.7 ml/min for small volume samples. The column was then washed with 100 %B 
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and re-equilibrated with 100 %A prior to any additional injections. The elution was 
collected by a Frac-950 fraction collector in 14.5 ml fractions for the SP FF 16/10 column 
and 2 ml fractions for the Mono S 5/50 column. The elution profile from the column was 
measured by UV absorbance at 280 nm.  
Characterization of each fraction was performed using RP-HPLC. The mobile 
phases were 0.1 % TFA in DI water as mobile phase A and 0.1 % TFA in acetonitrile as 
mobile phase B. Samples of 50 μl were run through a Waters Spherisorb® C8 column (5 
μm, 4.6 x 250 mm) using a Waters 2695 separations module equipped with a 996 
Photodiode Array detector (Milford, MA) at a 1 mL/min. A gradient from 35-65 % 
mobile phase B was run for 35 minutes. Purified fractions with greater than 90 % purity 
of di-BOCLysB29/GlyA1 insulin were then used for PEGylation. The remaining fractions 
were recycled as described below. All fractions were then dialyzed with a MWCO 3500 
membrane against 0.01M NH4HCO3 for three days, changing the dialysate twice daily. 
The dialyzed fractions were then frozen overnight and lyophilized. 
 
6.2.3. Recovery of Impure Diboc Treated Insulin 
As a proof of concept, products collected from the FPLC purification of diboc 
treated insulin which were not deemed have two BOC groups or have sufficient purity for 
PEGylation were recycled. Any modification with BOC groups was removed from the 
product mixture by placing the lyophilized material in TFA at 0 °C for 90 minutes. The 
TFA was then diluted into 10 times the volume of DI water and dialyzed for 24 hours 
changing the dialysate three times. The recovered deprotected insulin product was then 
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frozen and lyophilized. This insulin was now simply regular human insulin and could be 
treated with diboc in a similar fashion as described above. 
 
6.2.4. Di-BOC Insulin PEGylation 
The purified di-BOCLysB29/GlyA1 insulin was reacted with mPEG-SPA to 
conjugate PEG to the PheB1 residue. Purified di-BOCLysB29/GlyA1 insulin powder was 
dissolved in 2 mL of DMSO containing 47.5 μL TEA. A 3:1 molar excess of mPEG-SPA 
was added to the reaction solution, and the reaction was allowed to proceed for 24 hours 
at room temperature. The products were then diluted into 100 mL of DI water, dialyzed 
and lyophilized in the same fashion as section 6.2.2.  
The lyophilized product was dissolved in TFA at 0°C for 90 minutes to remove 
the BOC protection groups from the newly formed PEGylated insulin. After 90 minutes, 
the TFA was diluted into 10 times the volume of DI water and dialyzed by the same 
fashion described above. The solution was purified to remove insulin and excess mPEG-
SPA using IEC in the same fashion as described above. The elution was again collected 
and the peaks were dialyzed and lyophilized. The major peak corresponding to the 
PheB1-PEG-insulin conjugate was recovered and stored under nitrogen at -20°C until 
needed. 
 
6.2.5. Di-BOC and PEGylated Insulin Characterization 
Both di-BOC and PEGylated insulin were characterized to validate the method 
to create a PEG-insulin conjugate in which the modification is only present at the PheB1 
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residue. Two of digestion techniques were required to identify individual sites of 
modification and are described below. 
 
6.2.5.1. PEGylated Insulin Digestion 
In one of the digestion methods used to determine the site of PEGylation, the 
disulfide groups were reduced to separate the A and B chains of insulin (Figure 6.1). Two 
mg of PEGylated insulin was dissolved in 5 mL denaturation buffer of 7 M urea, 0.2 M 
tris, and 2 mM EDTA at pH = 8.5 in a screw-cap test tube. The solution was flushed with 
nitrogen and heated to 50 °C for 30 minutes in a water bath. A 50-fold molar excess of 
DTT over the number of moles of disulfide present in insulin was then added and allowed 
to react for 4 hours. This reaction cleaved any disulfide bonds present in the protein. To 
keep the disulfide bonds from reforming, a 100-fold molar excess of iodoacetamide over 
the number of moles of disulfide present in insulin was added after the 4 hour reduction 
reaction. The solution pH was measured immediately following the addition of 
iodoacetamide and a small amount of ammonium hydroxide was added to maintain the 
pH of the solution at 8.5. The reaction was then allowed to proceed for 20 minutes at 
room temperature in the dark. This was done to limit the conversion of liberated iodide 
ion to iodine which would react with tyrosine residues in the protein [29]. After treatment 
with DTT, a precipitate formed in the solution. Following the final step of this reaction 
process, the precipitate was removed by centrifugation and analysis of the liquid was 
possible. As will be described later for PEGylated insulin, the B chain remained in 
solution while the A chain crashed out.  
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The second digestion process with PEGylated insulin was performed using a gel 
immobilized trypsin kit. This digestion cleaved two bonds in the amino acid sequence of 
insulin as seen in Figure 6.1. Trypsin specifically cleaves the carboxyl side of arginine 
and lysine residues. This allowed the LysB29 residue to be separated from the other two 
potential sites for amine specific PEGylation of insulin. One mg of PEGylated insulin 
was dissolved in 0.5 ml of 0.1 M NH4HCO3 at pH = 8.0. A slurry of 0.25 ml of the gel 
immobilized TPCK trypsin was then added to the solution in a 1.5 ml centrifuge tube. 
The mixture was flushed with nitrogen, sealed, and incubated overnight on a rapidly 
shaking tray in an oven at 37 °C. The immobilized trypsin was then removed from 
solution by centrifugation and the supernatant was recovered which contained the 
degraded insulin conjugate. Combination of the two digestion techniques allowed for 
clear identification of modification at any one of the three potential conjugation sites. 
 
6.2.5.2. MALDI-TOF Mass Spectroscopy 
Matrix assisted laser desorption ionization/time of flight mass spectroscopy 
(MALDI-TOF MS) was used to characterize many of the modified insulin or degraded 
insulin species throughout this study. Most of the work was performed on a VG TofSpec 
E MALDI-TOF (ThermoVG, Beverly, MA). Sinapic acid or DHB was used as the matrix 
for this instrument. Some of the final spectra shown in this report were processed using a 
Voyager DE Pro MALDI-TOF (Applied Biosystems, Foster City, CA). The matrix used 
for this instrument was CHCA.  
A 2500:1 ratio of matrix to analyte was used for each run. The sample protein or 
peptide was dissolved into a 50 % acetonitrile solution in DI water with 0.1 % TFA. This 
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was done so that any samples collected from RP-HPLC elution could be tested without 
changing solvents. The analytes were then dispersed into a 0.05 M solution of the matrix 
with proper volumetric ratios to give a 2500:1 molar ratio. Because this solution did not 
dry quickly upon spotting on the MALDI-TOF plate, the plate was placed in an oven at 
80 °C for about 5 minutes prior to spotting.  
 
6.3. Results and Discussion 
 
6.3.1. Synthesis of Di-BOC Insulin 
For clarity, di-BOCLysB29/GlyA1, insulin with BOC groups specifically at the 
LysB29 and GlyA1 residues, will henceforth be referred to as di-BOC insulin. This 
should be distinguished from diboc treated insulin which refers to insulin which has been 
reacted with di-t-butyl dicarbonate, but not purified. 
Di-BOC insulin was synthesized and purified from recombinant human insulin. 
RP-HPLC spectra for insulin, diboc treated insulin, and purified di-BOC insulin can be 
seen in Figure 6.3. The later the peaks eluted, the more hydrophobic they were. A shift to 
the right in the elution profile indicated the attachment of BOC groups to the insulin 
molecule. The peaks for insulin, mono-BOC insulin, di-BOC insulin, and tri-BOC insulin 
eluted at approximately 9.2, 12.2, 15.1, and 21.2 minutes as shown in Figure 6.3b. 
Additional peaks correspond to alternative locations of the BOC group. The reactivity of 
the amine groups in insulin proceeds with LysB29 ≥ GlyA1 > PheB1 when in the 
DMSO/TEA solution used in this study, so the alternative BOC locations should proceed 
accordingly [24]. The three major peaks in Figure 6.3b at 12.2, 15.1, and 21.2 minutes 
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corresponded to 13.40, 56.80, and 14.68 % of the total integrated area of the 
chromatogram. The peak of interest for di-BOC insulin was the major peak at 15.1 
minutes, so the yield of the BOC protection was 56.8 %.  
 
6.3.2. Purification of Di-BOC insulin 
Individual peaks of the impure mixture were separated using cation exchange 
chromatography on an FPLC. The isolation of each peak had some loss due to peak 
overlap causing a reduction in overall product yield. However, the recycle and recovery 
of discarded diboc treated insulin was possible and could be used to greatly improve 
overall yield. A sample elution profile for the separation of individual peaks is in Figure 
6.4. Fractions of 14.5 ml were collected throughout the elution. Because the separation 
was performed with cation exchange chromatography, the binding was dependent on the 
number of positively charged residues in the protein. The most highly substituted tri-
BOC insulin eluted first followed by di-BOC insulin, mono-BOC insulin, and native 
insulin. This was the reverse of the elution order as seen with RP-HPLC. After collection, 
the purity of collected fractions was determined by RP-HPLC. A set of collected fractions 
can be seen in a single chromatogram in Figure 6.5. The profiles for fractions 3, 4, and 5 
indicated samples with greater than 90 % purity of the major peak eluting at 17 minutes. 
This sample run was performed with a different batch of mobile phase which caused the 
slight shift seen between this di-BOC insulin sample retention time and that seen in 
Figure 6.3.  
While the RP-HPLC and IEC retention times are indicative of the changes 
expected from the modification of insulin with BOC groups, further analysis should be 
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included to validate the results. The most pure samples collected for each of the major 
peaks eluted from the FPLC cation exchange were tested using MALDI-TOF MS. Each 
BOC modification adds 100 Da to the molecular weight of the protein. Figure 6.6 shows 
the molecular weight of each species. Each of the molecular weights were not exactly as 
expected due to variances in the calibration files used. The molecular weight shifts 
ranged from 95-102 Da added between samples, which corresponded very well with the 
addition of a single BOC group. The smaller peaks which were slightly heavier than the 
main peaks were due to associated salts which were present in small amounts in the 
sample solutions.  
During the diboc insulin treatment and purification of process, the majority of 
product loss occurred. This was primarily due to the nature of the reaction which 
produced di-BOCLysB29/GlyA1 insulin as the major product, but also had several side 
products with BOC groups attached to other residues. Because the BOC modification was 
reversible, products deemed to be incorrectly modified or with low purity were recycled. 
The purpose of this exercise was a proof of concept that the overall yield could be 
improved through good chemical engineering techniques of recovery and recycling.  
The fractions of the diboc treated insulin which were not used for PEGylation 
following FPLC separation were dialyzed, frozen, and lyophilized. This product mixture 
was then recycled to native insulin by removing the BOC groups in TFA and purifying 
the sample by dialysis. A RP-HPLC spectrum of the recovered native insulin against an 
insulin standard is given in Figure 6.7. The major single peak of insulin was mirrored by 
the recovered insulin. Figure 6.8 indicated that the total absorbance spectrum for the 
recovered insulin sample was exactly the same as that of the insulin standard. However, a 
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second peak at 13 minutes was also present in the recovered insulin which was absent in 
the control sample. In Figure 6.9, the recovered insulin absorbance at 214 nm is overlaid 
with a crude insulin sample from the initial diboc treatment. The peak for mono-BOC 
modified insulin correlated very well with the secondary peak of the recovered insulin 
indicating that a small portion of the mono-BOC insulin was not removed from insulin. 
The recycled insulin was then reacted with diboc to create a “second pass” diboc treated 
insulin. Figure 6.10 compares the first and second pass diboc treated insulin samples. The 
two samples corresponded exceptionally well in retention time and relative peak sizes 
and areas. This work proved that insulin treated with diboc could be recycled and reused 
to generate more of the intermediate product. If this process were to be scaled up or used 
on a more consistent basis, this method should be utilized to improve yield of PEGylated 
insulin.  
This work shows definitively that the diboc modification worked to modify 
insulin with zero, one, two, or three BOC species. The majority of the reaction product 
was an insulin molecule with two BOC groups attached. The separation of individual 
species was successfully carried out using cation exchange chromatography. This 
indicated that the modification with BOC occurred at the free amine groups on insulin, 
which were positively charged in the mobile phase used for the ion exchange purification. 
Another result of this work is that the diboc treatment can be repeated with insulin in a 
way that impure products are recycled and reused. This could be used to greatly improve 
the yield of the diboc protection process. 
 
 
 175
6.3.3. Insulin PEGylation 
Di-BOC insulin samples with greater than 90 % purity were reacted with 
mPEG-SPA to created PEGylated di-BOC insulin. The molecular weight of the mPEG-
SPA was 5298 as determined by the manufacturer using gel permeation chromatography. 
A corresponding shift was seen in the molecular weight of the protein and was exhibited 
by several MALDI-TOF MS spectra which were used to characterize the reaction. Figure 
6.11 shows a physical mixture of di-BOC insulin with mPEG-SPA with DHB as the 
matrix. The matrix was chosen for this scan because it was able to charge both proteins 
and polymers in a single scan. The PEG is easily distinguished by its distribution in 
molecular weight in a Gaussian distribution with its center around 5628 and repeat units 
of ethylene glycol of 44 Da, the molecular weight monomer. Figure 6.12 shows a 
MALDI-TOF spectrum following the reaction of di-BOC insulin with mPEG-SPA. In the 
absence of salts, the matrix used for this scan, sinapic acid, was only able to charge 
proteins. The peaks associated with mPEG-SPA shifted up to ~ 11600 Da with the same 
distribution as seen for PEG alone and maintained the 44 Da repeat units of the polymer. 
This indicated the conjugation of one PEG molecule to di-BOC insulin. Some residual di-
BOC insulin was present because the sample had not yet been purified.  
After conjugation, the BOC protecting groups on insulin were removed using 
TFA. The elimination of residual reactants was then performed using cation exchange 
chromatography. In order to improve the efficiency of sample retention, a series of small 
injections were run on the FPLC instead of a single large injection. The entire series of 
elution spectra are displayed in Figure 6.13 with absorbance at 280 nm. The peak 
occurring between 2 and 12 ml in the elution profile was due to excess PEG, which did 
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not bind to the column. The first major peak at ~ 38 ml was PEGylated insulin and the 
second peak at 52 ml was native insulin. It was evident from this chart that the 
purification method was very repeatable and each peak was easily distinguishable with 
minimal overlap. The fractions for PEGylated insulin were collected and dialyzed to 
remove salts and solvents present in the IEX mobile phase. The purified sample solution 
was then lyophilized and the recovered powder was stored at -20 °C under nitrogen until 
needed. 
The purified sample of PheB1-PEGylated insulin was confirmed using MALDI-
TOF MS. A close up view of the distribution for the PEGylated insulin can be seen in 
Figure 6.14. The center of the distribution for this scan was at 11381, almost exactly 200 
Da lower than the center for the PEGylated di-BOC insulin in Figure 6.12. The drop in 
molecular weight was due to the loss of the two BOC protecting groups. The 44 Da 
molecular weight repeat unit was evident in this figure. MALDI-TOF scans in higher 
molecular weight ranges (data not shown) did not exhibit any peaks for PEGylated 
insulin which may have had two or three PEG conjugations.  
The final yield of PEGylated insulin after each of these steps was 68.6 mg. 
Taking the increased molecular weight of the protein conjugate into account, this 
constituted a yield of 6.9 %. While this was quite low, there were several key factors 
which could be addressed to improve the yield of the process. The majority of the loss for 
producing PheB1 PEGylated insulin was in the first step of the diboc treatment. This 
reaction had a yield of 56.8 % of di-BOC insulin. As discussed above, the side products 
and impure di-BOC insulin could be recycled for use in a second batch of PEGylated 
insulin. If the process were to be scaled up or performed more regularly, recovering and 
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recycling these extra diboc treated insulin species would greatly improve the efficiency of 
this process. The remaining loss was likely due to handling of lyophilized powders, 
transfer of solutions, dialysis, IEC purification of the final product, and sampling 
throughout the process to analyze intermediate products.  
 
6.3.4. Characterization of PEGylated Insulin 
To this point, the conjugation of a single mPEG polymer chain on insulin has 
been proven. However, the site of conjugation must be determined to prove that the 
PheB1 was in fact the only site modified. In order to do so, each potential site for 
PEGylation must be distinguished from one another. For proteins and peptides, the 
easiest way to do this is to utilize enzymatic or chemical cleavage of discrete points in the 
protein. In this work two degradation techniques were used: disulfide reduction and 
trypsin digestion. 
 
6.3.4.1. PEGylated Insulin Disulfide Reduction 
By eliminating disulfide bonds between cysteine residues in insulin, the A and 
B chains of the protein were separated from one another (Figure 6.1). This separation 
isolates the two chains allowed elucidation of the site of PEGylation being on the A chain 
at the GlyA1 or on the B chain at either the PheB1 or LysB29 site. In order to keep 
disulfide bond from reforming, they were stabilized with iodoacetamide according to the 
reaction shown in Figure 6.15. This reaction added 58 Da at each cysteine residue which 
was reduced by DTT.  
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Following the reaction protocol described above, the retentate was analyzed 
using the Voyager DE Pro MALDI-TOF MS. In a scan between 1000-6000 Da, a strong 
peak was evident at 2634 Da, as shown in Figure 6.16. This corresponded well to the 
expected peak for the A-Chain without conjugation with mPEG-SPA, which has a 
molecular weight of 2615 Da. When the same sample was observed between 5000-15000 
Da as shown in Figure 6.17, a molecular weight distribution was clear centered on 9036 
Da. Since the matrix used for this analysis, CHCA, did not charge polymers in the 
absence of salts, the PEG must have been conjugated to a digested fragment of insulin. 
The molecular weight corresponded well to the expected mass if mPEG-SPA was 
conjugated to the B-chain of insulin, a distribution which would have been centered at 
9174. If PEG was conjugated to the A-chain a similar distribution would be present 
centered at 8127, which was not evident in the MALDI-TOF spectra. These results 
confirm that the PEGylation of insulin took place at one of the two potential residues on 
the B-chain of insulin, PheB1 or LysB29, and not at the GlyA1 residue. 
 
6.3.4.2. PEGylated Insulin Trypsin Digestion 
The second method to determine the site of PEGylation for insulin was to digest 
the modified protein using trypsin. This method separated the two ends of the B chain 
and allowed for elucidation of which residue of the B chain was PEGylated. Trypsin 
specifically cleaves polypeptide bonds at the carboxyl side of lysine and arginine 
residues. For the case of insulin, the B-chain was cleaved at two locations indicated in 
Figure 6.1. This was relevant for PEGylated insulin because it isolated the LysB29 site 
from the other two residues which could be conjugated with amine reactive mPEG-SPA. 
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A MALDI-TOF MS spectrum for the mass range of 9000-13000 following the 
trypsin digestion is shown in Figure 6.18. The Voyager DE Pro MALDI-TOF MS with 
CHCA was used for this spectrum. There were two distinct peak distributions present. 
They exhibited the characteristic Gaussian distribution associated with PEG centered at 
10591 and 11356 Da. The expected shift in the molecular weight of the PEGylated 
insulin due to the loss of the 8 peptide sequence at the C-terminus of the B-chain 
(GFFYTPKT) was 959 Da. The shift in the peaks seen in Figure 6.18 indicated a shift of 
approximately 765 Da. This was most likely due to the significant amount of crossover of 
the two distributions near the center of the lower molecular weight, shifting the peak to 
the right. The only other peaks seen from this sample were due to the protein being 
doubly charged thus giving it a measured molecular weight distribution centered at 5654 
(not shown), roughly to ½ the molecular weight of the major peak at 11356. No other 
peaks were observed from this sample so the spectrum was truncated. These results 
corresponded very well to digested and undigested PEGylated insulin if the site for PEG 
conjugation was on either the GlyA1 or the PheB1, but not on the LysB29. Since the site 
of PEGylation was determined to not be present at the GlyA1 from disulfide digestion, 
this work confirms that the mPEG-SPA is conjugated exclusively to the PheB1 residue of 
insulin. These results are the clearest representation of this site-specific, mono-
conjugation of PEG to the PheB1 residue of insulin to date, and the methods used should 
be employed by others who wish to target specific residues for conjugation with insulin 
using this or other techniques.  
One interesting result that can be indirectly inferred from this data was the fact 
that less than half of the PEGylated protein was degraded by trypsin, even after the  
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digestion was performed for more than 3 times the recommended amount, due to the 
reduction of enzymatic proteolysis caused by PEGylation. This was a good indication 
that the covalent attachment of PEG to insulin would significantly increase the residence 
time of insulin in the intestinal milieu, increasing its opportunity for absorption across the 
intestinal epithelium.  
 
6.4. Conclusions 
The work presented in this chapter clearly displayed the successful PEGylation 
of insulin. The modification was specifically targeted to the PheB1 residue by reacting 
insulin with diboc prior to conjugation with PEG. The reaction products from diboc 
treatment included a mixture of mono-BOC, di-BOC, tri-BOC, and native human insulin, 
56.8 % of which was the primary di-BOCLysB29/GlyA1 peak. The crude mixture was 
characterized using RP-HPLC. The di-BOCLysB29/GlyA1 was purified using cation 
exchange chromatography. MALDI-TOF MS analysis of the all of the fractions collected 
from the IEX purification indicated the presence of zero, one, two, or three BOC groups 
attached to insulin for individual elution peaks, confirming the results of the RP-HPLC 
characterization. Approximately 80 % of the purified di-BOC sample was present with 
≥90 % purity and was isolated for reaction with mPEG-SPA 5000. Thus, 45.6 % of the 
initial amount of insulin treated with diboc was used for PEGylation. As a proof of 
concept, the remaining diboc treated insulin was recycled and returned insulin to its 
native state. The recycled insulin was reacted again with diboc. The recycled insulin and 
second pass diboc treated insulin products corresponded very well with controls of native 
human insulin and first-pass crude product of diboc treated insulin, respectively. This 
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indicated that this technique could be used to significantly improve yield of the 
intermediate di-BOC insulin. 
Purified di-BOC insulin was reacted with a molar excess of mPEG-SPA 5000. 
The BOC groups were then removed and the conjugate was purified using IEC to 
produce the PheB1-mPEG-insulin conjugate. PEGylated insulin was characterized using 
a series of protein digestion methods in conjunction with MALDI-TOF MS. By process 
of elimination, the PheB1 residue was confirmed as the only site of PEG conjugation. 
Additionally, the difficulty in degrading insulin with trypsin indicated the improved 
enzymatic resistance of PEGylated insulin.   
The final yield of PEGylated insulin was 6.9%. Several changes and 
improvements of the process are possible for future production including: minimal 
sampling of intermediate steps, improved purification resolution, increased PEGylation 
reaction yield from di-BOC insulin, and especially recycling of reaction by-products for 
both the diboc and the PEGylation reactions.  
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Figure 6.1. Amino acid sequence for human insulin with digestion pathways indicated 
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Figure 6.2. Space filled, three dimensional image of an insulin monomer (White = 
insulin receptor binding site, Red = GlyA1, Orange = LysB29, Green = PheB1) 
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(c) 
Figure 6.3. RP-HPLC absorbance at 214 nm for (a) insulin (b) crude diboc treated insulin 
(unpurified) and (c) purified di-BOCLysB29/GlyA1 insulin 
 
 185
 
 
 
 
-10
0
10
20
30
40
50
60
70
0 200 400 600 800 1000 1200
Elution (ml)
A
bs
or
ba
nc
e 
@
 2
80
 n
m
 (m
A
U
)
0
20
40
60
80
100
120
C
on
ce
nt
ra
tio
n 
of
 B
uf
fe
r B
 (%
)
crude diboc
% B
 
Figure 6.4. FPLC elution profile of crude diboc treated insulin using cation exchange 
chromatography with absorbance at 280 nm. 
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Figure 6.5. RP-HPLC stacked plot of fractions collected from FPLC elution with 
absorbance at 214 nm 
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Figure 6.6. MALDI-TOF MS for fractions collected from FPLC separation of crude 
diboc treated insulin species 
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Figure 6.7. RP-HPLC spectra of recovered insulin following removal of BOC groups as 
compared to an insulin standard with absorbance at 214 nm. 
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Figure 6.8. RP-HPLC total absorbance spectrum of (a) recovered insulin following 
removal of BOC groups and (b) native insulin standard 
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Figure 6.9. RP-HPLC spectra of recovered insulin following removal of BOC groups as 
compared to a crude diboc treated insulin sample prior to purification 
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Figure 6.10. RP-HPLC spectra of recovered insulin treated a second time with diboc as 
compared to a first pass crude diboc treated insulin 
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Figure 6.11. MALDI-TOF MS of a physical mixture of di-BOC insulin and mPEG-SPA 
with a 2500:1 molar ratio of DHB to analyte 
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Figure 6.12. MALDI-TOF MS of PEGylated di-BOC insulin prior to eliminating 
unreacted components with a 2500:1 molar ratio of sinapic acid to analyte 
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Figure 6.13. Cation exchange elution profile of PEGylated insulin following removal of 
the BOC groups 
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Figure 6.14. Close up view of  MALDI-TOF MS of purified PEGylated insulin 
following removal of BOC protecting groups 
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Figure 6.15. Reaction of iodoacetamide with a cysteine residue on insulin 
 197
 
 
 
 
 
 
 
 
Figure 6.16. MALDI-TOF MS spectra of the A-chain of PEGylated insulin following 
disulfide reduction and alkylation with DTT and iodoacetamide 
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Figure 6.17. MALDI-TOF MS spectra of the B-chain of PEGylated insulin following 
disulfide reduction and alkylation with DTT and iodoacetamide 
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Figure 6.18. MALDI-TOF MS spectrum for the trypsin digested PEGylated insulin 
sample 
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CHAPTER 7: IN VITRO AND IN VIVO TESTING OF PEGYLATED INSULIN 
WITH P(MAA-g-EG) HYDROGELS 
 
7.1. Introduction 
The evaluation of a design for oral insulin delivery requires a thorough 
knowledge of several important parameters influencing the system such as the 
physiology, pharmacokinetic and pharmacodynamic (PK/PD) profile, and designed 
delivery mechanism. Poly(methacrylic acid-g-ethylene glycol), P(MAA-g-EG), 
hydrogels have already exhibited the ability to adequately inhibit the degradation of 
insulin in the gastric environment [1, 2], bind to the mucus layer of the small intestine [3, 
4], reduce enzymatic activity in the lumen of the small intestine [5, 6], locally and 
reversibly permeate the tight junctions the epithelial layer [7], and deliver insulin to the 
bloodstream in a number of in vitro and in vivo tests [8-10]. The current results of 
previous work has been somewhat promising with bioavailabilities as high as 9.5 % [8]. 
One limitation of the current design is that while P(MAA-g-EG) reduces enzymatic 
activity of the pancreatic enzymes present in the lumen and brush-border of the small 
intestine, most insulin that is released from the hydrogel does not remain localized to the 
hydrogel. Only insulin which is still in very close proximity to the hydrogel will be able 
to utilize its enzyme reducing effects and exhibit a sustained presence in the GI tract. 
Increasing the residence time as an undigested protein in the small intestine should 
greatly increase the likelihood that it will be absorbed as an in tact protein by paracellular 
transport. As discussed in Chapter 6, insulin PEGylation can greatly increase the 
enzymatic resistance of the protein. This behavior was apparent in the very low amount 
of degradation of the protein when exposed to a concentrated amount of a pancreatic and 
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brush-border enzymes [11-14]. By combining the increased enzymatic resistance of 
PEGylated insulin with P(MAA-g-EG) hydrogels the bioavailability of the protein may 
be increased following oral delivery. The in vitro interaction between a PEGylated 
insulin molecule and P(MAA-g-EG) hydrogels should also change. In Chapter 5, the 
uptake and release of insulin from the hydrogel was characterized and appeared to be at 
least partially dependent on the weak bonds formed between the protein and the hydrogel. 
A PEG modified insulin molecule should retain these bonds, but additional bonds may be 
possible between the hydrogel and the PEG chain of the conjugate. Modifying the 
characteristics of insulin through PEGylation will also have an impact on its biological 
effect, as is seen for other PEG modified proteins.  
In this work, the in vitro application of the P(MAA-g-EG) hydrogels with 
PEGylated insulin is performed. The uptake and release of PEGylated insulin is measured 
for three different hydrogel formulations in a similar fashion as was tested for regular 
human insulin. In doing so, changes in the loading or release behavior with PEGylated 
insulin can be attributed to the presence of the covalently attached PEG moiety. 
Characterization of the interaction between PEGylated insulin and P(MAA-g-EG) 
hydrogels may further bolster the conclusions reached based on the testing with native 
human insulin and insulin glargine. 
Application of this drug delivery design is also investigated using an in vivo 
model in rats. Because the protein is inherently different, its activity must be compared to 
the native insulin molecule. From this testing, the PK/PD profiles can be determined 
based on different dosing techniques used to determine bioactivity of PEGylated insulin. 
The use of human insulin in rats is critical because the human an insulin glargine can be 
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distinguished from one another using enzyme linked immunosorbent assay (ELISA) to 
determine concentration. The biological effect of human insulin in rats, however, is 
nearly identical to that of murine insulin. The combined system is also challenged with 
the most rigorous in vivo work performed with P(MAA-g-EG) on rats using in situ dosing 
techniques. In doing so, significant insight can be gained for future designs and 
approaches for oral insulin delivery with P(MAA-g-EG) hydrogels. 
 
7.2. Materials and Methods 
 
7.2.1. Materials 
The materials used to make PEGylated insulin and P(MAA-g-EG) hydrogels 
were the same as used in previous chapters. Bicinchoninic acid (BCA) assays were 
purchased from Pierce Chemical Company (Rockford, IL). Enzyme linked 
immunosorbent assays were purchased from ALPCO diagnostics (#80-INSHU-E10, 
Salem, NH). Male Sprague Dawley rats between 280-320 g were purchased from Harlan 
(Indianapolis, IN). Isofluorane, pentobarbital, and euthanasia solution were provided by 
the veterinary staff at Thomas Jefferson University. An insulin pump was used for 
subcutaneous dosing of insulin (Disetronic Roche Diagnostics, Palo Alto, CA). Blood 
glucose meters and glucose strips were purchased from Hemocue (Lake Forest, CA). 
Liquid diet mix was purchased from Bio-Serv (Frenchtown, NJ). 
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7.2.2. Synthesis of P(MAA-g-EG) Hydrogels 
Only three formulations of P(MAA-g-EG) hydrogels were used for this testing 
due to the limited amount of PEGylated insulin available. The three formulations used 
were chosen to contain low, medium, and high levels of covalent crosslinks based on 
their formulations which were 0.75/33, 1.25/50, and 2.0/66, respectively, where the ratios 
represent mol% of PEGDMA/wt% of monomer present during polymerization. Two 
different types of each formulation were tested. The first set of hydrogels had a 1:1 
monomer ratio of MAA:EG groups. This is the monomer ratio which has been used 
throughout this entire work. A second set of hydrogels had a 3:2 monomer ratio of 
MAA:EG. These samples were only tested in this chapter and were examined to 
emphasize the interaction between P(MAA-g-EG) hydrogels and PEGylated insulin as 
will be discussed in the results of this chapter. 
 
7.2.3. PEGylated Insulin Loading and Release 
The loading of regular human insulin and PEGylated insulin was performed 
according to the same techniques as seen in Chapter 5 for regular human insulin. Release 
studies were performed in PBS at pH levels of 4.7, 5.6, 6.2, 6.8, and 7.4 to adequately 
encompass the range in which P(MAA-g-EG) exhibits the largest change in swelling and 
ionic state. The protein concentrations were determined for the in vitro testing using a 
bicinchoninic acid (BCA) protein assay. This assay does not distinguish between 
different types of proteins, so standard curves were established for both human insulin 
and PEGylated insulin against the supplied bovine serum albumin standards. Briefly, 
aliquots of 25 μl of solution were added to a clear, polystyrene, flat-bottomed, 96-well 
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plate. Each well was filled with 200 μl of working reagent which was supplied by the 
manufacturer. The well was then covered and allowed to incubate at 37 °C for 30 
minutes. The plate was allowed to cool to room temperature before measuring the total 
absorbance of each well at 550 nm using a plate reader (BioTek Elx800, Winooski, VT).  
 
7.2.4. In Vivo Determination of PEGylated Insulin Bioactivity 
All in vivo studies performed in this work were approved by the Institutional 
Animal Control and Use Committee (IACUC) at Thomas Jefferson University under 
protocol number 355 version V. The bioactivity of PEGylated insulin was measured 
against native human insulin following intravenous (IV) and subcutaneous (SC) injection 
into healthy rats. Male Sprague Dawley rats between 280-320 grams were allowed to 
acclimatize to their environment for a minimum of 3 days before use. The rats were 
fasted overnight to reduce their endogenous stores of glycogen which would counteract 
an induced hypoglycemic effect caused by insulin. During fasting, the rats were placed in 
cages with wire mesh bottoms which allowed feces to drop through the wiring so that 
they would not ingest them during the night. They were provided with unlimited amounts 
of water during their fast. The following morning, the rats were put under general 
anesthesia by a SC injection of 40-50 mg/kg of pentobarbital. Once anesthetized, each rat 
was weighed to determine accurate dosing levels and restrained in the supine position 
under a neonatal heating lamp by surgical tape. The rats were placed on a small piece of 
cardboard covered with aluminum foil to reflect the radiant heat back into the animal and 
help maintain their body temperature. Each rat was connected by a nose cone to a source 
of 100 % oxygen flowing through an isofluorane vaporizer. General anesthesia was 
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maintained throughout the test with 1-2 % isofluorane. The body temperature of each rat 
was monitored using an anal thermometer and maintained between 98-100 °F. Up to six 
rats could be connected in series under the neonatal lamp and connected to the vaporizer.  
Blood samples were collected directly from the jugular veins which were 
accessed bilaterally by incisions of about 2 cm along the trachea anterior from the 
clavicle. Cotton balls were placed over the incision sites and intermittently saturated with 
normal saline to maintain the pliability and hydration of the tissues. Blood samples of 0.2 
ml were collected with a 1.0 ml syringe equipped with a 27-gauge needle. For 
intravenous (IV) testing, the doses were injected directly into the circulation using the 
jugular vein. Blood samples were taken at 1, 5, 10, 15, 30, 45, 60, 120, 180, 240, 300, and 
360 minutes following dosing. Three baseline samples were also taken following surgery, 
but prior to dosing to establish the initial blood glucose levels in each rat. Subcutaneous 
(SC) testing doses were injected under the skin of the rat in the abdomen using an insulin 
pump. Blood samples were taken following SC injection at 1, 5, 10, 15, 30, 45, 60, 120, 
180, 240, 300, 360, 420, and 480 minutes. Three baseline samples were also taken as was 
done for IV testing. Following the testing the rats were euthanized using a 0.5 ml IV 
injection of the euthanasia solution according to the Panel on Euthanasia of the American 
Veterinary Medical Association. 
The sample groups for IV and SC studies were dosed with either phosphate 
buffered saline (PBS), regular human insulin, or PEGylated insulin. Solution 
concentrations were adjusted such that a 200 μl dose would be administered for a 300 
gram rat at the desired dosing levels of IU/kg. The rats tested with insulin or PEGylated 
insulin were given doses of 1.0 IU/kg for IV and SC studies or 4.0 IU/kg in one test for 
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SC administration. The dose at 4.0 IU/kg was too high for the rats and induced acute 
hypoglycemia which was counteracted by IV administration of glucose. Once glucose 
was administered, the blood glucose levels of the rats were no longer valid, but the rate of 
onset for the drugs still provided useful information for the pharmacokinetics of the 
drugs. Levels for IU of PEGylated insulin were based on the same as that for human 
insulin of 6 nmol/IU [15]. The conversion of nmol to μg for PEGylated insulin was then 
adjusted according to the increased molecular weight of the protein conjugate.  
 
7.2.5. In Situ Testing of P(MAA-g-EG) Hydrogels 
In an attempt to simulate an orally delivered dose, samples were placed in situ 
into the small intestines of rats. The method used in this study were somewhat different 
from previously reported methods in an attempt to more accurately mimic oral 
administration of P(MAA-g-EG) hydrogels. In situ testing on anesthetized rats was used 
rather than trying to examine the behavior in conscious rats for several reasons. First, 
orally dosing conscious rats is quite difficult because they will resist the dose and not 
normally eat a pill. Second, the number and frequency of blood samples used in this 
study would have been very difficult in conscious rats and impossible to take from the 
jugular vein. Third, by working with anesthetized animals, as many as six rats could be 
run in a single day. That would not have been possible with conscious rats due to the 
additional handling and restraint involved.  
In an attempt to maintain normal GI enzymatic activity the rats were switched 
to an all liquid diet 48 hours prior to testing. By delivering an all liquid diet to the rats 
their GI tract was free from solid materials and feces but still working on digesting the 
food through enzymatic degradation. The diet consisted of 1 kcal/ml of mix with 35 % of 
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calories from fat, 18 % from protein, and the remaining 47 % from carbohydrates. The 
liquid diet was mixed with water and supplied as the only source of food and water for 
the rats during their fast. The rats were given 100 ml of the liquid diet 48 hours before 
testing. An additional 80 ml was provided 24 hours prior to testing. The liquid diet was 
removed the evening prior to testing approximately 14-16 hours prior to testing and the 
rats were given unlimited water overnight. By removing the liquid diet the night before 
testing again the glycogen and glucose stores of the rats were reduced and the chyme in 
the small intestine was greatly reduced but not eliminated.  
Anesthesia, restraint, and blood sampling was performed in the same fashion as 
was done for the bioactivity determination. In this study the controls and samples were 
dosed directly to the small intestines of the rats. The peritoneal cavity was accessed 
through a midline incision. Doses of normal saline, unloaded P(MAA-g-EG) particles, 
insulin in PBS (20 IU/kg), insulin loaded P(MAA-g-EG) particles (20 IU/kg), PEGylated 
insulin in PBS (20 IU/kg), or PEGylated insulin loaded P(MAA-g-EG) particles (20 
IU/kg) were preloaded into a 18-gauge silicon intraspinal catheter. Minimal solution 
volumes were used for each type of dose. For saline, 400 μl of solution was dosed. 
Insulin solutions were made in PBS at 500 μg/ml and PEGylated insulin solutions were 
made at 2 mg/ml. Doses were administered accordingly to deliver 20 IU/kg rat based on 
the conversion of 6 nmol/IU. For insulin and PEGylated insulin loaded polymer samples 
an adequate amount of polymer was first weighed into a 0.6 ml centrifuge tube. The 
polymer was suspended by 50 μl of PBS at pH = 2.7. The low pH solution was used for 
the suspension to ensure that the polymer would not swell and release its contents until 
after it was dosed to the small intestine. The catheter was pre-filled with normal saline at 
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pH = 7.4 and connected to a 1 ml syringe with 200 μl of saline in it. This volume served 
as the liquid to rinse out all of the solution or polymer suspension present in the catheter. 
The suspended polymer particles were drawn into the silicone catheter from the tip. By 
drawing the suspension into the tip of the catheter rather than trying to fill from the back 
the polymer remained within the length of the catheter and could be easily rinsed out. 
This process was repeated two or three times to ensure complete transfer of the polymer 
from the centrifuge tube to the catheter. The volume of the catheter was measured and 
determined to be between 220-250 μl. By using less than that volume for polymer doses, 
mixing of the low pH and neutral pH buffers could be minimized. In experimental 
samples where the suspending buffer was at pH = 7.4 the polymer rapidly swelled and 
either could not be drawn into the catheter or clogged the catheter and could not be 
removed for dosing. 
The pylorus of the rat was used as the anatomical marker for the start of the 
small intestine. The doses were administered to the duodenum just below the duodenal 
curve. The intestines were accessed using a 14-gauge touhy needle. The 18-gague 
catheter could then be fed into the small intestine through the needle. The catheters were 
marked for length every 2 cm. A length of 8-10 cm of the catheter was gently fed into the 
small intestines of each rat at which point the access point of the intestine was clamped to 
prevent backflow of the dosed liquid. The full amount of liquid or polymer suspension 
was then dosed directly and the catheter was slowly withdrawn from the intestine. The 
access point was clamped closed such that only the side of the intestines was occluded 
and movement of gastric juices could still proceed down the GI tract. The peritoneal 
cavity was then clamped closed for the duration of the test. Blood samples were 
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withdrawn from the jugular vein at 1, 5, 10, 15, 30, 45, 60, 120, 180, 240, 300, 360, 420, 
and 480 minutes following dosing. Three baseline samples were also taken to establish 
normal glycemic levels for each rat. Following each test, the rats were euthanized with a 
0.5 ml IV injection of euthanasia solution according to the Panel on Euthanasia of the 
American Veterinary Medical Association.  
 
7.2.6. Glucose and Insulin Determination 
The blood samples from the in vivo testing were first tested for levels of glucose 
by two different blood glucose analyzers in mg/dl, the standard measurement for blood 
glucose concentrations. This required roughly 20 μl of whole blood per sample. Both 
machines were verified using a control cuvette daily to ensure proper operation. The 
remaining blood was transferred to a serum separator tube and stored on ice for the 
duration of the test. When time permitted throughout the test the whole blood samples 
were centrifuged at 7500 rpm and the plasma was removed using a 200 μl pipette. The 
plasma samples were centrifuged a second time to eliminate any bubbles and then stored 
on ice until the end of the test. Following testing the plasma samples were stored at -80 
°C until they could be assayed for insulin concentration. 
The concentration of human insulin or PEGylated insulin in the rat plasma was 
determined using enzyme linked immunosorbent assay (ELISA). The kits purchased from 
ALPCO diagnostics had a cross reactivity with rat insulin of only 0.7 %, so any detected 
changes in insulin concentrations were attributed exclusively to the human insulin which 
was dosed to the rats. A standard curve of PEGylated insulin was also generated on the 
ELISA plates and used to adjust the concentrations determined directly from plasma. The 
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ELISA plates were pre-coated with an insulin antibody to which insulin or PEGylated 
insulin would bind. The procedure required 25 μl of a standard or sample in each well to 
be tested. The range of the kit was 3-200 μIU/ml. Any samples which tested high out of 
range were diluted to 1/100 or 1/1000 concentration using the zero standard provided 
with the ELISA kit.  
 
7.2.7. Statistics 
A one-way analysis of variance (ANOVA) of individual data groups was used 
to distinguish statistically relevant differences between the groups. The confidence value 
of p = 0.05 or 0.01 was used and is indicated with the data represented in the figures at 
the end of the chapter. 
 
7.3. Results and Discussion 
 
7.3.1. PEGylated Insulin Loading 
The loading for PEGylated insulin was first attempted using P(MAA-g-EG) 
hydrogels of formulations 0.75/33, 1.25/50, and 2.0/66 in which a 1:1 ratio of MAA:EG 
monomers was present. No loading of PEGylated insulin was observed with these 
samples. The same hydrogel formulations were able to load insulin at least to some 
degree as described in Chapter 5. The change in the ratio of the MAA:EG monomers 
caused by the addition of the PEGylated insulin may have caused the PEGylated insulin 
to be excluded from the hydrogel network. To investigate this hypothesis, a series of 
P(MAA-g-EG) hydrogels with the same formulations in terms of PEGDMA content and 
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monomer weight fraction were made with a 3:2 ratio of MAA:EG. If the complexation of 
the hydrogel is improved by moving toward a 1:1 ratio then the addition of PEGylated 
insulin should improve the complexation in these formulations.  
The loading efficiencies for insulin and PEGylated insulin are shown in Figure 
7.1. The loading of PEGylated insulin achieved the highest loading efficiencies of the 
three different formulations considered. It also had a higher loading efficiency than 
regular insulin in the P(MAA-g-EG) formulations made with a 3:2 ratio of MAA:EG. 
Interestingly, the loading efficiency for regular insulin increased when the monomer ratio 
was changed from 1:1 to 3:2 for formulations 1.25/50 and 2.0/66, but not for formulation 
0.75/33. However, PEGylated insulin in the formulation 0.75/33 had significantly higher 
loading efficiency than insulin for either monomer ratio with 90.4 % of available 
PEGylated insulin loaded into the hydrogel. This result indicates that the PEGylated 
insulin does interact with the P(MAA-g-EG) hydrogel in a favorable manner with regard 
to its loading. Even when insulin cannot be efficiently loaded into the hydrogels due to 
very low crosslink density, as is the case with formulation 0.75/33, PEGylated insulin can 
be incorporated within the hydrogel and maintain its presence in excess of 90 % 
efficiency. Therefore the conjugation of PEG to insulin increases the attractive forces 
between the protein conjugate and the hydrogel. This is most likely due to the hydrogen 
bonds which can be formed between MAA and the PEG group now conjugated to insulin. 
This results further supports the findings in Chapter 5 which suggests that the interaction 
between P(MAA-g-EG) and insulin controls uptake and release more so than the 
diffusive restrictions of the network mesh size.  
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The release of insulin and PEGylated insulin from P(MAA-g-EG) hydrogels 
polymerized with a 3:2 ratio of MAA:EG is shown in Figure 7.2. In a similar fashion as 
was seen for regular insulin in Chapter 5, the release of insulin and PEGylated insulin did 
not exceed 20 % until the pH of the release buffer was 6.2 or greater. There was one 
exception to the rule with regular human insulin in the same formulation (0.75/33) as was 
seen before and presented in Chapter 5. For insulin, the fractional release for samples at 
pH ≥ 6.2 exceeded 80 % with insulin for all three formulations except for one sample 
which still exceeded 70 %. However, for PEGylated insulin an increasing release trend 
was seen as the pH of the release buffer increased from 6.2 to 7.4. Additionally, the 
relative release amounts of PEGylated insulin were always lower than those seen for 
native human insulin between pH = 6.2-7.4. These results indicate that PEGylated insulin 
maintained a greater affinity for the P(MAA-g-EG) hydrogels than native human insulin. 
Because of that, the fractional release of PEGylated insulin did not exceed 67 % until the 
pH of the release buffer was at pH = 7.4. This behavior could be advantageous for oral 
insulin delivery because the protein will maintain a higher concentration within the 
hydrogel as it passes through the GI tract. Previous work has already shown that insulin 
can be protected only when it is in close proximity to P(MAA-g-EG). If the release is 
sustained for a significant period of time through the intestine based on local pH, then the 
possibility for protein transport can be sustained as the polymer moves down the GI tract.  
 
7.3.2. Bioactivity and PK/PD for IV Administration 
The applicability of PEGylated insulin for the treatment of diabetes relies on its 
ability to maintain its biological activity following modification. If the bioactivity of the 
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modified insulin is lost, then it has little clinical potential for oral delivery. The 
determination of the bioactivity is generally found by comparing its effect to IV 
administration of a control drug. In this experiment the comparison was made with 
regular human insulin in rats. A control group of PBS was also used to eliminate the 
effects of the surgeries on the biological effects seen in the rats. 
The biological effect can be measured according to pharmacokinetic (PK) or 
pharmacodynamic (PD) behavior. As defined by Gibaldi and Perrier, pharmacokinetics is 
the study of the time course of drug and metabolite levels in different fluids, tissues, and 
excreta of the body, and of the mathematical relationships required to develop models to 
interpret such data [16]. Pharmacodynamics, on the other hand, is the science of 
evaluation of the drug action on the body as well as the relationship between drug 
concentration and effect [17]. A simpler description often used as a heuristic is that the 
pharmacokinetics is what a drug does to the body and pharmacodynamics is what the 
body does to the drug. The pharmacodynamic behavior of insulin is primarily related to 
the blood glucose (BG) levels in the circulation due to its effect on insulin receptors and 
subsequent transfer of glucose to the liver, muscular, and adipose tissues. Other effects of 
insulin are also related to its pharmacodynamic behavior, however, in this study only 
blood glucose was considered.  
A chart of the pharmacokinetic behavior of insulin and PEGylated insulin 
following IV and SC delivery of 1 IU/kg in healthy male Sprague Dawley rats is shown 
in Figure 7.3. This figure displays the full scale of the concentrations determined using 
ELISA from blood serum levels. The concentrations are very high following IV 
administration because both PEGylated and regular insulin are delivered directly to the 
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bloodstream. For healthy adults, insulin concentrations reach concentrations of 60-90 
μU/ml (360-540 pmol/l) for postprandial levels [18]. The IV concentrations are greater 
than 150 times that of normal postprandial circulating levels immediately following 
dosing, but the levels rapidly drop due to clearance and binding to insulin receptors. A 
closer look at the lower concentrations gives more information of the pharmacokinetics 
of IV and SC administration and the differences between regular and PEGylated insulin. 
Figure 7.4 displays the insulin and PEGylated insulin concentrations following IV 
administration of 1.0 IU/kg in rats. Initial points are excluded because their 
concentrations exceed 500 μIU/ml. Normal human insulin drops below 500 μIU/ml 10 
minutes after IV administration, but PEGylated insulin required 30 minutes to drop to the 
same level. Normal levels for postprandial concentrations of insulin (< 100 μIU/ml) are 
reached for normal human insulin after 30 minutes. After 60 minutes the concentration of 
normal human insulin is 14.6 μIU/ml and it is almost completely cleared from the 
circulation after 120 minutes. PEGylated insulin, on the other hand, sustained significant 
plasma concentrations for the duration of the 6 hour test. It does not drop below 100 
μIU/ml until 120 minutes after administration and maintains a concentration of 43.1 
μIU/ml after 6 hours. These results indicate that PEGylated insulin is slower to be cleared 
by the body and may also have a slower binding to the insulin receptor. Because it has a 
higher residence time in the bloodstream, the biological effect of PEGylated insulin in the 
body may also be sustained when compared to that of normal human insulin. 
The natural pharmacodynamic action of insulin is to transport glucose into the 
tissues of the body. When insulin levels exceed basal levels in the absence of a meal they 
induce a hypoglycemic effect. In order to determine the biological activity of PEGylated 
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insulin must induce the same effect. The pharmacodynamic effect of the IV administered 
insulin and PEGylated insulin can be seen in Figure 7.5. A control group of PBS is also 
displayed in the figure. The BG levels are represented as the fraction of the initial values 
measured by baseline blood samples. Both regular human insulin and PEGylated insulin 
induce hypoglycemia in healthy male Sprague Dawley rats following IV administration. 
A drop in the fractional BG levels was also exhibited after administering only PBS, 
indicating that a drop was induced by the surgical technique alone. Therefore, the BG 
levels for insulin and PEGylated insulin were normalized by this surgery-induced drop as 
is seen in Figure 7.5b. The pharmacodynamic effect of both regular human insulin and 
PEGylated insulin were very similar to one another. The area above the normalized curve 
(AAC) was calculated as the sum of the area of consecutive trapezoids between the curve 
and 1. The AAC values were then used to determine the biological activity of PEGylated 
insulin were determined. The AAC values for normal human insulin were 61.63 after 4 
hours and 61.69 after 6 hours versus 68.42 and 75.43 for PEGylated insulin after 4 and 6 
hours, respectively. The units for these values are: 
 [ ] min)( ∗⎟⎟⎠
⎞
⎜⎜⎝
⎛=
oC
tCAAC      (Eqn 7.1)  
where C(t) is the concentration of glucose at time t and Co is the initial concentration of 
glucose. According to these values the bioactivity of PEGylated insulin is 111.0 % and 
122.3 % that of normal human insulin following IV administration after 4 and 6 hours, 
respectively.  While these bioactivity values may seem misleading they are explained not 
by the potency of PEGylated insulin, but in its increased residence time in the 
bloodstream. The reduced rate of clearance causes it to have an extended action and 
therefore a prolonged hypoglycemic effect. The potency of PEGylated insulin versus 
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regular insulin requires more information for the binding coefficient and residence time 
of each species with the insulin receptor which cannot be determined using these 
methods. A summary of the PK/PD data for IV insulin and PEGylated insulin 
administration is given in Table 7.1. Significant changes in the PK/PD profile were not 
expected following IV administration of PEGylated insulin versus that of regular human 
insulin. Administration of the proteins by IV injection does not allow a pharmacokinetic 
determination because they are placed directly into the circulation. Each induces a rapid 
hypoglycemic effect because of the high initial concentrations. While elevated, the 
endogenous production of insulin in healthy rats is effectively stopped and the transport 
of glucose from the bloodstream is carried out by the exogenous insulin or PEGylated 
insulin. The PK/PD profile for PEGylated insulin following SC dosing is much more 
likely to exhibit a more profound difference from regular human insulin because of the 
altered PK behavior. 
 
7.3.3. Bioactivity and PK/PD for SC Administration 
Subcutaneous administration is the typical route of delivery for insulin. 
Therefore a comparison between PEGylated insulin and regular human insulin following 
SC injection is meaningful in addition to the standard IV comparison. The PK profile of 
SC administered insulin and PEGylated insulin at doses of 1.0 IU/kg is given in Figure 
7.6. A dose of PBS was also administered as a control group. The concentrations of both 
insulin and PEGylated insulin initially increase following dosing as they are absorbed 
into the bloodstream. Regular human insulin levels reach a maximum concentration 
(Cmax) after 30 minutes at 132.5 μIU/ml. PEGylated insulin levels do not reach Cmax until 
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120 minutes after dosing at 195.0 μIU/ml. The time for maximum concentration is 
referred to as tmax. Similar to IV dosing, the PEGylated insulin exhibits a sustained 
elevation in concentration versus that of regular human insulin. The concentration of 
regular human insulin decreases to near zero after 300 minutes while PEGylated insulin 
still has a concentration of 13.5 μIU/ml at the completion of the test at 480 minutes.  
The pharmacokinetic profile of PEGylated insulin when delivered 
subcutaneously indicates a slower rate of absorption from the interstitial fluids to the 
bloodstream. This is most likely due to the increased size of the protein conjugate and is 
exhibited by the later peak concentration. As insulin and PEGylated are absorbed into the 
bloodstream they are concomitantly removed by metabolism in the liver and the 
reticuloendothelial system (RES). This is the reason that the concentrations never reach 
the incredibly high levels seen following IV administration. The maximum concentration 
for the insulin or PEGylated insulin occurs when the rate of clearance is greater than the 
rate of absorption. Because SC administration deposits only a finite amount of insulin or 
PEGylated insulin, the rate of absorption decreases as the local amount is reduced. 
Regular human insulin is rapidly absorbed from the SC depot, thus the rate or absorption 
also decreases rapidly. The rate of clearance from the bloodstream quickly supersedes the 
rate of absorption and Cmax occurs with a tmax of 30 minutes. The reduced rate of 
absorption of PEGylated insulin means that the rate of absorption also decreases more 
slowly than for regular insulin. In conjunction with the lower rate of clearance from the 
bloodstream, as was indicated by the IV data described above, tmax does not occur until 
120 minutes. Additionally, the value of Cmax in comparison to regular human insulin is 
significantly higher. The relative rates of absorption and clearance also account for the 
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higher value for Cmax exhibited for PEGylated insulin versus that of regular human 
insulin. A summary of this data is given in Table 7.1. 
The pharmacodynamic effect of subcutaneously administered insulin and 
PEGylated insulin is seen in Figure 7.7. Again the effects of the surgery induced a drop in 
BG levels indicated by the control group dosed with only PBS. A normalized version of 
this chart is seen in Figure 7.7b in which the effects of the surgery on glucose levels are 
removed. A similar trend is exhibited in the BG levels as was seen for insulin levels in 
the plasma: a delayed onset of action followed by a sustained effect for PEGylated insulin 
when compared to regular human insulin. The hypoglycemic effect of regular human 
insulin is almost instantaneous and can be seen after only 5 minutes. PEGylated insulin, 
however does not exhibit a hypoglycemic effect until after 30 minutes have passed. After 
60 minutes, the BG concentration drops to 90% of initial values. The maximum 
hypoglycemic effect for normal insulin is seen after 60 minutes when BG levels are at 
52.9 % of initial levels. For PEGylated insulin, the maximum hypoglycemic effect occurs 
360 minutes after SC administration at when BG levels are 58.6 % that of the initial 
levels. This sustained effect is due to the extended residence time of PEGylated insulin in 
the bloodstream as was seen in the pharmacokinetic data. This lengthened duration of 
action is a very interesting result for PEGylated insulin because it indicates that it can 
have a sustained effect in comparison to regular insulin. If the same behavior can be 
observed when PEGylated insulin is absorbed across other tissues, such as the intestinal 
epithelium, then it may be able to induce a greater effect than regular insulin.  
The bioavailability of subcutaneously delivered PEGylated insulin was 
determined by comparison to regular human insulin delivered in the same fashion. The 
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values for the AAC of the normalized curves determined as the sum of consecutive 
trapezoids integrated to 1 were 97.3 and 111.8 for normal insulin after 6 and 8 hours, 
respectively. The AAC values for PEGylated insulin were 98.2 and 142.9 for 6 and 8 
hours, respectively. The units of these values are the same as found for IV dosing. Using 
these AAC values, the biological activity of PEGylated insulin was 100.9 % and 127.8 % 
that of regular human insulin. Similar to the IV dosed insulin samples, the higher 
bioactivity is due to the sustained hypoglycemic effect induced by PEGylated insulin, not 
an increase in potency of the PEG-modified insulin species. 
 
7.3.4. In Vivo Effect of a High Dose of Insulin and PEGylated Insulin 
An early test was performed in which a dose of 4.0 IU/kg was given to rats 
through SC injection. This dose ended up being too high for the rats and induced acute 
hypoglycemia which had to be countered through the intravenous administration of 
glucose to keep the animals from expiring. The tests were not repeated and subsequent 
doses were lowered for later tests. Nonetheless, the information gathered on the BG 
levels prior to the administration of additional glucose gives further information for the 
pharmacodynamic effect of PEGylated and regular human insulin in rats. The data is 
truncated at the point when exogenous glucose administration occurred and is shown in 
Figure 7.8. For normal human insulin, this occurred 60 minutes after dosing. PEGylated 
insulin, however, did not require exogenous glucose administration over the duration of 
this shortened 4 hour study. These results further indicate the reduced rate of absorption 
of PEGylated insulin. Even when the dose was 4.0 IU/kg, PEGylated insulin did not 
induce acute hypoglycemia which would have manifested itself as seizures in the rats. 
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The BG levels did continue to drop even after 4 hours, though, and a severe 
hypoglycemic state may have eventually occurred in these rats.  
 
7.3.5. In Situ Testing 
The design of the in situ testing method was adapted from previous methods 
used by our group and others working on oral insulin delivery with P(MAA-g-EG) 
hydrogels [10, 19]. The methods used in this study were in an attempt to more accurately 
mimic an orally delivered dose on fully anesthetized animals and there were several key 
changes. First, previous designs used a closed-loop in situ design in which the insulin 
loaded polymer was placed into the ileum of rats. By placing the samples in the ileum, 
the duodenum and jejunum are directly bypassed, which would not happen following oral 
administration. The current method dosed into the duodenum in a location that is close to 
where the pH shift would occur in the GI tract. Second, the closed-loop method isolates a 
segment of the small intestine by tying off the section to be dosed using sutures. By 
closing a segment, normal peristalsis in the intestine cannot occur. The current method 
was an open loop technique in which the intestine were not occluded above or below the 
site selected for dosing. Third, previous closed-loop methods thoroughly washed the 
intestine in the targeted tissues prior to dosing. In doing so, the mucus layer and lumenal 
and brush-border enzymes are reduced by physical removal. This would greatly alter the 
environment normally found in the GI tract and should falsely increase the amount of 
insulin which can be transported across the epithelial layer. In the current method, the 
intestines were not pretreated in any way in an attempt to maintain normal levels of 
mucus and enzymatic activity. Fourth, the fasting period in previous methods was 24 
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hours or more. The current techniques only used a 12 hour fast, close to a normal 
overnight fast. Extended periods of fasting reduce the enzymatic activity in the GI tract. 
Finally, by using a dosing method which used a catheter and guide needle an attempt was 
made in the current method to minimize physical manipulation of the intestines. This was 
not attempted in previous closed-loop techniques. 
The serum insulin and PEGylated insulin levels following in situ dosing can be 
seen in Figure 7.9. The maximum concentration seen by any sample was 11.5 μIU/ml for 
PEGylated insulin loaded hydrogels. This is equivalent to the normal basal levels of 
insulin which are between 5 and 15 μIU/ml. However, in order to induce a hypoglycemic 
effect in healthy rats, plasma concentrations of PEGylated or regular human insulin must 
exceed basal levels in the absence of a meal. Circulating concentrations of PEGylated 
insulin remained above 5 μIU/ml for 180 minutes following dosing of PEGylated insulin 
loaded polymer samples. Interestingly, the levels of PEGylated insulin following dosing 
as a solution into the duodenum also increased above basal levels and reached a 
maximum concentration of 10.4 μIU/ml one minute after dosing. The plasma 
concentration quickly dropped and only remained above 5 μIU/ml for 15 minutes. For 
regular human insulin delivered as a solution or from insulin loaded polymer particles, 
the maximum plasma concentration never reached 5 μIU/ml at any point throughout the 
test.  
The normalized relative blood glucose levels for the rats dosed by in situ 
administration can be seen in Figure 7.10. None of the rats tested exhibited a 
hypoglycemic effect. This is expected based on the levels of insulin seen in the PK data. 
Because the plasma concentrations for PEGylated and regular human insulin never 
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exceed basal levels, a hypoglycemic effect should not occur. A sustained increase of BG 
is seen for all samples due to the sympathetic effects caused by the surgery. Because the 
circulating insulin levels never exceeded basal concentrations, the endogenous glucose 
production by the healthy rats was able to compensate for the increased concentrations. 
Nonetheless, the transfer of some insulin and PEGylated insulin was apparent from the 
ELISA data represented in Figure 7.9. The lack of the expected pharmacodynamic effect 
is due to the fact that healthy rats were used in a test where the increase in insulin 
concentration did not approach or exceed postprandial levels. Using a higher dose, or a 
diabetic rat model, would likely exhibit a more significant PD effect.  
Several important results are inferred from this in situ dosing study. First, 
PEGylated insulin was able to be absorbed from the small intestine to a greater extent 
than that seen for native human insulin. This was true when the protein was administered 
as a solution as well as following its incorporation into P(MAA-g-EG) hydrogels. This is 
most likely due to the additional enzymatic resistance of the PEGylated species. In fact 
plasma concentrations for PEGylated insulin delivered as a solution exceeded those of 
insulin following its incorporation into P(MAA-g-EG) hydrogels. Therefore, by 
PEGylating insulin, its absorption was increased in relation to normal human insulin. 
Secondly, the presence of P(MAA-g-EG) only slightly increased the absorption of insulin 
and PEGylated insulin from the small intestine. The hydrogel is highly effective at 
maintaining the integrity of insulin in a gastric environment; however upon exposure to 
the intestinal environment the release apparently occurs too rapidly for the hydrogel to 
greatly enhance the protein absorption. This rapid release was seen with in vitro testing 
presented in Chapter 5. Insulin and PEGylated insulin are most likely released to a large 
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extent into the lumen of the small intestine and do not localize with the hydrogel on the 
apical surface of the epithelium. Third, because the pharmacokinetic and 
pharmacodynamic effect of P(MAA-g-EG) hydrogels loaded with regular human insulin 
was significantly lower that what has been seen in previous studies, it is clear that the 
closed-loop in situ technique induces insulin transport across the intestinal epithelium. 
While this is gives good results and a higher apparent bioavailability, it falsely increases 
the insulin absorption in a non-physiological way. The techniques used in this work more 
adequately mimic the natural pathway for orally administered drugs and drug 
formulations.  
There are still significant limitations to the open-loop method used in this study. 
The most important one is the large reduction in intestinal motility induced by the 
surgical technique. A study performed by De Winter et. al. showed that abdominal 
surgery on rats caused a very large drop in the movement of a dye through the intestines 
[20]. If peristalsis is lost, the drug loaded polymer systems may not adequately bind to 
the mucus layers of the small intestine. Further, the release of PEGylated insulin did not 
approach 100 % until the pH of the release buffer was 7.4. This pH level is achieved in 
the GI tract, but not until the most proximal areas of the small intestine such as the ileum 
or in the colon. If the movement of the PEGylated insulin loaded polymer was restricted, 
then the release of the protein may not have completely occurred.   
 
7.4. Conclusions 
Regular human insulin and PEGylated insulin was successfully loaded into 
P(MAA-g-EG) hydrogels with low, moderate, and high levels of crosslinking formulated 
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with a MAA:EG ratio of 3:2. Loading efficiencies were higher than those seen for 
P(MAA-g-EG) with a 1:1 ratio of monomers for insulin for all three formulations. 
PEGylated insulin loading was not observed in the hydrogel formulations with a 1:1 
monomer ratio. However, in hydrogels formulated with a MAA:EG ratio of 3:2 
PEGylated insulin had the highest loading efficiencies for all three levels of crosslinking, 
most prominently in formulation 0.75/33 with greater than 90 % of available protein 
loaded into the hydrogel. The same hydrogel formulation with monomer ratios of 1:1 and 
3:2 had loading efficiencies lower than 55 % for regular human insulin. The addition of 
PEGylated insulin to the hydrogels formulated with a 3:2 monomer ratio increased the 
amount of PEG available for complexation with MAA groups, thus shifting the monomer 
ratio closer to 1:1. Hydrogels formulated with a 1:1 ratio had shown the highest levels of 
complexation in previous work [21]. Therefore the increased availability of hydrogen 
bonding with MAA is likely the reason for the increased loading efficiencies of 
PEGylated insulin.  
The release of PEGylated insulin and regular insulin from hydrogels with a 3:2 
monomer ratio showed similar release tendencies with minimal protein loss until the pH 
of the release buffer was at 6.2 or greater. The fractional release of PEGylated insulin 
increased as the pH increased from 6.2 to 7.4 and was lower than regular human insulin 
for these pH levels. These results indicate that PEGylated insulin maintained a greater 
affinity for P(MAA-g-EG) hydrogels than regular human insulin. This could be 
advantageous in future designs for oral insulin delivery because of the potential for 
sustained localization of the drug within the hydrogel.  
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The retention of the bioactivity of PEGylated insulin was confirmed using 
intravenous (IV) and subcutaneous (SC) dosing. A hypoglycemic effect was seen for both 
methods of administration for PEGylated and regular human insulin at a dosing level of 
1.0 IU/kg in healthy male Sprague Dawley rats. In IV dosing, the PK/PD profile 
exhibited a sustained elevation in PEGylated insulin concentrations for the entire duration 
of the 6 hours test versus that of regular human insulin, although the induced 
hypoglycemia was almost identical. The bioactivity of PEGylated insulin following IV 
administration was 111.0 % and 122.3 % that of regular human insulin based on the ratio 
of AAC values of relative blood glucose levels after 4 and 6 hours, respectively. 
Subcutaneous administration yielded significantly altered PK/PD profiles for PEGylated 
insulin. PEGylated insulin had a slower absorption and sustained hypoglycemic along 
with a higher Cmax than seen for regular human insulin. Initially regular human insulin 
had higher plasma concentration levels and a greater drop in blood glucose levels. After 
60 minutes the plasma concentration of PEGylated insulin exceeded that of regular 
human insulin and maintained a higher concentration until 8 hours following 
administration. After 120 minutes the hypoglycemic effect of PEGylated insulin was 
greater than that of regular human insulin and lower blood glucose concentrations were 
maintained through the remaining duration of the 8 hour test. The bioavailability of 
PEGylated insulin for SC administration was 100.9 % and 127.8 % that of regular human 
insulin after 6 and 8 hours, respectively.  
Previous work on PEGylated insulin suggested that the molecular weight of 
PEG greater that 750 Da would cause a decrease in the biological activity of insulin [14]. 
However, the results of the work presented in the current study indicate that PEGylated 
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insulin in which a 5000 Da PEG chain conjugated to the PheB1 site of insulin fully 
maintained its biological activity in vivo. This is an important result because higher MW 
PEG species are able to impart more of the beneficial effects of PEGylation on proteins 
than lower MW PEG chains. Most important to oral insulin delivery is the increased 
resistance to proteolytic degradation caused by PEG conjugation. The additional benefit 
of the improved interaction with P(MAA-g-EG) hydrogels enhances the potential for the 
oral delivery of PEGylated insulin. 
The administration of P(MAA-g-EG) loaded with regular human insulin or 
PEGylated insulin using in situ dosing exhibited limited transport of insulin to the 
bloodstream and a negligible hypoglycemic effect with 20 IU/kg doses. The highest 
amount of transport into the bloodstream was seen from PEGylated insulin loaded 
polymer samples which achieved plasma concentrations in the range of basal insulin 
levels for 180 minutes following dosing. PEGylated insulin delivered in situ as a solution 
also achieved plasma concentrations in the basal range, though only for 15 minutes 
following administration. Regular human insulin never achieved plasma concentrations 
greater than the minimum level for basal levels in the bloodstream administered as a 
solution or from insulin loaded polymer samples. Because the concentrations never 
exceeded basal levels for either PEGylated or regular human insulin, a hypoglycemic 
effect was not seen for the healthy rats tested in this study. The same study performed on 
diabetic rats would likely have exhibited a drop in blood glucose because the levels of 
PEGylated insulin in the bloodstream did increase to what would be expected in healthy 
animals for 3 hours. One important consideration for these results lies in the fact that the 
intestinal motility was significantly reduced by the in situ testing. Because the polymer 
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never proceeded down the GI tract, it may not have reached areas of the small or large 
intestine with the highest pH. As seen in the in vitro studies of PEGylated insulin with 
P(MAA-g-EG) hydrogels, the release did not approach 100 % until the release buffer was 
at pH = 7.4. Therefore, a significant portion of dosed PEGylated insulin may have 
remained within the hydrogel and not been available for absorption. If true, the potential 
bioavailability of PEGylated insulin may have been higher than seen in this study. 
Another conclusion of this work is that the open-loop technique used for the in 
situ testing of this work is superior to the closed-loop technique used in previous studies. 
By dosing to the duodenum rather than the ileum the drug loaded polymer is exposed to 
the first area of the small intestine which would exhibit a near neutral pH. The open-loop 
design allows the natural movement of the lumen down the small intestine. The closed-
loop method physically prevents this movement. The open-loop method requires less 
manipulation of the intestinal tract than the closed-loop method. Finally, the open-loop 
technique does not wash or clean the small intestines prior to dosing, thus maintaining 
near normal enzymatic activity and mucus layer integrity. The closed-loop technique 
washes the section of the intestines to be dosed which physically removes a large portion 
of the mucus layer and lumenal and brush-border peptidases thereby skewing the 
absorption and degradation of insulin. Overall, the open-loop in situ method is maintains 
a more normal state of the GI tract than the closed-loop method and more accurately 
simulates an oral dose in anesthetized rats. However, the technique can still be improved 
such that it does not cause such a reduction in the natural intestinal motility which would 
be seen in rats. 
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Table 7.1. PK/PD summary of IV and SC administration of insulin and PEGylated 
insulin at 1.0 IU/kg to healthy male Sprague Dawley rats 
 
 IV administration SC administration 
 
AAC 
min)( ∗⎟⎟⎠
⎞
⎜⎜⎝
⎛
oC
tC
 Bioavailability
AAC 
min)( ∗⎟⎟⎠
⎞
⎜⎜⎝
⎛
oC
tC Bioavailability Cmax (μIU/ml)
tmax 
(min) 
Human 
insulin 61.69 N/A 111.8 N/A 132.5 30 
PEGylated 
insulin 75.43 122.3 % 142.9 127.8 % 195.0 120 
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Figure 7.1. Loading efficiencies for regular human insulin and PEGylated insulin in 
P(MAA-g-EG) hydrogels with MAA/EG monomer ratios of 1/1 or 3/2 (+ S.D., ** p < 
0.01, * p < 0.05) 
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Figure 7.2. Insulin loaded polymer (ILP) and PEGylated insulin loaded polymer (PILP) 
release from P(MAA-g-EG) hydrogels with a MAA:EG monomer ratio of 3:2 following 
3 hours of dissolution in PBS at 37 °C (+ S. D., n = 3) 
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Figure 7.3. Insulin and PEGylated insulin plasma concentrations following IV and SC 
injection of 1.0 IU/kg in rats (+ S. D., n = 6) 
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Figure 7.4. Zoom in of insulin and PEGylated insulin plasma concentrations in healthy 
male Sprague Dawley rats following IV injection of 1.0 IU/kg (+ S.D., n = 6) 
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Figure 7.5. (a) Blood glucose levels and (b) normalized blood glucose levels of healthy 
male Sprague Dawley rats following IV administration of 1.0 IU/kg of insulin and 
PEGylated insulin (- S.D., n = 6) 
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Figure 7.6. Insulin and PEGylated insulin plasma concentrations following SC injection 
of 1.0 IU/kg in healthy male Sprague Dawley rats (+ S. D., n = 6) 
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Figure 7.7. (a) Blood glucose levels and (b) normalized blood glucose levels of healthy 
male Sprague Dawley rats following SC administration of 1.0 IU/kg of insulin and 
PEGylated insulin (- S.D., n = 6) 
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Figure 7.8. Blood glucose levels of healthy male Sprague Dawley rats following SC 
administration of 4.0 IU/kg of insulin and PEGylated insulin (- S.D., n = 4)  
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Figure 7.9. Insulin and PEGylated insulin plasma concentrations following in situ 
administration of solutions or protein loaded polymers to the duodenum of healthy male 
Sprague Dawley rats at 20.0 IU/kg (+ S.D., n = 6) 
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Figure 7.10. Normalized blood glucose levels of healthy male Sprague Dawley rats 
following in situ administration of 20.0 IU/kg of insulin and PEGylated insulin solutions 
and insulin and PEGylated insulin loaded polymers (- S.D., n = 4-6) 
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CHAPTER 8: CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE 
WORK 
 
8.1. Conclusions 
The oral delivery of insulin for the treatment of Type 1 and Type 2 diabetes 
remains an elusive goal. The challenges of the enzymatic and physical barrier in the 
gastrointestinal tract can be addressed to a large extent by hydrogels composed of 
polymethacrylic acid grafted with polyethylene glycol chains (P(MAA-g-EG)). The 
overall goal of this work was to further investigate the interaction between P(MAA-g-
EG) hydrogels and insulin and to improve the overall design of the delivery system by 
using PEG modified insulin.  
A significant body of work characterizing the hydrogel structure was presented 
in Chapter 4. Throughout this work the ratio of the monomers remained 1:1 in terms of 
the monomeric repeat groups, MAA:EG. The crosslink density of these hydrogel 
formulations was altered by using monomer concentrations of 33, 50, or 66 wt% in 
solution and PEGDMA 200 concentrations of 0.375, 0.75, 1.25, and 2.0 mol%. All 
formulations were characterized according to their swelling and mechanical 
characteristics. They all exhibited an increase in swelling and decrease in tensile modulus 
as the pH of the buffer increased. The apparent pKa of the hydrogel based on these 
studies was between 5.8 and 6.0. The swelling and tensile data was then used to model 
the network characteristics of each formulation at each pH tested. The average molecular 
weight between crosslinks, eM , and the network mesh size, ξ, both increased with 
increasing pH in the same fashion as the swelling and mechanical data. Irrespective of 
environmental pH, increasing crosslink density was seen with increasing concentrations 
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of monomers and PEGDMA. Higher crosslink density caused decreases in eM  and ξ at 
all pH levels. The variance for ξ between different P(MAA-g-EG) formulations was not 
very large and ranged between 7 nm and 12 nm at pH = 2.2 and 15 nm and 28 nm at pH = 
6.8. 
In vitro testing with insulin and insulin glargine was used to elucidate the 
mechanism of the protein loading and release from P(MAA-g-EG) hydrogels. Insulin was 
successfully loaded into all 11 formulations tested and the loading efficiency increased 
with increasing crosslink density. Insulin glargine was also loaded into 4 hydrogel 
formulations with the same result. The release of these proteins from P(MAA-g-EG) 
generally did not exceed 20 % until the pH of the release buffer exceeded both the pKa of 
the hydrogel and the pI of the incorporated protein. The exception to this rule was seen in 
the most loosely crosslinked hydrogel formulation investigated which indicated that a 
critical mass of polymer is required in the hydrogel to maintain a high retention of insulin 
near the ionic transition points of the hydrogel and the protein. In conjunction with the 
results from Chapter 4, these results suggested that insulin and insulin glargine were 
maintained within the hydrogel at low pH levels due in large part to weak bonds formed 
between P(MAA-g-EG) and the protein. At low pH, the network mesh size of the 
hydrogel was more than 5 times the hydrodynamic radius of an insulin monomer for all 
formulations investigated. At this ratio, the proteins would have slowly diffused from the 
hydrogel unless local interactions, such as hydrogen bonding, were able to further restrict 
their release. The release results indicated that the release of the insulin and insulin 
glargine at pH levels above the ionic transition points occurred because of the loss of 
these bonds and ionic repulsion between the hydrogel and the protein. By understanding 
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this interaction, more thoughtful approaches to oral protein delivery using P(MAA-g-EG) 
hydrogels can be attempted in the future.  
In Chapter 6, the conjugation of PEG to insulin is described and characterized. 
The modification known as PEGylation was achieved specifically at the PheB1 residue of 
insulin in order to maintain its biological activity. In order to do so, the alternative free 
amine groups of insulin had to be modified by a protecting group prior to PEGylation. 
This was achieved through with di-t-butyl dicarbonate to create diboc treated insulin. 
Crude diboc treated insulin created through this reaction was purified using ion exchange 
chromatography (IEC) and characterized using RP-HPLC and MALDI-TOF MS. The 
purified di-BOCLysB29/GlyA1 insulin was subsequently reacted with amine reactive mPEG-
SPA. Following reaction, the protecting BOC groups were removed and PheB1-mPEG-
insulin was purified using IEC. The site of PEG modification was confirmed using 
MALDI-TOF MS following degradation of the conjugate using DTT or trypsin digestion. 
This work indicated that a site specific, mono-substituted PEGylated insulin can be made. 
The final yield was rather low for this process with 6.7 % of initial insulin being 
recovered as the desired product. However, the majority of loss occurred in the diboc 
treatment step. As a proof of concept this process was shown to be reversible such that 
impure side products of the protection reaction could be recovered and used again as a 
reactant. In doing so, the efficiency of this process could be easily improved and scaled 
up with a higher efficiency for the synthesis of PEGylated insulin product. 
In vivo testing with PEGylated insulin and regular human insulin exhibited 
retention of the biological activity of PEGylated insulin. Dosing healthy male Sprague 
Dawley rats with 1.0 IU/kg of PEGylated insulin and regular human insulin caused 
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increases in plasma protein concentrations and drops in blood glucose levels. Based on 
IV administration the bioactivity of PEGylated insulin was 111.0 % and 122.3 % that of 
regular human after 4 and 6 hours, respectively. Subcutaneous administration yielded 
bioavailability of PEGylated insulin of 100.9 % and 127.8 % that of regular human 
insulin after 6 and 8 hours, respectively. This testing proved that PEGylated insulin in 
which a 5000 Da PEG chain conjugated to the PheB1 site of insulin fully maintained its 
biological activity in vivo. When delivered in situ to the duodenum of rats using an open-
loop technique very little protein transport occurred from 20 IU/kg doses. The highest 
plasma concentrations were achieved with PEGylated insulin loaded polymer samples, 
achieving basal levels for 180 minutes following dosing. However, no hypoglycemic 
effect occurred in correlation with the increase in plasma levels of PEGylated insulin. 
The open-loop technique more accurately mimicked an actual oral dose than previously 
used closed-loop techniques and showed that previous results were skewed by the closed-
loop method. However, the effect of the open-loop method on normal intestinal motility 
is a concern that should be addressed in future studies using this technique. 
 
8.2. Recommendations for Future Work 
There are several critical improvements in the design of this drug delivery 
system that are clearly indicated by this work. The network structure of P(MAA-g-EG) is 
less important than its ionization and the formation of weak bonds between the hydrogel 
and insulin. Previous investigations with protein delivery using P(MAA-g-EG) has either 
overlooked this potential interaction when investigating the mechanisms involved in drug 
loading and release [1] or mentioned it in passing without further investigation [2]. This 
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interaction can be utilized in other ways that have yet to be investigated and could 
significantly enhance future designs. Therefore, future work with P(MAA-g-EG) should 
take into account the pI and charge density of the protein to be investigated in an attempt 
to further enhance its loading and release. If unfavorable, the protein can be altered with 
PEG or another molecule or polymer that improves its interaction with P(MAA-g-EG). 
Alternatively, because the hydrogel becomes negatively charged, the drug could be 
designed to have a positive charge at neutral pH levels. In doing so, the drug should stay 
localized within the hydrogel in the lumen of the GI tract and have a greater likelihood of 
being transferred across the intestinal epithelium once the hydrogel binds to the mucus 
because glycoproteins in the mucus are also negatively charged [3].  
In designing a method by which insulin or another drug is delivered more 
effectively delivered directly to the mucosal layer covering epithelial cells, the 
mucoadhesive behavior of P(MAA-g-EG) should be improved. The mucoadhesive 
behavior of these hydrogels has been characterized and is due to either the adsorption or 
diffusion theory of mucoadhesion, both of which are based on non-specific interactions 
[4-6]. Improving the mucoadhesion has already been investigated with P(MAA-g-EG) 
using what germ agglutinin (WGA) which is conjugated onto one end of a PEG chain 
with the other end containing a methacrylate group [7]. Initial results indicated that the 
loading of insulin was not greatly affected and that the mucoadhesion was increased in 
these hydrogels.  
Improving the mucoadhesion can only address one of the problems in the 
current designs of P(MAA-g-EG). Another major concern is the likelihood for a majority 
of insulin release occurring into the lumen of the small intestine rather than into the brush 
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border of the epithelium. One approach which would be generic in design would be to 
have a unidirectional release of the protein toward the side of the hydrogel which is 
bound to the mucosal layer. If the release could be controlled in this way, then release of 
the protein to the lumen of the GI tract would first require that the protein diffuse through 
the mucus layer thus coming in close contact with the apical side of epithelial cells and 
greatly increasing the opportunity for paracellular transport in the presence of P(MAA-g-
EG) hydrogels.  
Alternatively, the conjugated PEG group could be used as a linker. By using 
PEG as a linker the benefits exhibited in this work could be retained and another material 
could be attached which would improve the drug delivery design. One obvious choice 
would be a material such as transferrin or vitamin B12 which is transcytosed across 
epithelial cells, though these choices may be limited by total amount of transport and size 
of the conjugated group. Another choice would be some material which improves its 
interaction with P(MAA-g-EG) such as a cationic moiety of some sort. This would 
require quite a bit of work and would likely be difficult to create without significant loss 
during synthesis. Nonetheless, it could represent a promising alternative if carefully 
performed. 
Finally, the in vivo testing design should be improved in future studies with 
P(MAA-g-EG). An optimal test would be performed on conscious animals in which the 
material is actually dosed orally. This can be done and is currently done for quite a few 
studies with rats [8], however, in a study in which blood samples have to be frequently 
drawn it represents a significant challenge. Also, when antagonized, rats and other 
animals exhibit increases in blood glucose levels which would skew results found using 
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these techniques. A similar approach to what was performed on the in situ testing in this 
work is a good alternative to oral administration, though further improvement is possible. 
The most notable problem with the methods used here is the severe drop in intestinal 
motility of the rats. Transit in the GI tract of rats was inhibited in a study by De Winter 
et. al. in which the rate of transport in the intestine was tracked using Evans blue dye. The 
transit of the dye was affected by surgical techniques with decreasing rates of transit 
where skin incision > laparotomy > laparotomy plus mechanical stimulation of the 
intestines [9]. Each surgical technique caused a significant drop from control rats. 
However, a significant increase in the intestinal motility was apparent after dosing with a 
prokinetic agent, cisapride. If this were administered during the in situ methods used in 
this study, it would more accurately mimic the natural movement in the GI tract. 
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